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Abstract
Winchell, Adam Martin PhD. The University of Memphis. December 2015.
Implementation and Assessment of Novel Functional Hemodynamic MRI Measurements
in the Brain for Evaluation of Disease and Treatment. Major Professor: Eugene Eckstein,
PhD.

The characterization and quantification of cerebral hemodynamics can provide
critical biological information of current physiology. Divergent hemodynamic processes
can provide integral knowledge into different pathophysiologies and aid in the diagnosis
and evaluation of treatment. A variety of different magnetic resonance (MR) imaging
techniques were implemented to quantify cerebral hemodynamics in a diverse set of
neurological conditions.
The first study investigated the association of blood flow and blood volume of a
diffuse intrinsic pontine glioma tumor by arterial spin labeling (ASL) and dynamic
susceptibility weighted contrast MR as a predictive marker of survival. Higher tumor
blood flow and maintenance of higher blood flow was associated with longer progression
free survival.
In the following study, ASL was used to evaluate the association of resting state
perfusion and neurocognitive impairment in long-term survivors of pediatric acute
lymphoblastic leukemia and Hodgkin lymphoma. Systematic differences in resting state
perfusion and neurocognitive performance was observed between the cancer survivor
groups.
In the last few studies, a variety of different MR techniques were implement to
investigate the hemodynamic properties of Sickle cell disease (SCD). Susceptibility
weighed imaging (SWI) was used to investigate differences in the cerebral venous
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vascular system integrity between SCD patient and healthy controls. A segmentation
procedure was introduced to quantify the normalized visible venous volume (NVVV).
The study showed that SCD effects SWI venous conspicuity by having a lower NVVV
with a global isointense venous contrast. A follow-up study improved the accuracy of the
NVVV quantification by removing hypointense arterial vessel contamination. This new
segmentation framework combined information from SWI and MR angiography.
In the final study, intracranial blood velocity measurements made by MRI and
transcranial Doppler ultrasound were compared in a cohort of SCD patients. Excessive
intracranial blood velocity is a clinical indicator of elevated stroke risk in SCD patients.
Blood velocities correlated well between the different modalities; however, MR
systematically underestimated the blood velocity.
The ability to noninvasively image, quantify, and monitor biological processes
represent a powerful diagnostic toolkit for physiological evaluation. Characterizing
cerebral hemodynamics only represents a small but vital tool for the future of medicine.
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Preface
Chapter 4, MR Imaging Assessment of Tumor Perfusion and 3D Segmented
Volume at Baseline, during Treatment, and at Tumor Progression in Children with Newly
Diagnosed Diffuse Intrinsic Pontine Glioma, is published in the American Journal of
Neuroradiology.
Chapter 6, Evaluation of SWI in Children with Sickle Cell Disease, is published
in the American Journal of Neuroradiology.

iv

Table of Contents
Chapter 1 INTRODUCTION ...................................................................................... 1
1.1

Clinical Motivation for Functional Hemodynamics Magnetic
Resonance Measurements in the Brain for Different Disease States .... 1

1.2

Cerebral Vascular Physiology............................................................... 2

1.3

Cerebral Autoregulation........................................................................ 3

1.4

Human Brain Anatomy ......................................................................... 5

1.5

Dissertation Overview .......................................................................... 8

Chapter 2 MR TECHNIQUES TO ASSESS CEREBRAL HEMODYNAMICS. 11
2.1

General Magnetic Resonance Imaging ............................................... 11
2.1.1

Nuclear Spin and Magnetic Moment ..................................... 11

2.1.2

Relaxation Time Constants .................................................... 14

2.1.3

Magnetic Resonance Imaging ................................................ 18

2.2

Spin Echo Sequence ............................................................................ 21

2.3

Gradient Echo Sequence ..................................................................... 22

2.4

Echo Planar Imaging ........................................................................... 24

2.5

MR Angiography ................................................................................ 25

2.6

MRI Perfusion Measurements ............................................................ 27
2.6.1

Dynamic Susceptibility-Weighted Contrast MRI .................. 29

2.6.2

Arterial Spin Labeling............................................................ 32

2.7

Susceptibility Weighted Imaging ........................................................ 36

2.8

Phase Contrast MRI ............................................................................ 42
2.8.1

Theory of Phase Contrast MRI .............................................. 42

2.8.2

Velocity Encoding Sequence ................................................. 44

2.8.3

Errors in Phase Contrast......................................................... 47

Chapter 3 MOTIVATION FOR FUNCTIONAL HEMODYNAMICS MR
MEASUREMENTS IN DIFFERENT DISEASE STATES ................ 51
3.1

Longitudinal Perfusion Changes in Diffuse Intrinsic Pontine Glioma in
Response to Therapy ........................................................................... 52

3.2

Perfusion Changes in Long-term Pediatric Cancer Survivors ............ 54

3.3

Hemodynamic Changes in Sickle Cell Disease .................................. 59

v

MR IMAGING ASSESSMENT OF TUMOR PERFUSION AND 3D
SEGMENTED VOLUME AT BASELINE, DURING TREATMENT,
AND AT TUMOR PROGRESSION IN CHILDREN WITH NEWLY
DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA ............. 63
4.1

Introduction ......................................................................................... 63

4.2

Materials and Methods ........................................................................ 64

4.3

4.2.1

Phase 1 Clinical Study ........................................................... 64

4.2.2

MR Imaging ........................................................................... 65

4.2.3

Image Postprocessing............................................................. 66

4.2.4

Statistical Analysis ................................................................. 67

Results ................................................................................................. 68
4.3.1

MR Imaging ........................................................................... 69

4.3.2

Survival Analysis ................................................................... 74

4.3.3

Sedation Effects ..................................................................... 76

4.4

Discussion ........................................................................................... 77

4.5

Conclusions ......................................................................................... 82

Chapter 5 GRAY MATTER PERFUSION AND ITS ASSOCIATION WITH
NEUROCOGNITIVE PERFORMANCE TO EVALUATE LATE
EFFECTS OF CANCER TREATMENT ............................................. 83
5.1

Introduction ......................................................................................... 83

5.1

Patients and Methods .......................................................................... 84
5.1.1

Patients ................................................................................... 84

5.1.1

Neurocognitive Testing .......................................................... 85

5.1.2

Magnetic resonance imaging and analysis ............................. 85

5.1.3

Statistical Analysis ................................................................. 87

5.2

Results ................................................................................................. 88

5.3

Discussion ........................................................................................... 92

5.4

Conclusion .......................................................................................... 98

Chapter 6 EVALUATION OF SWI IN CHILDREN WITH SICKLE CELL
DISEASE ................................................................................................. 99
6.1

Introduction ......................................................................................... 99

6.2

Materials and Methods ...................................................................... 100
6.2.1

Patient Demographics and MR Imaging .............................. 100

6.2.2

Image Analysis..................................................................... 102
vi

6.2.3

Statistical Analysis ............................................................... 104

6.3

Results ............................................................................................... 104

6.4

Discussion ......................................................................................... 109

6.5

Conclusions ....................................................................................... 112

Chapter 7 REMOVAL OF ARTERIAL VESSEL CONTRIBUTIONS FROM
SUSCEPTIBILITY-WEIGHTED IMAGES FOR IMPROVED
QUANTIFICATION OF NORMALIZED VISIBLE VENOUS
VOLUME............................................................................................... 113
7.1

Introduction ....................................................................................... 113

7.2

Material and Methods ....................................................................... 114
7.2.1

Patients and Study Design ................................................... 114

7.2.2

Qualitative Analysis ............................................................. 115

7.2.3

Quantitative Analysis ........................................................... 115

7.3

Results ............................................................................................... 117

7.4

Discussion ......................................................................................... 122

7.5

Conclusion ........................................................................................ 126

Chapter 8 MR FLOW MEASUREMENTS IN SICKLE CELL DISEASE ....... 127
8.1

Clinical Significance of Velocity Measures in Sickle Cell Disease . 127

8.2

4D Flow Validation Study ................................................................ 129

8.3

8.2.1

Experimental Setup .............................................................. 130

8.2.2

Calibration of flow measurements ....................................... 132

SCD MR 4D Flow Patient Study ...................................................... 136
8.3.1

Study Population .................................................................. 136

8.3.2

MR Imaging and TCD Ultrasound ...................................... 136

8.3.3

Data Processing and Flow Quantification............................ 138

8.3.4

Statistical Analysis ............................................................... 139

8.3.5

Results .................................................................................. 140

8.3.6

Discussion ............................................................................ 142

8.3.7

Conclusion ........................................................................... 146

Chapter 9 CONCLUSION AND OUTLOOK........................................................ 147

vii

List of Tables
Page
TABLE 1-1 List of previous chapter sections corresponding to projects presented in
chapters 4-8. .................................................................................................................... 10
TABLE 4-1 Baseline and immediate post-RT parameters compared by the Wilcoxon
signed-rank test ............................................................................................................... 72
TABLE 4-2 Results of linear and quadratic mixed-effects models of parameter changes
with time evaluated for time points during ..................................................................... 73
TABLE 4-3 Spearman rank correlation coefficients (ρ) in a cross-sectional analysis of
association of tumor volume with tumor perfusion variables CBF and ASL-CBF ........ 73
TABLE 4-4 Cox proportional hazard ratios and P values of PFS and OS associated with
tumor parameters at baseline and their change during RT as fixed covariates and after RT
as time dependent covariates relative to baseline ........................................................... 76
TABLE 4-5 Spearman rank correlation coefficients (ρ) in a cross-sectional analysis of
association of diastolic blood pressure and etCO2 with tumor perfusion variables ........ 77
TABLE 5-1 Areas showing impaired neurocognitive outcome in survivors of ALL
and HL .............................................................................................................................. 89
TABLE 6-1 Correlation of NVVV with hematologic parameters ............................... 101
TABLE 8-1 Results of the linear regression analysis from the average flow velocity by
MRI against the average velocity delivered by a programmable peristaltic pump. The
results indicate a high degree of correlation independent of the velocity encoding value
between average flow velocities . .................................................................................. 134

viii

List of Figures
Page
Figure 1-1 The arterial blood vessels in the brain join to form the circle of Willis as
shown in this schematic. ................................................................................................... 3
Figure 1-2 A sagittal schematic diagram of major brain structures from a midline interior
view. The brainstem consists of the midbrain, pons, and medulla. ................................. 6
Figure 1-3 A schematic diagram of the four lobes subdividing the cerebral cortex. Each
hemisphere of the cerebral cortex can be divided into the four cortical lobes. ................ 8
Figure 2-1 Formation of the magnetic moments of protons due to in an external magnetic
field parallel to the z-axis. In thermal equilibrium, slightly more spins are aligned
parallel to B0 and form the macroscopic or magnetization M0. ...................................... 12
Figure 2-2 (A) In presence of the main magnetic field, the magnetization vector is
aligned parallel along the z axis and contains a longitudinal magnetization component
only. (B) An applied radio frequency (RF) pulse with a flip angle of 90° results in the
magnetization vector to align in the transverse plane (Mxy). (C) An applied radio
frequency (RF) pulse with a flip angle of 180° results in a negative longitudinal
magnetization -Mz. .......................................................................................................... 14
Figure 2-3 Spin-spin relaxation (T2 relaxation). Spin-spin interactions create a loss of
phase coherence resulting in a faster decay of the transverse magnetization (solid line).
Additional external field inhomogeneities cause an even faster loss of phase coherence
and a faster signal decay. This is refered to as T2* relaxation (dashed line). ................. 16
Figure 2-4 Spin-lattice relaxation (T1 relaxation). After the 90º RF pulse, the transverse
magnetization is at its maximum, the longitudinal magnetization is zero. As the spins
release their energy to the surrounding tissue in a process known as spin-lattice
relaxation, the longitudinal magnetization begins to recover. The time it takes for 63% of
the maximum longitudinal magnetization to recover is known as the T1 relaxation time.
........................................................................................................................................... 17
Figure 2-5 An RF-pulse with a fixed frequency bandwidth (ΔωRF) excites all spins which
exhibit a corresponding resonance frequency. Different slice thicknesses (ΔZ1 <ΔZ2) can
be selected by different gradient strengths (GΔZ1 > GΔZ2). A slice can be described by its
center frequency and bandwidth. The actual position of the slices can be selected by
shifting the center frequency with fixed RF bandwidth to higher or lower frequencies.
........................................................................................................................................... 19

ix

Figure 2-6 The k-space is a matrix that contains the raw data of spatial frequencies as
seen on the left. Low spatial frequencies are located closer to the center and high spatial
frequencies are located away from the center. A 2D Fourier Transform of k-space results
in the MR image on the right. ......................................................................................... 20
Figure 2-7 A diagram of a spin echo sequence. The spin echo sequence consists of two
radiofrequency excitation pulses where the 180-degree refocusing is applied at half the
echo time. The signal echo occurs at the echo time or half the echo time after the
refocusing pulse. The repetition time is the time between two 90 degree excitations with
different phase encoding steps. ....................................................................................... 22
Figure 2-8 A diagram of a gradient echo sequence with the addition of spoiler gradients.
A slice is excited at flip angle alpha. The combination of a short negative readout
gradient and positive readout gradient will generate a gradient refocused echo. ........... 23
Figure 2-9 Sequence diagram of a single shot gradient echo sequence. The diagram
represents the gradient and RF events required to produce and acquire the signal of an
imaging slice. If multiple slices are imaged, the sequence is repeated for each slice. .. 25
Figure 2-10 A diagram illustrating how moving spins effect contrast in a magnetic
resonance angiography image. This is known as the inflow effect. .............................. 27
Figure 2-11 Examples of hemodynamic parameter maps calculated using dynamic
susceptibility-weighted contrast-enhanced perfusion MRI. (A) The arterial input function
(AIF) selected from a feeding artery shows the loss of signal intensity as the bolus of
contrast passes through the artery (dip). Based on the AIF and the signal intensity time
curves of every voxel, the following hemodynamic parameters can be calculated and
displayed as grayscale values: cerebral blood volume (B), cerebral blood flow (C), mean
transit time (D). ............................................................................................................... 31
Figure 2-12 Difference between pulsed ASL labeled and control images (the location of
the image slices are shown in violet). In the labeled image (left), an inversion slab (lower
box) is used to invert the arterial blood proximal to the imaging slices. In the control
image, the same off-resonance RF pulse as in the labeled images is used but without the
slab-selection gradient to control for magnetization transfer effects. Therefore, no arterial
blood is inverted proximal to the imaging slices in the control images. ......................... 33
Figure 2-13 An example of cerebral blood flow (CBF) quantification by arterial spin
labeling (ASL) in a patient with sickle cell disease. Only gray matter CBF is depicted in
the example images. White matter CBF is lower than the threshold for reliable signal
quantification by ASL. .................................................................................................... 34
Figure 2-14 An example of a minimum intensity projection (mIP) of SWI images over a
volume of 16mm. The example illustrates the excellent venous conspicuity of the deep
medullary and cortical veins by the SWI technique. ...................................................... 38

x

Figure 2-15 (A) Original unfiltered SWI phase image. (B) The result of filtering image
(A) with a low pass filter. (C) The high pass homodyne filter phase images which is the
result of complex division of the original unfiltered phase image (A) with the low pass
filtered image (B). Image (C) depicts the microscopic field variations caused by local
susceptibility differences between tissues. ..................................................................... 39
Figure 2-16 A workflow diagram of the post-processing procedure for creating an
susceptibility weighted image (SWI). A high pass filter phase image is created from the
phase image. A phase mask is created from the filter phase image to emphasize a certain
phase characteristic. The phase mask is multiplied with the original magnitude image to
create the SWI image. ..................................................................................................... 41
Figure 2-17 A schematic diagram of the accumulated phase change associated with static
and moving spins during a bipolar gradient configuration. The moving spins did not
experience an equal but opposite phase accumulation. This results in the phase offset,
which is proportional to the velocity of the moving spins. ............................................. 43
Figure 2-18 A schematic diagram of how the 4D flow sequence collects data during the
cardiac cycle. The cardiac cycle is divided into a number of time points. During each
time point, one k-space line is collected for each of the four images (reference, Vx,
Vy,Vz). In this example without image acceleration, the overall imaging time is equal to
the time to acquire a specific number of heartbeats, which is equal to the number of kspace lines required for image reconstruction. ............................................................... 47
Figure 2-19 An example of a phase wrapping error which occurs when the velocity
induced phase shifts exceeds the dynamic range of the phase image. Panels A and B
represent measurement at the same velocity, however, phase wrapping occurred in B
because the velocity exceeded the VENC value. Increasing the VENC value will
eliminate phase wrapping as depicted in A. .................................................................... 48
Figure 4-1 T2-weighted image with outlined tumor region of interest (row A) and
corresponding maps of CBF (row B), CBV (row C), and ASL-CBF (row D, color bar of
ASL-CBF is given in absolute units of milliliters per minute per 100-g tissue) of different
time points during therapy. The course of therapy and time points of the images are
depicted at the bottom. Changes of tumor tissue appearing in T2-weighted images and
changes in tumor perfusion can be seen. ........................................................................ 70
Figure 4-2 Time course of ASL-CBF (A), CBF (B), CBV (C), and tumor volume (D)
during and after RT. Beginning and end of RT are marked by dotted straight gray lines at
time points 0 and 1.4 months. Red bold dashed curves indicate the time trend of the most
statistically significant linear or quadratic model. Solid lines denote individual time
course of each patient and patients who used steroids after RT are marked in blue. Box
plots were overlaid to highlight the distribution of values at each time point. ............... 71

xi

Figure 5-1 A red cluster in the left temporal lobe (P<0.001, FWE corrected) indicated a
positive association between resting-state blood flow and FSIQ in a combined group of
ALL and HL survivors. The arrow indicates (peak-level P=0.001, FWE corrected) that
the highest positive correlation was in the left superior temporal gyrus. The significance
level used for thresholding the T statistic map was P<0.001 (t>3.3, uncorrected). ....... 90
Figure 5-2 Resting-state blood flow in a combined group of ALL and HL survivors was
positively correlated with variability in sustained attention in a cluster (P<0.001, FWE
corrected, red) spanning from the right precuneus (peak-level P=0.023, FWE corrected)
to the right posterior cingulate (peak-level P=0.053, FWE corrected, red). A cluster was
also observed in the right superior temporal gyrus (P=0.013, FWE corrected; peak-level
P=0.054, FWE corrected, green) and in the inferior parietal lobule but did not reach
statistical significance (P=0.054, FWE corrected; peak-level P=0.053, FWE corrected,
blue). The significance level used for thresholding the T statistic map was P<0.001 (t
>3.3, uncorrected). .......................................................................................................... 91
Figure 5-3 The red cluster in the left middle and superior temporal gyri showed a
positive correlation with FSIQ and perfusion in HL survivors, as indicated by the arrow
(P=0.004 FWE corrected, peak-level P=0.055). The significance level used for
thresholding the T statistic map was P<0.001 (t>3.5, uncorrected). .............................. 92
Figure 5-4 Perfusion shown as a red cluster spanning from the right precuneus (peaklevel P=0.043, FWE corrected) to the right posterior cingulate (peak-level P=0.066, FWE
corrected) was positivity associated with variability in sustained attention in HL
survivors. The significance level used for thresholding the T statistic map was P<0.001
(t>3.5, uncorrected). ........................................................................................................ 92
Figure 6-1 SWI, mIP SWI, and segmented vein maps for a representative control (top
row, NVVV = 0.032) and patient with SCD (bottom row, NVVV = 0.013). In the mIP
SWI and segmented vein maps, there is visually less venous contrast in the examination
from the patient with SCD. The arrows point to loss of cortical venous conspicuity in the
frontal (A), temporal (B), occipital (C), and deep medullary (D) areas, indicating a global
decrease in signal. ......................................................................................................... 105
Figure 6-2 An SCD mIP SWI (A) with several hypointense-appearing vessels that could
be interpreted as veins (black arrowheads). The corresponding MIP TOF (B) indicated
that many of the hypointense-appearing vessels on the mIP SWI correlate with a
hyperintense arterial signal from the TOF (white arrowheads). The arrows indicated
arterial contribution of more distal branches of the left and right (anterior to posterior)
bilateral anterior, middle, and posterior cerebral arteries. This example received a grade
of II because of a hypointense arterial signal on the mIP SWI in the anterior Sylvian
fissure through to the posterior temporal lobe. ............................................................. 106

xii

Figure 6-3 Representative mIP SWI from the same volunteer who underwent scanning at
1.5T (A) and 3T (B) depicts similar venous anatomy. The combination of higher SNR
and venous contrast at 3T results in an improved venous conspicuity and a higher venous
vessel likelihood from the Frangi filter. Several veins (eg, deep medullary veins) appear
larger at 3T. The combination of larger appearing veins and a higher vessel likelihood we
believe were attributed to the increased conspicuity of NVVV at 3T. ......................... 107
Figure 6-4 Boxplot of the NVVV in the SCD group (1.5T = 0.013 ± 0.004; 3T = 0.011 ±
0.006), control group (3T = 0.031 ± 0.009), and volunteers (1.5T = 0.024 ± 0.006; 3T =
0.028 ± 0.009). The difference in NVVV between the 3T SCD and control groups was
significant (P < .001) when assessed by the Wilcoxon rank sum test. Volunteer
measurements at 1.5T and 3T indicate increased conspicuity of NVVV at 3T (P = .03)
when assessed by the Wilcoxon signed rank test. ......................................................... 108
Figure 7-1 Diagram of the post processing workflow to remove hypointense arterial
vessels from SWI images for improved quantification of venous conspicuity. SWI,
susceptibility-weighted imaging; mIP, minimum intensity projection; MRA, magnetic
resonance angiography. ................................................................................................. 117
Figure 7-2 Representative mIP SWI (A) from a patient with SCD showing several
hypointense vessels that could be interpreted as veins (uNVVV = 0.014). The
corresponding MIP TOF (B) of the mIP indicates that many of the hypointense vessels on
the mIP SWI correlate with the hyperintense arterial signal from the TOF. A MIP of the
corresponding artery mask which was created by the 2D Frangi filter (C). The corrected
mIP SWI (D) shows the effectiveness of arterial signal removal (cNVVV = 0.007). .. 119
Figure 7-3 Representative original mIP SWI (left column), MIP TOF (middle column),
and corrected mIP SWI (right column) images from the qualitative review showing the
degree of arterial vessel contamination. (A)–(D) represent scans from patients with SCD
with increasing qualitative scores (scores 0 to III, respectively) of hypointense arterial
vessel contamination found in the original mIP SWI. The image in (D) demonstrates that
the amount of arterial vessel contamination can be quite large. Note the change in the
number of hypointense vessels between the corrected and original mIP SWI. ............ 120
Figure 7-4 Box plot of the NVVV in 21 patients with SCD before [uNVVV= 0.012 ±
0.005] and after arterial signal correction [cNVVV= 0.008 ± 0.003 (mean ± SD)]. .... 121
Figure 7-5 Comparison of the original mIP SWI (A) and the corrected mIP SWI (B)
illustrates incomplete removal of the hypointense M1 segment of the MCA as indicated
by the arrows. ................................................................................................................ 122
Figure 8-1 A schematic of the transtemporal Doppler ultrasound approach to measure
blood velocities in the distal internal carotid and the proximal middle cerebral artery.
The schematic also illustrates the transorbital approach. .............................................. 128

xiii

Figure 8-2 A schematic diagram of the experimental setup for the flow calibration study.
In order for the pump to achieve the required high velocities, a reduction in the tube
diameter occurred before flowing into the imaging phantom. Note, the tube reduction
occurred outside of the MRI magnet. This was done to prevent any equipment damage if
a leak would occur at the tube union. The small tube was one continuous piece. ....... 130
Figure 8-3 A representative magnitude weighted image slice through the flow phantom
(A). Through plane (Z direction) phase difference image (B-H) for different pump flow
settings. As the flow values increase from B to H, phase wrapping occurred in phase
images (E-H) as indicated by the change in the phase sign. This occurs when the
velocities exceeds the velocity encoding value. ........................................................... 133
Figure 8-4 Scatter plot of average velocity in a flow phantom by 4D flow MRI against
the average velocity delivered at several programmable peristaltic pump settings.
Different color markers represent the four different VENC values in cm/s. The gray line
represents the fitted linear regression for VENC = 200 cm/s (y= 0.96x+3.3, R=0.99).
......................................................................................................................................... 134
Figure 8-5 Bland-Altman indicating a bias in measured average flow velocities between
4D flow with VENC value of 200 cm/s and the programmable pump velocities. As the
average velocity increases, 4D flow measures a smaller velocity compared calculated
pump velocities. Overall, the mean difference is 3.3 cm/s with a standard deviation of
2.3 cm/s. ........................................................................................................................ 135
Figure 8-6 A scatter plot of the left (black) and right (red) maximum mean velocities
measured in the MCA by 4D flow and TCD ultrasound. The gray line is the linear
regression (r=0.82) with a relationship of y = 1.15x + 14.8. ........................................ 141
Figure 8-7 The Bland-Altman indicates a bias in maximum mean flow velocities
between 4D flow and TCD ultrasound measured in the left and right MCA. As the
maximum mean velocity increases, 4D flow measures a lower maximum mean velocity
compared TCD ultrasound. The mean difference between methods is 28.7 cm/s with a
standard deviation of 15.0 cm/s. ................................................................................... 142

xiv

List of Abbreviations
𝐵0
ACA
AD
AIF
ALL
ASL
BOLD
BW
CBF
CBV
CNS
CRT
DIPG
DMN
DSC
ECG
EGFR
EPI
FA
FID
fMRI
FOV
FSIQ
FWE
G
GLM
GM
GRE
HbS
Hct
HL
ICA
MCA
MCI
MIP
mIP
MR
MRA
MRI
MTT
NVVV
OS
PASL
PC

Main Magnetic Field
Anterior Cerebral Artery
Alzheimer Disease
Arterial Input Function
Acute Lymphoblastic Leukemia
Arterial spin labeling
Blood Oxygen Level Dependent
Bandwidth
Cerebral Blood Flow
Cerebral Blood Volume
Central Nervous System
Cranial Radiation Therapy
Diffuse Intrinsic Pontine Glioma
Default Mode Network
Dynamic Susceptibility-Weighted Contrast Enhanced
Electrocardiogram
Epidermal Growth Factor Receptor
Echo Planar Imaging
Flip Angle
Free Induction decay
functional Magnetic Resonance Imaging
Field of View
Full Scale Intelligence Quotient
Family Wise Error
Gradient
General Linear Model
Gray Matter
Gradient Echo
Hemoglobin S
Hematocrit
Hodgkin Lymphoma
Internal Carotid Artery
Middle Cerebral Artery
Mild Cognitive Impairment
Maximum Intensity Projection
Minimum Intensity Projection
Magnetic Resonance
Magnetic Resonance Angiography
Magnetic Resonance Imaging
Mean Transit Time
Normalized Visible Venous Volume
Overall Survival
Pulsed Arterial Spin Labeling
Phase Contrast
xv

P-FIT
PFS
PWI
RBC
RF
ROI
SCD
SE
SNR
STD
SWI
T1
T2
TAMMV
TCD
TE
tNVVV
TOF
TR
VEGF
VENC
WM
Y
α
λ
χ

Parieto-Frontal Integration Theory
Progression Free Survival
Perfusion-Weighted Image
Red Blood Cell
Radio-frequency
Region of Interest
Sickle Cell Disease
Spin Echo
Signal-to-Noise Ratio
Standard deviation
Susceptibility Weighted Imaging
Spin-Lattice / Longitudinal Relaxation Time
Spin-Spin / Transverse Relaxation Time
Time Average Mean of Maximal Flow Velocity
Transcranial Doppler
Echo Time
True Normalized Visible Venous Volume
Time-of-Flight
Repetition Time
Vascular Endothelial Growth Factor
Velocity Encoding
White Matter
Fraction of Oxygenated Hemoglobin to Total Hemoglobin
Labeling Efficiency
Brain / Blood Partition Coefficient
Magnetic Susceptibility

xvi

Chapter 1
INTRODUCTION

1.1

Clinical Motivation for Functional Hemodynamics Magnetic Resonance

Measurements in the Brain for Different Disease States
Structural magnetic resonance (MR) imaging (MRI) has been a mainstay in
providing both qualitative and quantitative morphometric descriptions like shape, size,
and location of neoplasms. Over the years, tumor shrinkage, measured from this limited
set of descriptive information, has become a primary descriptor of therapy response.(1)
Tumor size, however, is not always an accurate predictor of tumor response because
interobserver variation, irregular shapes, and poorly circumscribed borders can adversely
affect the accuracy of the measurement.(2-6) More importantly, substantial changes in
tumor biology can occur before contributing to effects in tumor sizes.(7) Accurate
measures of a tumor response to treatment, especially in the early stage, can determine
whether therapy is effective, which can decrease toxic effects from unnecessary treatment
and minimizing the delay in starting an alternative therapy. Additionally, not all
neurological diseases are the manifestation of a tumor. Alzheimer, Parkinson, and
neurocognitive impairment are a few examples of neurologic diseases or neurologic
conditions that are not associated with large, easy visualized, morphological structural
changes. Therefore, it is important to develop new physiology-based functional
biomarkers to quantitatively evaluate a tumor or tissue response following therapy as well
as pathological characterization and biological processes of neurologic diseases or
neurologic conditions.

1

The brain is a complex organ that requires 20% of the cardiac output and 25% of
the total body oxygen consumption.(8) This large and exclusively aerobic metabolic
demand of the brain has resulted in a complex mechanism of cerebral autoregulation to
maintain the necessary supply of oxygen and nutrients for cellular health. Measuring the
cerebral hemodynamics by MRI, which describes the delivery of blood to the tissue, is an
example of a biological metric that provides physiological information independent of
structural morphometry. Cerebral hemodynamic changes can occur without structural
abnormalities, for example in the form of a vessel stenosis. The diversity of information
collected from measuring cerebral hemodynamics may provide useful knowledge when
cerebral autoregulation is disrupted. For example, the failure to maintain adequate blood
flow could result in cerebral ischemia or hyper-vascularization, which is indicative of an
aggressive tumor. Hemodynamic information, such as the arterial and venous
vasculature structure, blood volume, and blood flow offer the potential for improving the
evaluation of cerebral health.

1.2

Cerebral Vascular Physiology
The brain is one of the most perfused organs in the body because of its high

metabolic demand. Arterial blood to the brain is supplied by two artery pairs: the left and
right internal carotid and the left and right vertebral arteries. The two vertebral arteries
join to form the basilar artery. The carotid arteries supply the cerebrum, and the two
vertebral and basilar arteries supply the cerebellum and brainstem. At the base of the
brain, the two internal carotid arteries and basilar artery join with other communicating
arteries to form the circle of Willis (Figure 1-1). Emerging from the circle of Willis are
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the anterior, middle, and posterior cerebral arteries. These arteries progressively
subdivide into smaller arterioles eventually supplying small portions of the brain tissue
with arterial blood. [A schematic of the circle of Willis is shown in Figure 1-1.] The
communicating arteries in the circle of Willis are an example of the collateral circulation
circuit, which allows for the redirection of critical blood flow to the tissue when the
primary vessel supply is occluded.(9) However, the circle of Willis’ anatomy is often
variable and asymmetric.(9)

Figure 1-1 The arterial blood vessels in the brain join to form the circle of Willis as
shown in this schematic. This figure is adapted from Rhoades and Tanner.(8)

1.3

Cerebral Autoregulation
Cerebral autoregulation refers to the compensatory properties of the brain vessels

to fluctuations of arterial blood pressure in order to maintain steady state blood flow.(6)
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Cerebral autoregulation maintains constant cerebral blood flow over a wide range of
arterial blood pressures through adaptive changes in the vascular resistance by a
combination of myogenic, neurogenic, or metabolic mechanisms.(10-13) The dynamics
of cerebral autoregulation can be noninvasively evaluated by measuring changing
cerebral blood flow velocities by transcranial Doppler ultrasound (TCD) in response to
manipulation of arterial blood pressure.(14) Cerebral autoregulation measurements are
also made by performing 133Xe SPECT studies with stimuli of either carbogen gas or
vasoactive medications.(14,15)
Paralleling Ohm’s law, cerebral vascular resistance is proportional to the pressure
difference divided by viscous flow. Cerebral vascular resistance has a considerable
influence in modulating cerebral blood flow. The pressure difference (ΔP, Pa) is the
cerebral perfusion pressure and is the difference between arterial and venous pressure.
Poiseuille’s law indicates that vascular resistance depends linearly upon blood viscosity
(η, Pa∙s) and vessel length (l, m), but is inversely related to the fourth power of the vessel
radius (R, m) (Eq. 1.1).

𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 =

𝛥𝑃
8𝜂𝑙
=
𝐹𝑙𝑜𝑤
𝜋𝑅 4

Eq. 1.1

This relationship indicates that small changes in the vessel radius result in large changes
in vascular resistance and in cerebral blood flow. Vessel constriction occurs in response
to elevation in arterial blood pressure and vessel dilation in response to a decreasing
arterial blood pressure. However, there is a limited range of cerebral autoregulation and
significant tissue injury can occur when cerebral autoregulation is lost.(8) When arterial
blood pressure falls below the autoregulation limits, the reduced cerebral blood flow is
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compensated by an increase in the oxygen extraction fraction.(16) When the increased
oxygen extraction fraction is unable to maintain metabolic homeostasis, cerebral
ischemia will occur.(17,18) Dividing the cerebral blood flow by the cross sectional area
of the blood vessel results in cerebral blood velocity. Changes in cerebral blood
velocities are directly proportional to changes the cerebral perfusion pressure and vessel
radius, and inversely related to changes in blood viscosity.

1.4

Human Brain Anatomy
The central nervous system is comprised of the brain and spinal cord. The central

nervous system receives sensory information from the external environment like taste,
touch, smell, sight, and sound. The brain also receives sensory information from the
environment within the body. The afferent neurons transmit this sensory information to
the brain where the information is collected, sorted, and processed to transmit an
appropriate efferent response with which to interact with the environment. The brain
consists of two main cell types, neuron and glia. The neurons transport and receive the
nerve impulses. The more numerous glia cells, of which there are four types (astrocytes,
oligodendrocytes, microglia, and ependymal cells) support and protect the environment
of the neurons. To protect this soft tissue organ from injury, the brain is encased in a
protective bony structure called the skull.
The brain consists of three main structures, the cerebrum, cerebellum, and
brainstem (Figure 1-2). The brainstem is continuous with the spinal cord and consists of
the medulla, pons, and midbrain. The brainstem maintains homeostasis for body systems
like breathing, circulation, as well as sleep. The cerebellum is attached to the posterior
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portion of the brainstem and helps maintains proper body position in space as well as
coordinated muscle movements and tone. The cerebrum is the largest of these structures
and consists of the cerebral cortex and subcortical structures.

Figure 1-2 A sagittal schematic diagram of major brain structures from a midline interior
view. The brainstem consists of the midbrain, pons, and medulla. [This figure was
adapted from Henry Gray (19).]

The cerebrum is subdivided in half into two hemispheres, but remain connected through
the corpus callosum. Surrounding the cerebrum is a thin layer of gray matter known as
the cerebral cortex. The gray matter consists mainly of neuronal cell bodies and their
dendritic projections. Just below the cerebral cortex is a thicker more central core of
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white matter, which consists of myelinated nerve fibers. However, deep within the white
matter at the base of the cerebrum is a group of subcortical gray matter nuclei known as
the basal ganglia. Each basal ganglium is composed of the striatum (claudate nucleus
and putamen), globus pallidus, subthalamic nucleus, and the substantia nigra. Blood
perfusion is higher in gray matter tissues then in white matter and can be quantitatively
measured by the arterial spin labeling technique presented in section 2.6.2
The cerebral cortex in each hemisphere is further subdivided into four cortical
lobes: frontal, temporal, parietal, and occipital (Figure 1-3). These cortical lobes are
divided by anatomical landmarks to provide a basic functional map of the cortex. The
smallest of the four lobes, the occipital lobe, is located in the posterior portion of the
cerebrum. The occipital lobe is responsible for processing visual sensory information.
The temporal lobe is located below the Sylvian fissure or the lateral sulcus, which
separates the temporal lobe from the frontal and parietal lobe. The temporal lobe is
responsible for auditory and other sensory processing including vision, which also occurs
in the occipital lobe. The temporal lobe includes the hippocampus and the amygdala,
which have an important role in short-term and long-term memory formation and recall.
The central sulcus served to separate the frontal and parietal lobe. Located behind the
central sulcus is the parietal lobe. The parietal lobe includes the primary somatosensory
cortex, which receives sensory information from the body. Adjacent to the
somatosensory cortex on the other side of the central sulcus is the primary motor cortex.
The primary motor cortex controls voluntary skeletal muscle movements. The primary
motor cortex is located in the frontal lobe. In addition to skeletal muscle control, the
frontal lobe is also responsible for speaking, thought, and more executive type functions.
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Figure 1-3 A schematic diagram of the four lobes subdividing the cerebral cortex. Each
hemisphere of the cerebral cortex can be divided into the four cortical lobes. [This figure
was adapted from Henry Gray (19).]

1.5

Dissertation Overview
The works presented in this dissertation are designed to fill a critical void in our

understanding of how cerebral hemodynamic information can provide novel functional
information in a diverse set of neurological conditions. The experiments in this
dissertation illustrate how cerebral hemodynamic information can provide biological
information in conditions where there is a large visible abnormality such as in a tumor.
However, the works also illustrate that cerebral hemodynamic information can also
provide unique knowledge into the brain function or health when there is no visible
abnormality. The new knowledge gain from cerebral hemodynamic information will
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hopefully direct improved patient care or to answer basic science questions in cerebral
perfusion.
The dissertation is subdivided into the following chapters.


Chapter 2 provides a general description of some key concepts of MRI.
The chapter also provides a general description of the MRI sequences used
in this collection of works to measure cerebral hemodynamics.



Chapter 3 provides a greater in-depth knowledge of the specific clinical
motivation and background for the hemodynamic studies found in
chapters 4, 5, and 6. The three sections in this chapter correspond to the
background of chapters 4-6. The reader should be aware that the sections
in this chapter are not a continuous work and can be read individually.



Chapter 4 presents the work of a study investigating different
hemodynamic parameters of an aggressive pediatric brainstem tumor
response to therapy as a predictive marker of survival. The work in this
chapter is already published in the American Journal of
Neuroradiology.(20)



Chapter 5 presents an exploratory study investigating the possible
relationship between population based hemodynamic changes and
neurocognitive impairments in long-term survivors of pediatric cancers.



Chapter 6 presents a study in Sickle Cell Disease (SCD) investigating how
venous vessel contrast is altered in this hematologic disorder. The work in
this chapter is already published in the American Journal of
Neuroradiology.(21)
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Chapter 7 presents a study, which represents a continuation of the work
presented in chapter 6. In this chapter, a novel post-processing framework
is described to improve the accuracy of the venous vessel segmentation
results used in the study found in chapter 6.



Chapter 8 provides the background and clinical motivation for using MR
to measure the blood flow velocities in major intracranial vessels of SCD
patients. The chapter presents preliminary results of an ongoing
prospective clinical study.



Chapter 9 provides a summary of the work presented in this dissertation
along with significant findings. The chapter also identifies areas for
further development or ideas for future research.

For improved clarity to the reader, TABLE 1-1 provide a cross-reference linking
the background of individual MR techniques and scientific background to the individual
projects contained in chapters 4-8.

TABLE 1-1 List of previous chapter sections corresponding to projects presented in
chapters 4-8.
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Chapter 8

MR Techniques
2.6, 2.6.1, 2.6.2
2.6.2
2.7
2.5, 2.7
2.8, 2.8.1, 2.8.2, 2.8.3
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Motivational Background
3.1
3.2
3.3
3.3
3.3

Chapter 2
MR TECHNIQUES TO ASSESS CEREBRAL HEMODYNAMICS

2.1
2.1.1

General Magnetic Resonance Imaging
Nuclear Spin and Magnetic Moment
Atoms are composed of a central nucleus surrounded by a cloud of negatively

charged electrons. The atomic nucleus contains positively charged protons and
electrically neutral neutrons. These subatomic particles possess an intrinsic angular
momentum (spin).(22) A magnetic moment is associated with the spin. Inside the
nucleus, protons and neutrons pair up due to the Pauli Exclusion Principle, canceling the
effect of most of the individual spins. 1H is the only stable nuclide with no neutron.
Many nuclei have a net nuclear spin larger than zero and possess a magnetic moment (1H
(protons), 2H, 3He, 23Na or 31P). Protons possess the greatest magnetic moment among
the stable isotopes and are in great abundance in biological materials. Therefore, 1H is
the principle isotope used in MRI. In the following we will confine our discussion on 1HMRI.
In MRI, an ensemble of spins in a volume or voxel (volume element) is observed.
Generally, their magnetic moments are randomly oriented, canceling out the effects of the
individual magnetic moments. In the presence of a strong external magnetic field (B0),
the individual 1H spins can assume two possible energy states: parallel (lower energy
state) and anti-parallel (higher energy state) to the external field. In equilibrium, more
spins are orientated parallel than anti-parallel and produce a net magnetic moment M0 in
the direction of B0 (Figure 2-1). The distribution between these two states depends on the
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temperature, according the Boltzmann distribution. Transitions between the two states
require absorption or emission of a photon at resonance frequency, ω0. The energy
difference ΔE = ħ ω0 , where ħ=6.63×10-34 Js is the reduced Planck constant, between the
two states is dependent on the Larmor frequency (Eq. 2.1):
𝜔0 = 𝛾𝐵0

Eq. 2.1

where γ is the gyromagnetic ratio that is unique to each element (Hydrogen γ=42.58
MHz/T) and B0 is the applied magnetic field in Tesla (T). Therefore, in a given magnetic
field, the resonance (or Larmor) frequency ω0 is different for every distinct nucleus
because of a unique γ.

Figure 2-1 Formation of the magnetic moments of protons due to in an external magnetic
field parallel to the z-axis. In thermal equilibrium, slightly more spins are aligned
parallel to B0 and form the macroscopic or magnetization M0.
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Macroscopically, a B0 field in the z-direction polarizes the sample, inducing a net
magnetization vector M of amplitude M0 pointed along the z-direction. Let us define a
coordinate system with the axis z aligned parallel to B0, but with the xy plane rotating
with frequency ω0 around the z-axis. This coordinate system is known as the rotating
frame. In the rotating frame, the magnetization vector M can be described by two vector
components: the longitudinal magnetization Mz and the transverse magnetization Mxy. At
equilibrium, there is no transverse magnetization and the magnetization vector is
described by only the longitudinal magnetization as seen in Figure 2-2(A). The
equilibrium magnetization vector can be displaced into the transverse plane when the
magnetic component of a radio frequency (RF) pulse B1 at resonance frequency ω0 is
applied perpendicular to B0. This tipping of the magnetization vector by a certain angle
away from B0 is known as the flip angle (α) with
𝛼 = 𝛾𝐵1 ∆𝑡.

Eq. 2.2

The longer the duration Δt or the stronger the applied B1 field, the further the
magnetization vector will move away from its initial state parallel to B0. A 90° flip angle
results in the largest transverse magnetization Mxy and zero longitudinal magnetization
Mz as seen in Figure 2-2(B). A 180° flip angle results in negative longitudinal
magnetization and zero transverse magnetization as seen in Figure 2-2(C).

13

Figure 2-2 (A) In presence of the main magnetic field, the magnetization vector is
aligned parallel along the z axis and contains a longitudinal magnetization component
only. (B) An applied radio frequency (RF) pulse with a flip angle of 90° results in the
magnetization vector to align in the transverse plane (Mxy). (C) An applied radio
frequency (RF) pulse with a flip angle of 180° results in a negative longitudinal
magnetization -Mz.

2.1.2

Relaxation Time Constants
After the application of an RF pulse at resonance frequency, the perturbed

magnetization vector returns to the lowest energy state in the direction of the main
magnetic field. Two material specific time constants, known as relaxation parameters,
are used to describe this process: the T1, or spin-lattice relaxation, time describes the
recovery of the longitudinal magnetization Mz, and the T2, or spin-spin relaxation, time
describes the loss of transverse magnetization Mxy.
T2 relaxation is caused by Brownian motion and the interaction of individual spins
with each other inducing small magnetic field inhomogeneities. As a result, some
individual spins precess at different frequencies which results in a loss of phase
coherence and a decrease in the transverse magnetization in the rotating frame. The
decay of the transverse magnetization is described mathematically as
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𝑀𝑥𝑦 (𝑡) = 𝑀0 𝑒

−𝑡⁄
𝑇2

Eq. 2.3

where M0 is the magnetization at t=0, and T2 is the transversal relaxation time. T2 is
therefore the time it takes the signal to decay to 37% of the maximum transverse
magnetization. Figure 2-3 depicts the loss of phase coherence and the resulting loss in
the transverse magnetization component. In addition to intrinsic (microscopic) field
inhomogeneities of the sample, external (macroscopic) field inhomogeneities exist,
caused by an imperfect B0 or paramagnetic or ferromagnetic materials, which further
accelerate the transverse signal decay. The characteristic time of such an accelerated
signal decay is refered to as T2* relaxation time, which is always shorter than T2. The
T2* is given by Eq. 2.4 where T2′ is the signal decay associated with the macroscopic
field inhomogeneities.

1
1
1
=
+
𝑇2∗
𝑇2′ 𝑇2
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Eq. 2.4

Figure 2-3 Spin-spin relaxation (T2 relaxation). Spin-spin interactions create a loss of
phase coherence resulting in a faster decay of the transverse magnetization (solid line).
Additional external field inhomogeneities cause an even faster loss of phase coherence
and a faster signal decay. This is refered to as T2* relaxation (dashed line). Figure
adapted from Bushberg.(23)

After the RF pulse is switched off, the magnetization returns to equilibrium. The
excess energy from the B1 excitation is exchanged with the surrounding tissue (also
referred to as lattice). This process is known as spin-lattice relaxation (T1) and describes
the exponential return of the longitudinal magnetization Mz to its equilibrium state. The
spin-lattice relaxation process is shown schematically in Figure 2-4.
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Figure 2-4 Spin-lattice relaxation (T1 relaxation). After the 90º RF pulse, the transverse
magnetization is at its maximum, the longitudinal magnetization is zero. As the spins
release their energy to the surrounding tissue in a process known as spin-lattice
relaxation, the longitudinal magnetization begins to recover. The time it takes for 63% of
the maximum longitudinal magnetization to recover is known as the T1 relaxation time.
Figure adapted from Bushberg.(23)

The T1 relaxation time is the time it takes for 63% of the longitudinal magnetization to
recover and is mathematically described as
𝑀𝑧 = 𝑀0 (1 − 𝑒

−𝑡⁄
𝑇1 ).

Eq. 2.5

In general the change in magnetization of the system is described by the Bloch Eq.
2.6.(24) Eq. 2.3 and Eq. 2.5 are the solutions to the Bloch equation for a system that
freely returns to equilibrium after a perturbation.
𝑑𝑀𝑥
𝑀
⃗⃗ × 𝐵
⃗) − 𝑥
= 𝛾(𝑀
𝑥
𝑑𝑡
𝑇2
𝑑𝑀𝑦
𝑀
⃗⃗ × 𝐵
⃗) − 𝑦
= 𝛾(𝑀
𝑦
𝑑𝑡
𝑇2
𝑑𝑀𝑧
𝑀 − 𝑀𝑥
⃗⃗ × 𝐵
⃗) − 𝑧
= 𝛾(𝑀
𝑧
𝑑𝑡
𝑇1
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Eq. 2.6

T1 and T2 relaxation times are characteristics of different tissue types and are the basis for
the contrast between tissues on T1- or T2-weighted MR images.

2.1.3

Magnetic Resonance Imaging
MRI uses RF antennas, also known as coils, to detect the transverse magnetization.

The processing spins produce a change in flux in the transverse receive coil. The change
in flux induces a voltage across the coil (Eq. 2.3). This sinusoidal (in the stationary
reference frame) dampened, voltage is known as a free induction decay (FID) and is
directly proportional to the magnitude of the transverse magnetization vector.

2.1.3.1

Slice Selection

In order to confine the MR signal to an imaging volume (slice), RF excitation needs
to be restricted to spins within the imaging volume. This can be accomplished by an
additional, spatially varying magnetic field that increases linearly and is applied
perpendicular to the desired slice. This slice selective gradient (Gz) needs to be combined
with a RF pulse with a specific excitation bandwidth (BW). Assuming a slice
perpendicular to the z-axis, the slice thickness Δz is then defined by:
𝐵𝑊 = 𝛾𝐺𝑧 ∆𝑧.

Eq. 2.7

Eq. 2.7 shows that at a fixed bandwidth, a stronger gradient will excite a thinner slice
than a weaker gradient (Figure 2-5).
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Figure 2-5 An RF-pulse with a fixed frequency bandwidth (ΔωRF) excites all spins which
exhibit a corresponding resonance frequency. Different slice thicknesses (ΔZ1 <ΔZ2) can
be selected by different gradient strengths (GΔZ1 > GΔZ2). A slice can be described by its
center frequency and bandwidth. The actual position of the slices can be selected by
shifting the center frequency with fixed RF bandwidth to higher or lower frequencies.
Figure adapted from Liang and Lauterbur.(25)

2.1.3.2 2D Spatial Encoding
After slice excitation, the signal from the slice needs to be spatially encoded in the
remaining two spatial directions (x and y for a slice perpendicular to the z-axis). In the x
direction, a gradient (Gx) is applied during signal detection known as the frequency
encoding gradient. This gradient results in different precession frequencies along the xdirection. Fourier Transformation of the acquired data yields a spatial map, where the
individual frequency components correspond to a certain position along the xdirection.(26)
To spatially encode the y-direction, a gradient (Gy) is applied between the RF
excitation and signal detection for a period of time. While the gradient is applied, the
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spins process at different frequencies as a function of their y-position, which results in a
linear phase variation along the y-direction. This process is called phase encoding and is
repeated for subsequent acquisition periods by changing the amplitude of the phase
encoding gradient in small increments.
A Fourier Transform along the y-direction yields the spatial information along
this axis. The resolution of the Fourier transformed signal is limited by the number of
phase encoding steps. The Nyquist-Shannon sampling theorem (27), as applied here,
states that the number of phase encoding steps needs to be equal or larger than the
number of pixels to be resolved in the y-direction. With each phase encoding step, a socalled k-space line is sampled. The k-space formalism is used to describe a matrix that
contains all sampled raw data (spatial frequencies) of an MRI experiment.(28,29) Low
spatial frequencies are located close to the center of k-space and the highest spatial
frequencies are at the edges of k-space. A 2-D Fourier Transform of k-space will result
in an MR image as seen in Figure 2-6.

Figure 2-6 The k-space is a matrix that contains the raw data of spatial frequencies as
seen on the left. Low spatial frequencies are located closer to the center and high spatial
frequencies are located away from the center. A 2D Fourier Transform of k-space results
in the MR image on the right.
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2.2

Spin Echo Sequence
Hahn proposed the spin echo (SE) (Figure 2-7) sequence to overcome the

additional rapid dephasing of the transverse magnetization that occurred as the result of
the spatially inhomogeneous magnetic field of the early MR systems.(30) In these early
systems, after a 90° RF excitation pulse, the spins quickly dephased causing a signal drop
at a rate of T2*. The addition of a 180° RF pulse refocuses the addition dephasing due to
field inhomogeneities. The time of the signal echo (TE) is twice the time between the
initial 90° and 180° refocusing pulse (TE/2). [The sequence diagram of a SE sequence is
shown in Figure 2-7.] This additional 180° refocusing pulse compensates for the
inhomogeneity of the main magnetic field and removes the T2̍ (Eq. 2.4) component from
the measured signal. By adjusting the TE and repetition time (TR), a SE sequence can
produce either T1, T2 or proton density weighted images. The signal magnitude (S) of a
SE sequences is dependent on TE, TR, and T1 of the tissue.
𝑆 = 𝑀𝑜 (1 − 𝑒

−𝑇𝑅⁄
−𝑇𝐸⁄
𝑇1 ) 𝑒
𝑇2
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Eq. 2.8

Figure 2-7 A diagram of a spin echo sequence. The spin echo sequence consists of two
radiofrequency excitation pulses where the 180-degree refocusing is applied at half the
echo time. The signal echo occurs at the echo time or half the echo time after the
refocusing pulse. The repetition time is the time between two 90 degree excitations with
different phase encoding steps.

2.3

Gradient Echo Sequence
In a gradient echo sequence (GRE) (Figure 2-8), a signal echo is generated

without the 180° refocusing pulse found in the SE sequence (Figure 2-7). A gradient
echo is created by the combination of two readout gradients. A negative dephasing
gradient is applied to partially dephase the spins.(31,32) The positive readout gradient
rephases the spins creating an echo when the area of the positive readout gradient equals
the area of the negative dephasing gradient. Figure 2-8 depicts a general diagram of a
GRE pulse sequence. These gradient refocused echoes are only possible because of a
very homogeneous main magnetic field. A GRE sequence has several distinct
advantages. First, without the refocusing pulse, a GRE is faster than a SE and deposits
22

less RF energy. Second, GRE sequences are also faster because spins can be excited at a
smaller flip angle. A smaller flip angle creates a shorter T1 recovery period, which
allows for a shorter TR and overall shorter sequence acquisition. However, a GRE is
sensitive to main magnetic field inhomogeneities and susceptibility effects. Excessive
susceptibility effects can result in complete signal loss in parts of the image.

Figure 2-8 A diagram of a gradient echo sequence with the addition of spoiler gradients.
A slice is excited at flip angle alpha. The combination of a short negative readout
gradient and positive readout gradient will generate a gradient refocused echo.

It is possible, at the end of any pulse sequence, that residual transverse
magnetization remains. To avoid any potential echoes from residual transverse
magnetization from previous RF excitations, the remaining transverse magnetization can
be destroyed by applying large spoiling gradients.(33) In Figure 2-8 the phase encoding
direction is reversed and a large spoiling gradients is added at the end of the readout
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gradient. This addition is known as a spoiled GRE sequence. The signal magnitude (S)
of a spoiled GRE sequences is dependent on flip angle, TR, and T1 of the tissue.

𝑆=

𝑀0 sin 𝜃 (1 − 𝑒
(1 −

−𝑇𝑅⁄
𝑇1 )

−𝑇𝑅
cos 𝜃 𝑒 ⁄𝑇1 )

∙𝑒

−𝑇𝑅⁄ ∗
𝑇2

Eq. 2.9

The signal from Eq. 2.9 is maximized at a flip angle known as the Ernst angle, which is
dependent on TR and T1 of the tissue.(34)
𝐸𝑟𝑛𝑠𝑡 𝑎𝑛𝑔𝑙𝑒(𝜃) = cos −1 (𝑒

2.4

−𝑇𝑅⁄
𝑇1 )

Eq. 2.10

Echo Planar Imaging
A SE and GRE sequences typically acquire one phase encoding line per RF

excitation, which can result is long image acquisition time. It is possible to collect
multiple or all phase encoding steps per RF excitation to reduce the image acquisition
time. In echo planar imaging (EPI) the entire imaging k-space is collected from a single
RF excitation.(35,36) The echo formation is based on the gradient configuration of a
GRE sequence. An additional benefit to the faster image acquisition is the reduced
sensitivity to patient motion. However, the T2* signal decay limits the number of useful
k-space data samples that can be collected within a given TR. The T2* relaxation
constraint permits the formation of low-resolution images. In addition, EPI is sensitive to
field inhomogeneities, which can result in sever image distortion. A single-shot gradient
EPI is a common sequence used in Arterial Spin Labeling (ASL). EPI uses a series of
bipolar readout gradients to generate a train of gradient echoes after a single RF
excitation. Each gradient echo is individually phase-encoded and all k-space lines are
sampled in one shot. [Figure 2-9 depicts a sequence diagram of a single-shot gradient
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echo EPI.] A typical EPI-based ASL image has 64 phase encoding steps. The phase and
readout gradients would continue in their respective patterns to produce 64 echoes (only
10 are shown in Figure 2-9). The sequence diagram represents events for a single slice
and is repeated for additional slices.

Figure 2-9 Sequence diagram of a single shot gradient echo sequence. The diagram
represents the gradient and RF events required to produce and acquire the signal of an
imaging slice. If multiple slices are imaged, the sequence is repeated for each slice.

2.5

MR Angiography
MR angiography (MRA) describes a group of contrast and non-contrast enhanced

imaging techniques to visualize the vascular system.(37,38) Although the mechanisms
differ between contrast and non-contrast enhanced methods, both techniques rely on
increasing the vessel signal intensity relative to the stationary background signal. Timeof-flight (TOF) MRA is a non-contrast enhanced method commonly employed in the
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brain to image the cerebral arterial vascular system.(39,40) A TOF MRA is routinely
included in a neurological evaluation of SCD patients to screen for stenotic or occluded
arterial vessels.(41,42) The clinical utility of MRAs in SCD is also important in the
diagnosis of aneurysms or other vascular pathophysiologies like moyamoya disease.(4345) Later in chapter 7, an MRA is included in a unique image post-processing method to
spatially identify arterial vessels for improved quantification of the visible venous
volume in susceptibility weighted imaging (SWI).
The principal contrast mechanism implemented in TOF MRA relies on the
difference in signal intensity between the increased arterial vessel signal due to flow
related enhancement and the decreased saturated background signal.(40,46) TOF can be
either a 2D or 3D technique, where the imaging volume of interest is repeatedly excited
by RF pulses, creating a lower steady state longitudinal magnitization signal. The result
is a saturated background signal. Any inflowing blood, either arterial or venous, into the
imaging volume has not experienced any RF excitation and therefore remains
unsaturated. The longitudinal magnitization of the unsaturated (hyperintese) blood signal
is consideribly larger than the saturated (hypointense) background signal creating the
desired contrast in TOF imaging. To supress venous vessel contributions, an RF
saturation pulse is placed generally superior (venous upstream) to the imaging volume.
In TOF imaging, the enhaced contrast due to inflow effect of unsaturated blood is
dependent on the refilling rate of fresh blood into the imaging volume (Figure 2-10). In
the case of no flow, the magnitization will experience an RF history similar to the
background tissue resulting in a similar hypointense signal. Therefore, a completely
occluded arterial vessel with no flowing blood will appear isointense to stationary tissue.
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For slow flowing blood, some portion of the blood in the imaging volume will experience
multiple RF excitations resulting in partial saturation of the blood signal and a decreased
in contrast. The proportion of blood that is saturated is dependent on the velocity of the
blood and the TR. Maximum contrast is achived when fresh blood completely fills the
imaging volume between successive RF pulses (TR).

Figure 2-10 A diagram illustrating how moving spins effect contrast in a magnetic
resonance angiography image. This is known as the inflow effect. Figure is adapted
from Wheaton et. al.(37)

2.6

MRI Perfusion Measurements
Perfusion is the vital function that describes the delivery of oxygen and nutrients

(e.g., glucose) to tissue by means of blood flow. As an example, the human brain
receives approximately 20% of the cardiac output and consumes 25% of the total
glucose.(8) Cerebral blood flow (CBF) is also coupled to brain metabolism in such a
manner that variations in neural activity cause changes in CBF. In addition to assessing
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brain physiology or pathology, regional blood flow changes may serve as a surrogate
marker for changes in regional brain activity.(47)
Perfusion, in MRI, describes the amount of water in the blood delivered by the
microvascular network to a unit of tissue in a certain period of time. Perfusion is
measured in tissue specific units of milliliters of blood per 100 gram of tissue per minute
(ml blood/100g tissue/min).
MR perfusion measurements have been applied to diverse clinical populations.
The most common application is the assessment of stroke (48), where a possible
mismatch between diffusion and perfusion images may indicate reversible tissue
damage.(49) More recently, perfusion MRI has also been utilized for the assessment of
brain tumors (50,51) and degenerative diseases like Alzheimer’s disease (52). Studies,
summarized and reviewed by Deibler (53,54), have shown the diagnostic importance of
perfusion measurements in a range of clinical conditions.(55-59)
Perfusion measurement by MRI can be performed within a few minutes, which
allows this important functional tool to be added easily to many clinical protocols. This
is more time- and cost-efficient than performing separate perfusion examination by
positron emission tomography (PET). In addition, MRI perfusion measurements are
acquired with higher spatial resolution than nuclear medicine techniques and can easily
be co-registered to the high-resolution structural images acquired during the same MRI
exam.
Currently two MR perfusion methods are implemented clinically. The methods
differ in the use of either an exogenous or an endogenous blood tracer. Dynamic
susceptibility-weighted contrast (DSC) MRI requires a fast intravenous bolus injection of
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a contrast agent, typically gadolinium chelates. ASL is based on labeling the arterial
blood via an RF inversion pulse, which results in a different magnetic state between
inflowing blood and static tissue. The two techniques are briefly discussed in the
following sections. A more detailed discussion of MRI perfusion techniques can be
found in the review articles of Barbier (60) and Thomas (61).

2.6.1

Dynamic Susceptibility-Weighted Contrast MRI
DSC perfusion MRI requires the intravascular injection of an exogenous contrast

agent such as gadopentetate dimeglumine (Gd-DTPA) or gadodiamide. The magnetic
susceptibility of these paramagnetic agents in solution is assumed to be directly
proportional to the concentration of the agent.(62) These paramagnetic contrast agents
increase the magnetic susceptibility of blood resulting in strong magnetic field gradients
in close proximity to the vascular bed. In this situation the dephasing of the transverse
magnetization is accelerated, thus reducing the T2* relaxation times and altering the
contrast in T2*-weighted images.(63) A short bolus of contrast agent passing through the
brain can be followed by rapidly acquiring a time series of T2*- sensitive images. This
image series can be used to generate signal intensity vs. time curves in the tissue of
interest, or, after calibration, concentration vs. time curves as explained below.
Assuming a healthy intact blood brain barrier, contrast agent flows remains within
the vasculature and represents a non-diffusible tracer. Applying non-diffusible tracer
kinetic models (64) three important hemodynamic parameters can be calculated: (1) CBF;
(2) the cerebral blood volume (CBV); and (3) the mean transit time (MTT). An example
of the calculated hemodynamic maps is found in Figure 2-11.

29

The hemodynamic parameters CBF, CBV, and MTT calculated by DSC are based
on classical non-diffusible tracer kinetic models.(64) The microvasculature in the brain
is modeled as a system, which has both inflowing and outflowing blood. The total flow
of contrast agent into the tissue is the product of the concentration of the tracer in the
arterial blood supply (CAIF) and the arterial blood flow (CBF). The net tissue
concentration (CT) is then determined by how much contrast agent flows into the volume
and how long it resides in the tissue (R(t), residue function). The tissue residue function
represents an ideal tissue response and describes the distribution of transit times of
contrast agent through the microvasculature. This is described mathematically in Eq.
2.11, where * represents the convolution of CAIF and R(t).
𝐶𝑇 (𝑡) = 𝐶𝐵𝐹 ∙ 𝐶𝐴𝐼𝐹 (𝑡) ∗ 𝑅(𝑡)

Eq. 2.11

CBF is calculated as the deconvolution of tissue concentration and arterial blood supply
concentration. By definition, R(0) = 1, or is maximum, when the contrast agent first
arrives in the microvasculature. This calculation also requires knowledge of the arterial
input function (AIF). The AIF represents the arterial concentration of contrast agent over
time and is typically estimated by the concentration time curve inside a major feeding
artery.
The CBV is calculated as the ratio of the areas under the curve of the tissue
concentration and AIF concentration.
∞

𝐶𝐵𝑉 =

∫0 𝐶𝑇 (𝑡)𝑑𝑡
∞

∫0 𝐶𝐴𝐼𝐹 (𝑡)𝑑𝑡

Eq. 2.12

By the central volume theorem, the MTT of blood through the microvasculature
describes the relationship between CBV and CBF (Eq. 2.13). MTT is also calculated as
the area under the curve of the tissue residue function.
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𝑀𝑇𝑇 =

𝐶𝐵𝑉
𝐶𝐵𝐹

Eq. 2.13

Figure 2-11 Examples of hemodynamic parameter maps calculated using dynamic
susceptibility-weighted contrast-enhanced perfusion MRI. (A) The arterial input function
(AIF) selected from a feeding artery shows the loss of signal intensity as the bolus of
contrast passes through the artery (dip). Based on the AIF and the signal intensity time
curves of every voxel, the following hemodynamic parameters can be calculated and
displayed as grayscale values: cerebral blood volume (B), cerebral blood flow (C), mean
transit time (D).

Excellent reproducibility of DSC measurements has been shown previously.(65)
However, there are several limitations in DSC measurements. An invasive intravenous
injection of contrast agent is required. The slow renal excretion of the contrast agent
does not allow for immediately repeated measurements. The concentration temporal
profile of the contrast agent bolus is dependent not only on external parameters, such as
the injection technique, but also on physiological parameters, such as cardiac output and
vascular geometry.(66) The selection and shape of the AIF representing the
concentration of the tracer entering the tissue, is commonly estimated from images of a
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major feeding artery.(67) However, the AIF is known to vary throughout the slice due to
altered blood flow patterns of a particular location. This can cause a delay or dispersion
to the shape of the true AIF. Delays or dispersion in the AIF cause an underestimation of
CBF and an overestimation of MTT.(68) DSC also assumes an intact blood brain barrier
where the contrast agent resides within the intravascular space. This assumption is not
always valid when characterizing tumors or diseases such as multiple sclerosis that affect
the integrity of the blood brain barrier.(69)

2.6.2

Arterial Spin Labeling
In contrast to DSC perfusion, ASL uses arterial blood water as a freely diffusible

tracer to quantify CBF.(70) The essential requirement for ASL is the inflow of arterial
blood which has been magnetically labeled (inverted by an 180º RF pulse) at a location
upstream to the blood flow in the imaging slice. As the labeled blood flows into the
imaging slice, the magnitude of the longitudinal magnetization of the arterial blood is
different from the fully relaxed magnetization of the tissue. The labeled arterial blood
water exchanges its magnetization with extravascular tissue water, which reduces the
longitudinal magnetization in the voxel. The image obtained when the magnetization
exchange occurs is referred to as labeled image. To measure the loss of signal created by
the inverted arterial water, a control image is measured where the inflowing arterial water
was not inverted. The labeled image is then subtracted from the control image. The
signal differences between labeled and control images is small, approximately 1%. Many
labeled and control image pairs are acquired and averaged to increase the SNR of this
small signal change. This difference image is a perfusion-weighted image (PWI) where
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the signal intensity is directly proportional to CBF. The principle of an ASL experiment
is depicted schematically in Figure 2-12.

Figure 2-12 Difference between pulsed ASL labeled and control images (the location of
the image slices are shown in violet). In the labeled image (left), an inversion slab (lower
box) is used to invert the arterial blood proximal to the imaging slices. In the control
image, the same off-resonance RF pulse as in the labeled images is used but without the
slab-selection gradient to control for magnetization transfer effects. Therefore, no arterial
blood is inverted proximal to the imaging slices in the control images.
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Figure 2-13 An example of cerebral blood flow (CBF) quantification by arterial spin
labeling (ASL) in a patient with sickle cell disease. Only gray matter CBF is depicted in
the example images. White matter CBF is lower than the threshold for reliable signal
quantification by ASL.

Quantification of perfusion requires modification of the Bloch equation to account
for the inflowing magnetization (Eq. 2.14). This modified signal intensity change
describing the new tissue water magnetization was derived by Detre (70)
𝑑𝑀𝑏 (𝑡)
𝑀𝑏0 − 𝑀𝑏 (𝑡)
𝑓
=
+ 𝑓𝑀𝑎 (𝑡) − 𝑀𝑏 (𝑡)
𝑑𝑡
𝑇1𝑏
𝜆

Eq. 2.14

where f is CBF in ml/g/s; λ is the brain/blood partition coefficient and represents the ratio
of tissue water to blood water in ml/g; Mb is the longitudinal magnetization of brain
tissue; Mb0 is the longitudinal magnetization under fully relaxed conditions; Ma is the
longitudinal magnetization of arterial blood; T1b is the relaxation time of brain tissue.
The inflowing magnetization is represented as fMa, with out-flowing magnetization as
fMb/λ. This description of ASL perfusion quantification represents a single compartment
freely diffusible kinetic model. The model assumes rapid exchange of water between the
capillaries and surrounding tissue.

34

Simplistically, the ASL sequence can be subdivided into a labeling preparation
module and an independent image acquisition module. This flexibility has resulted in
many different ASL variations with different labeling or imaging modules. This work
employed the Pulsed ASL (PASL) QUIPSSII variation, which uses a spatially selective
inversion pulse to label the blood water in a large slab proximal to the imaging
slices.(71,72) CBF quantification using the PASL variation is given in Eq. 2.15.
∆𝑆 = 𝑓 ∙ 2𝛼

𝑇𝐼2
𝑀𝑏0
⁄
𝑇𝐼1 𝑒 𝑇1𝐴
λ

Eq. 2.15

ΔS is the perfusion weighed signal; TI1 the bolus width, TI2 the transit delay time, α the
labeling efficiency, and T1A the T1 of blood.
There are several advantages of ASL compared to DSC. The principle advantage
is that ASL is completely non-invasive and does not require the use of exogenous
contrast agents. This enables perfusion to be performed in people that cannot receive
intravenous contrast agents, e.g., patients with severe renal disease, healthy volunteers,
and those who are in need of repeated examinations. The high temporal resolution of
only a few seconds allows ASL to be repeated as often as desired, even creating the
ability to perform functional MRI measurements.(73) ASL perfusion values have shown
good agreement with H215O PET studies in gray matter, but an underestimation was noted
for white matter measurements. This has been attributed to higher arterial transit times in
white matter compared to gray matter.(74)
The main disadvantage of ASL is its poor signal-to-noise ratio (SNR) due to the
small effect of the labeled blood on static tissue. SNR is improved in ASL by reducing
the spatial resolution and increased signal averaging. Another disadvantage of ASL is the
relatively short T1 relaxation time of blood, which limits the available time to measure
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the labeled blood signal. This is of particular importance when CBF is quantified in the
presence of cerebral vascular diseases. The transit time of the blood can increase to the
point where no signal is left when the labeled blood reaches the tissue. Therefore, it is
desirable to perform ASL at higher field strengths since there the T1 relaxation time of
blood is increased. Higher field strengths provide the additional benefit of a higher SNR,
which scales approximately linearly with field strength, but can increase EPI related
distortions.

2.7

Susceptibility Weighted Imaging
Susceptibility Weighted Imaging (SWI) is a relatively new imaging technique that

generates a unique contrast based on the differences in magnetic susceptibility between
adjacent tissues or blood.(75,76) Magnetic susceptibility is a property of the material that
describes its magnetic response to an external magnetic field.
⃗⃗ = (1 + χ) ∙ 𝐵
⃗⃗ 0
𝐵

Eq. 2.16

⃗ due the susceptibility of the material (χ)
Eq. 2.16 describes the induced magnetization 𝐵
⃗ 0. The dimensionless susceptibility (χ)
in the presence of an uniform magnetic field 𝐵
constant is related to the permeability (μ) of the material and the permeability in vacuum
(μ0 = 4π∙10-7 N/A2).
χ=

𝜇
−1
𝜇0

Eq. 2.17

Materials with χ < 0 are diamagnetic and have paired electrons, which induce an
opposing magnetic field causing a small decrease in the local magnetic field. Most
tissues in the body are diamagnetic. Paramagnetic materials have unpaired electrons and
χ > 0. The unpaired electrons result in a magnetic moment, which aligns with the
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external magnetic field causing the local magnetic field to increase. Eq. 2.16 also
indicates that the induced magnetization or susceptibility effects are directly proportional
to the main magnetic field. A GRE sequence with a long TE results in a T2* weighted
image.
In clinically diagnosis, SWI is routinely incorporated to evaluate the integrity of
the cerebral venous vasculature system. Additionally, SWI is also emerging as an
important tool for evaluating traumatic brain injury, neurological disease, or vascular
malformations.(77-80) The venous vasculature contrast is due to differences in magnetic
susceptibility of approximately 0.264 ppm between the highly concentrated
deoxhemoglobin found in veins and the surrounding oxygenated tissue.(81) The
susceptibility difference arises from the paramagnetic properties of deoxhemoglobin,
which is due to the unpaired electrons in the four iron ions (Fe++) in hemoglobin. [Figure
2-14 is a typical example of a minimum intensity projection (mIP) over several SWI
images.] To increase venous conspicuity, it is common to compute mIP images over a
larger slice thickness volume.
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Figure 2-14 An example of a minimum intensity projection (mIP) of SWI images over a
volume of 16mm. The example illustrates the excellent venous conspicuity of the deep
medullary and cortical veins by the SWI technique.

The overall susceptibility of blood ( χ𝑏𝑙𝑜𝑜𝑑 ) is described in Eq. 2.18 and is a function of
hematocrit (Hct), the fraction of oxygenated hemoglobin to total hemoglobin
concentration (Y), and the difference in χ between deoxhemoglobin and
oxyhemoglobin.(82)
χ𝑏𝑙𝑜𝑜𝑑 = 𝐻𝑐𝑡 ∙ (1 − 𝑌) ∙ (χ𝑅𝐵𝐶,𝑑𝑜𝑥 − χ𝑅𝐵𝐶,𝑜𝑥 )

Eq. 2.18

However, the contrast change in SWI is any tissue with different susceptibility from its
surrounding tissue like deoxhemoglobin, hemosiderin, or calcium. In SWI, susceptibility
effects cause spin dephasing and an offset in the resonance frequency. This causes a
signal loss in the magnitude image and a shift in the phase image. The SWI technique
includes a series of post-processing steps to maximize the susceptibility effects in the
magnitude images by incorporating the susceptibility effects in the phase images.
Typically, only signal information describing the magnitude of the magnetization
vector is used to reconstruct an image. The phase image provides both macroscopic and
microscopic information about the magnetic field variations in the object. The
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macroscopic variations are due to background field inhomogeneities or large field
gradients caused by air tissue interfaces. The microscopic field variations provide the
useful information in SWI. To expose the microscopic field variations, the phase images
are filtered to remove the macroscopic field variations. A popular method is applying a
homodyne filter.(83) [Figure 2-15 illustrates the steps in the filtering process.] A low
pass filtered image (Figure 2-15 (B)) is created by zero padding a small (64 x 64) central
portion of the original phase image (Figure 2-15 (A)). A high pass filter image (Figure
2-15 (C)) is created by complex division of the original phase image with the low pass
filter phase image. The complex division results in phase subtraction of the two images.
Phase wraps are also eliminated, which is an additional benefit of the homodyne filter.

Figure 2-15 (A) Original unfiltered SWI phase image. (B) The result of filtering image
(A) with a low pass filter. (C) The high pass homodyne filter phase images which is the
result of complex division of the original unfiltered phase image (A) with the low pass
filtered image (B). Image (C) depicts the microscopic field variations caused by local
susceptibility differences between tissues.

A phase mask is created from the high passed filtered phase image. The phase
mask is designed to maximize the susceptibility effects in the magnitude images that only
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contain a certain phase sign. Typically, a negative phase mask is used to increase the
venous conspicuity in SWI. The phase mask has a range between zero and one where
values less than one are used to enhanced contrast. An example of the negative phase
mask is created according to the condition in Eq. 2.19, where φ(x) is the phase at any
location x.
𝜑(𝑥) = {

(𝜑(𝑥) + 𝜋)/𝜋,
1,

−𝜋 ≤ 𝜑(𝑥) < 0
𝜑(𝑥) ≥ 0

Eq. 2.19

The last step in SWI post-processing is the combination of the SWI magnitude
image with the phase mask created from the high pass filter phase image. The phase
mask is multiplied with the magnitude image several times. Haacke et. al. demonstrated
that four multiplications of the phase mask results in good contrast to noise for venous
vessels.(76) Any areas in the image with a negative phase will have enhanced
hypointensity in the final SWI image. A diagram of the overall SWI post-processing
procedure is shown in Figure 2-16.
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Figure 2-16 A workflow diagram of the post-processing procedure for creating an
susceptibility weighted image (SWI). A high pass filter phase image is created from the
phase image. A phase mask is created from the filter phase image to emphasize a certain
phase characteristic. The phase mask is multiplied with the original magnitude image to
create the SWI image.

A few technical considerations should be considered when performing SWI. As
indicated in Eq. 2.20, it is advantageous to perform SWI at higher field strengths due to
the increase in susceptibility effect. Any spatially varying magnetic field due to
susceptibility differences will also impart the same spatial variation in the MR phase
signal. The phase in SWI can be expressed as a function of γ, Δχ, 𝐵0, and TE.(76)
𝜑 = −𝛾∆χB0 TE

Eq. 2.20

In order to maintain a similar phase change due to susceptibility effects between systems
of different field strength, the product B0∙TE should be equivalent. The additional benefit
of increased SNR at higher fields, offers the additional opportunity to reduce scan time
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with the addition of parallel imaging. The visualization of small venous vessels requires
a large acquisition matrix. The small voxel size is sensitive to the susceptibility
differences created by venous vessels while remaining insensitive to the macroscopic
field variations. A typical acquisition matrix has a high in-plane resolution (~0.6 mm)
and thicker slice (~2 mm).
In SWI, it is desirable that susceptibility is the only source of phase change.
However, moving spins from blood vessels are not refocused by the imaging gradients
and will accumulate a phase change that is dependent on its velocity. Therefore, velocity
compensation is included in all directions to refocus any phase accumulation that results
from moving spins with a constant velocity.(84,85) However, any phase accumulation
resulting from nonlinear velocity or acceleration is not eliminated by first order flow
compensation.

2.8

Phase Contrast MRI
A number of 4D flow MRI papers are already published and discuss in detail the

theory and limitations of 4D flow.(86-88) These papers would serve as a good reference.
The following sections discuss the theory, MRI sequence, and common error sources in
4D flow imaging.

2.8.1

Theory of Phase Contrast MRI
Phase contrast (PC) MRI is a technique that employs a flow-sensitizing gradient

waveform to image moving spins.(89) The flow-sensitizing gradients impart a phase
dependent shift in moving spins. In a rotating coordinate system, spins processing at the
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Larmor frequency are stationary. However, an additional phase will accumulate for any
spins processing faster or slower than the Larmor frequency. In the presence of a
magnetic field gradient, moving spins along the direction of the field gradient will
experience a spatially varying change in the magnetic field and will accumulate a phase
change that is dependent on the time and strength of the change in the local magnetic
field.
A bipolar gradient configuration comprised of two gradient lobes of equal area
but opposite polarity is the most common flow-sensitizing gradient waveform as seen in
Figure 2-17.(90)

Figure 2-17 A schematic diagram of the accumulated phase change associated with static
and moving spins during a bipolar gradient configuration. The moving spins did not
experience an equal but opposite phase accumulation. This results in the phase offset,
which is proportional to the velocity of the moving spins. This figure is adapted from
Bernstein.(91)

The net phase accumulation, for stationary spins in each gradient lobe of the
bipolar gradient is equal but in opposite direction. This results in a zero net phase
accumulation for stationary spins. However, spins moving in the direction of the bipolar
gradient will not have a zero net phase accumulation at the end of the bipolar gradient.
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The net change in phase is linearly proportional to the velocity of the moving spins. The
phase (φ) of the spins during the bipolar gradients can be expressed in terms of gradient
moments (Eq. 2.21):
𝜑(𝑡) = 𝛾(𝑋0 𝑀0 + 𝑣⃑𝑀1 +

𝑎⃑
𝑀)
2 2

Eq. 2.21

where M0, M1, and M2 represent the zero, first, and second gradient moments. γ is the
gyromagnetic ratio. X0 is the initial position of the spin with 𝑣⃑ and 𝑎⃑ representing the
velocity and acceleration vector components of the moving spin in the direction of the
gradient. Ignoring higher order components, according to Eq. 2.21 the change in phase
for a given constant velocity is dependent on the degree of change in the first gradient
moment. The first gradient moment of the bipolar gradient can vary according to the
strength of the gradient (G) and time duration (T) (Eq. 2.22).
𝑇 2
𝑀1 = 𝐺 ( )
2

Eq. 2.22

According to Eq. 2.21 and Eq. 2.22, in order to increase the phase accumulation,
the velocity, gradient strength, or duration of the gradient must increase. Therefore, in
order to image slower moving spins with a larger phase accumulation, stronger bipolar
gradients with a shorter duration are required.

2.8.2

Velocity Encoding Sequence
An important concept discussed in the previous section (2.8.1) is the bipolar

gradient waveform, which only measures the velocity of moving spins in the direction of
the applied bipolar gradient. Therefore, in order to describe moving spins along the three
principle axes, bipolar gradients must also be applied along the three principle axes. This
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requires three separate measurements. However, other phase sources not refocused by
bipolar gradients, like magnetic susceptibility and eddy currents, can contribute to the
phase signal. These other phase contributing sources must be eliminated from the
velocity encoded phase signal in order to isolate the velocity induced phase shifts. This is
typically done by acquiring a reference scan with identical imaging parameters to the PC
scan and subtracting this reference phase image from the velocity encoded phase
image.(92) In summary, in order to quantify the velocity of moving spins, a total of 4
measurements are required with the velocity encoding measurements along the three
principle axes and a reference measurement to remove non-velocity phase contributions.
This method is referred to as a four-point reference approach.(92)
Because four measurements are required for velocity quantification in 3D, the
most common PC method uses a fast RF-spoiled gradient echo sequence. A typically 4D
flow PC sequence is presented in Figure 2-18. 4D flow sequences are often gated to the
cardiac cycle to measure the periodic pulsatile blood velocity within blood vessels. This
results in a collection of 3D time velocity encoded images where blood velocity is
quantified at discrete time intervals within the cardiac cycle. The time between
successive heartbeats can be subdivided into a number of cardiac phases as indicated in
Figure 2-18. The minimum time of each cardiac phase is the amount of time necessary to
complete the four required flow measurements (4*TR). Typically, within each cardiac
phase only one line of imaging or k-space data is acquired. This process is repeated by
acquiring the same imaging data line for each successive cardiac phase within the same
heartbeat (Figure 2-18). The number of heartbeats required to complete the scan is equal
to the number of phase encoding steps multiplied by the number of imaging slices
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(assuming no acceleration techniques). This 4D flow imaging approach can result in
prohibitively long scan times. For example, a 3D volume comprised of 16 slices
requiring 128 phase encodes steps per slice will require 2048 heartbeats. Assuming a
heart rate of 60 beats per min will result in a scan time of approximately 35 minutes. One
method to reduce the overall scan time is to acquire two imaging data lines within each
cardiac phase. Now the time of each cardiac phase is 4 * TR * the number of data lines
required. This approach reduced the overall scan time to approximately 17 minutes for
the example above. However, the tradeoff of acquiring multiple imaging data lines
within a cardiac phase is a reduction in the velocity quantification temporal resolution.
Therefore, the velocities temporal resolution is inversely related to the number of
additional imaging data lines acquired within the cardiac phase.
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Figure 2-18 A schematic diagram of how the 4D flow sequence collects data during the
cardiac cycle. The cardiac cycle is divided into a number of time points. During each
time point, one k-space line is collected for each of the four images (reference, Vx,
Vy,Vz). In this example without image acceleration, the overall imaging time is equal to
the time to acquire a specific number of heartbeats, which is equal to the number of kspace lines required for image reconstruction. This figure is adapted from Markl.(87)

2.8.3

Errors in Phase Contrast
Previous studies have validated PC MRI velocity quantification in flow phantoms

and in-vivo with an approximate 5% mean error.(93,94) However, as with most
techniques, there are a few limiting factors that require consideration when performing a
PC MRI experiment.
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For accurate velocity quantification, the velocity induced phase shift cannot
exceed the dynamic range of the phase image. Any phase shift exceeding -π or π radians
will result in phase aliasing. As discussed in section 2.8.1, the degree of phase shift at a
given velocity is dependent to on the strength and or duration of the bipolar gradient (Eq.
2.21 and Eq. 2.22). The bipolar gradient configuration corresponding to a velocity with
a phase shift of π radians is the velocity encoding or VENC value, where ∆m1 is the
change in the first gradient moment.
𝑉𝐸𝑁𝐶 =

𝜋
𝛾|∆𝑚1 |

Eq. 2.23

Figure 2-19 depicts an example of two experiments performed at the same constant
velocity. In Figure 2-19(B), the VENC value was set below the maximum velocity
resulting in a phase wrapping error. Using a VENC value larger than the maximum
velocity as seen in Figure 2-19(A) eliminated the phase wrapping error.

Figure 2-19 An example of a phase wrapping error which occurs when the velocity
induced phase shifts exceeds the dynamic range of the phase image. Panels A and B
represent measurement at the same velocity, however, phase wrapping occurred in B
because the velocity exceeded the VENC value. Increasing the VENC value will
eliminate phase wrapping as depicted in A.
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For example, in an experiment with a VENC value of 100 cm/s, velocities of +50
and +100 cm/s correspond to a phase shift of +90° and +180° respectively. However, if
the actual velocity is +150 cm/s, the corresponding phase shift is +270°. A phase shift of
270° is indistinguishable from a phase shift of -90°. This corresponds to the +150 cm/s
velocity assigned a velocity of 50 cm/s, but in the opposite direction. Therefore, it is
important to have some prior knowledge of the system in choosing a VENC value. There
are a few phase unwrapping techniques, which rely on either spatial and or temporal
assumptions to determine appropriate corrections for phase wrapping errors.(95,96)
Although it is advantageous to choose a large VENC value to eliminate the
possibility of flow aliasing errors, large VENC values have a few limitations. Because
noise errors in phase images translate into velocity quantification errors, appropriate
experimental setup procedures should focus on minimizing noise in the phase images.
One way to minimize phase error is by increasing the SNR in the corresponding
magnitude image.(97) There is an inverse relationship between phase error and SNR in
the magnitude image. The velocity standard deviation (σv) can be estimated according to
Eq. 2.24.(97)
𝜎𝑣 =

√2 ∙ 𝑉𝐸𝑁𝐶
𝜋 ∙ 𝑆𝑁𝑅

Eq. 2.24

Eq. 2.24 indicates minimal phase errors occur when the VENC values is also minimized.
This relationship is visualized in the following scenario with similar image noise. Only
fast moving spins with velocity at VENC produce a maximum phase shift of π radians.
Slower moving spins have smaller phase shift, which result in a smaller velocity to noise
ratio in the image. This is analogous to slower moving spins producing less contrast in
the image, thereby lowering the contrast to noise ratio in the image. For a system with a
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mixture of fast and slow velocities, a large VENC value increases the velocity
quantification error in slow velocity regions.
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Chapter 3
MOTIVATION FOR FUNCTIONAL HEMODYNAMICS MR MEASUREMENTS
IN DIFFERENT DISEASE STATES

The following series of works are designed to illustrate how measuring cerebral
hemodynamic information can provide novel functional information in a diverse set of
neurological conditions. Our first study focuses on tumor hemodynamic changes before
and after a common treatment therapy. The study investigated if tumor hemodynamics
are better predicative markers of survival than tumor size in an aggressive pediatric tumor
(Chapter 4). The second study investigates how regional changes in blood flow correlate
with neurocognitive impairments in long-term survivors of cancer (Chapter 5). This
study probes a possible mechanism for investigating known neurocognitive dysfunction
that is not the consequence of structural abnormalities. The last few studies (Chapters 68) focus on how a hematologic disorder alters normal cerebral hemodynamics. These
proposed studies are designed to exhibit how cerebral hemodynamic imaging can impart
new knowledge in a variety of conditions.
For improved clarity to the reader, each section (3.1, 3.2, 3.3) in this chapter are
unique and can be read individually as needed. Each section provides all relevant
background information for the projects described in the later chapters.
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3.1

Longitudinal Perfusion Changes in Diffuse Intrinsic Pontine Glioma in
Response to Therapy
Approximately 20% of all pediatric brainstem tumors are malignant, and diffuse

intrinsic pontine glioma (DIPG) accounts for 80% of these malignant tumors.(98)
Chemotherapy treatment strategies have not produced any survival benefit to children
diagnosed with DIPG.(99) Local fractionated radiotherapy (RT) is the standard treatment
paradigm, but only offers temporary clinical and neurologic improvement.(100)
Therefore, children diagnosed with DIPG have a dismal prognosis with the median
survival rate of less than 1 year.(99) MRI is the standard for diagnosis of DIPG.(101)
However, conventional MR imaging evaluation metrics like tumor size have not provided
significant prognostic value.(102) Poor survival rates of DIPG and nonexistent
prognostic imaging metrics necessitate improved knowledge and treatment options for
children diagnosed with DIPG. Novel treatment strategies and new advanced functional
imaging metrics are necessary not only to improve survival, but also to reduce DIPG
knowledge gaps. The utility of novel functional imaging metrics lies in evaluating
efficacy of treatment strategies and guiding development of future treatment paradigms.
The current understanding of DIPG biology is relatively limited, and the few
DIPG tumor tissue samples collected indicate that these tumors are primarily high-grade
gliomas.(103,104) A characteristic of high-grade gliomas is overexpression of
angiogenesis markers making them one of the most vascularized neoplasms.(105,106)
This is a distinguishing characteristic when compared to low-grade gliomas.
Amplification of vascular endothelial growth factor (VEGF) is a pro-angiogenic pathway
believed to be central to tumor biology.(107,108) DIPG tissue also shows overexpression
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of epidermal growth factor receptor (EGFR), which is a tyrosine kinase receptor that
upon activation initiates several downstream pathways leading to DNA synthesis and
cellular proliferation.(109,110) Small molecule inhibitors of VEGF and EGFR would
represent a new treatment target for DIPG therapy. In addition, novel functional
hemodynamic imaging metrics could be employed longitudinally to measure the high
vascular compartment attributable to the pro-angiogenetic biology of DIPG tumors.
Functional hemodynamic metrics like blood flow and blood volume would not only aid
in evaluating the efficacy of this new inhibitory-targeted therapeutic strategy but will
quantify an important biological characteristic of DIPG tumors.
Vandetanib, an antiangiogenic drug, is a receptor tyrosine kinase inhibitor that
targets VEGF-2 and EGFR. As established above, angiogenesis is a hallmark of highgrade gliomas like DIPG. The neovascularization or new vessels formation to expand the
vascular network is a well-established requirement for tumor growth.(111,112) An
antiangiogenic drug like Vandetanib aimed at reducing or possibly eliminating the
proliferation of the tumor’s vasculature network is a particularly attractive method of
reducing tumor growth. Preclinical models of Vandetanib have shown inhibition of
tumor cell growth.(113-115) Vandetanib is included in a variety of adult clinical cancer
studies including non-small-cell lung carcinoma, breast cancer, and multiple
myeloma.(116-118) Vandetanib is a promising antiangiogenic drug that would represent
a novel treatment option for children diagnosed with DIPG.
Hemodynamic measurements by DSC imaging are showing increasing benefits in
assessing a variety of brain tumor conditions like grading, treatment response prediction,
and likelihood of malignant transformation. Relative CBV measures increased the
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reliability and sensitivity of predicting high-grade versus low-grade glioma.(119) Lowgrade glioma with a longer time to progression was associated with a lower baseline
relative CBV values.(120) Low-grade glioma transformations were associated with an
increase in relative CBV one year before apparent contrast enhancement of the
tumor.(121) Differences in CBF, measured by either DSC or ASL, also differentiate low
and high-grade gliomas.(122) Incorporating a longitudinal hemodynamic analysis of
DIPG has the potential to provide quantitative measurements related to the changing
DIPG biology through treatment and follow-up. It will answer the call to include more
quantitative parameters into DIPG studies.(102)
The details and results of a study investigating the hemodynamic parameters of
DIPG tumor therapy response as a predictive marker of survival is presented in Chapter
4.

3.2

Perfusion Changes in Long-term Pediatric Cancer Survivors
Advances in our understanding of cancer biology and refinements made in

developing effective treatments have greatly improved pediatric cancer survival rates.
Today, five year overall survival across all cancers has improved to over 80% compared
to 58% in the 1970s.(123,124) Unfortunately, as more pediatric cancer survivors are
reaching adulthood, they are accompanied by an increasing rate of late-effect
complications related to their primary treatments. Large spectrums of impairments are
found across a variety of physiological systems and include, but are not limited to,
neurocognitive and cardiopulmonary dysfunction, renal impairment, and secondary
malignancies.(125-127) Primary treatment effects place survivors at a lifelong increased
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risk of disease. One study found, 98% of pediatric cancer survivors had one or more
chronic medical condition and 67% had a severe or life-threatening condition.(126)
These substantial adverse consequences are the result of an increased morbidity burden
which negatively impacts the survivors’ quality of life.(128) The results of these studies
have brought about an increasing emphasis on research to understand the mechanisms of
primary treatment late-effects. The goal is to direct future treatments or intervention
strategies, which will provide a higher quality of life for future pediatric cancer survivors.
Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric cancer and
accounts for approximately 25% of all cancer diagnoses in children younger than 15
years.(129) Survival rates for ALL have steadily improved from 5-10% in the early
1960’s to over 93% today.(130) The addition of central nervous system (CNS)
prophylaxis cranial irradiation therapy contributed significantly to this increased survival.
Unfortunately, ALL predominantly occurs at a time of CNS myelination making that
tissue susceptible to chemical and radiation injury.(131) Recurrent ALL and secondary
neoplasms are a major cause of death in long-term survivors.(132) ALL survivors report
activity limitations, and decreased mental health when compared to sibling controls.(132)
Rates of marriage, college graduation, and employment are also lower, which contribute
to a lower quality of life in ALL survivors.(132)
Hodgkin’s lymphoma (HL) accounts for approximately 6% of pediatric cancers
and is highest in adolescents aged 15 to 19.(129) Historically, HL survival rates are high
and have steadily increased from 81% in 1970’s to more than 94% today.(133)
Treatment for HL consists of thoracic radiation with or without chemotherapy in the form
of anthracyclines or bleomycin. Cardiovascular dysfunction in the form of
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cardiomyopathy, myocardial infarction, and congestive heart failure is associated with
exposure to thoracic radiation and anthracyclines in HL survivors.(134-136) Bleomycin
and thoracic radiation exposure is associated with pulmonary dysfunction.(137)
With our incremental understanding of cancer biology and the development of
effective treatment strategies over the last few decades, more pediatric cancer patients are
surviving into adulthood with the expectation to live a full life. However, the cost of the
primary therapy in achieving the goal of survival has resulted in long lasting adverse
general, physical, and emotional impairments that obstruct the survivors quality of life in
adulthood. This new understanding has shifted our goal of primary survival, to develop
more risk adaptive treatment paradigms and intervention strategies that minimize adverse
late-effects to maximize the survivor’s quality of life. Elucidating mechanisms attributed
to adverse late-effects is an important area of research that is necessary to direct the
development of future treatment protocols. Functional imaging can non-invasively
provide a critical role in developing our understanding of longitudinal biological changes,
which is necessary to achieve the goal of minimizing adverse late-effects and maximizing
quality of life.
Neurocognitive impairments are a particularly devastating sequela of primary
therapy that can have vast repercussion on the survivor’s quality of life. For example,
damage to neural pathways or cortical neuro-networks contributing to executive function
will disrupt complex cognitive tasks related to goal-directed planning, time, inhibition,
self-monitoring, regulation of emotion, and motivation. Impairment in the attention
network limits directed and focused cognitive activities for the duration of a task. This is
an important attribute in maintaining goal-oriented behavior. The daily impediments of
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neurocognitive impairments to survivor quality of life can contribute, as reported in the
ALL survivors, to lower success in achieving some of life major goals like college
graduation, marriage, and employment.(132)
The cranial irradiation in ALL therapy is associated with significantly higher risk of
neurocognitive impairments.(138,139) Increased radiation dose and younger age
correlate with reduced academic performance in core cognitive skills such as attention,
processing speed, and working memory.(140-142) White matter volume loss, which
could reflect a disrupted tissue architecture, has correlated with neurocognitive
impairments in cranial irradiated ALL patients.(143) There is also an increased incidence
of cerebrovascular disease and an elevated risk of stroke from cranial irradiation
therapy.(144,145) While imaging studies in ALL survivors find leukencephalopathy
(146) and white matter volume changes (147) are associated with neurocognitive
impairment, new advanced functional imaging metrics like cerebral hemodynamics have
not been explored as measures of a potential mechanism of neurocognitive impairment.
HL survivors, who are not treated with cranial irradiation therapy, represent a group
not expected to be at risk of neurocognitive impairments. The thoracic radiation and
chemotherapy is known to elevate HL survivor’s risk of cardiovascular and pulmonary
dysfunction. However, evidence was shown in a non-cancer population of an association
between congestive heart failure or cardiovascular dysfunction with neurocognitive
impairment.(148-150) This association supports a recent finding of decreased
performance in sustained attention, short and long-term memory, working memory, and
cognitive fluency in long-term HL survivors.(151) MR imaging in the HL survivor also
revealed leukoencephalophy and evidence of cerebrovascular injury.(151) Again, new
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advanced functional imaging metrics like cerebral hemodynamics could be used to
explore the association of cardiovascular dysfunction and neurocognitive impairment in
HL survivors.
Perfusion changes associated with neurocognitive performance have not been
investigated in cancer survivors who are known to have an increased risk of
neurocognitive impairment. ASL has measured different regional patterns of
hypoperfusion in the frontal cortex, partial, and occipital lobes that correlate with mild
cognitive impairment (MCI) and Alzheimer disease (AD).(152,153) There is further
evidence that perfusion changes measured by ASL are as reliable as 15(O)-water PET
measurements in MCI and AD patients.(154) The researchers conclude that the noninvasive ASL method would be a reliable alternative to the traditional invasive 15(O)water PET to examine the pathophysiological changes in MCI and AD patients.(154)
ASL successes in measuring a hematological biomarker in the neurological disease of
AD illustrate the potential of ASL to detect new biomarkers of other neurological
diseases. We plan to investigate whether hematological changes in the brain correlate
with neurocognitive impairments in two different groups of long-term cancer survivors
with ASL.
This exploratory study’s primary focus is investigating the relationship between
altered hemodynamics and neurological impairments in long-term pediatric cancer
survivors. The details and results are presented in chapter 5.
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3.3

Hemodynamic Changes in Sickle Cell Disease
Sickle cell disease (SCD) is an autosomal recessive red blood cell disorder. SCD

occurs in approximately one in 500 African-American births and one in 12 AfricanAmericans carry the sickle cell trait.(155) The most common form, hemoglobin S (HbS),
is a point mutation in the beta globin gene where valine is substituted for glutamic acid at
the sixth amino acid position.(156) In the doexyhemoglobin form, the poorly soluble
HbS polymerizes, forming elongated rope-like fibers that give rise to the classic crescent
or sickle shape of the red blood cell (RBC).(157) Polymerized hemoglobin increases the
sickle RBCs stiffness and creates a poorly deformable cell. In the small vessel
circulation, sickle RBCs are prone to vaso-occlusion that results in tissue ischemia.
Additionally in SCD, the pathophysiology of vaso-occlusion is further increased due to
vascular injury from increased endothelial interaction of erythrocytes and inflammatory
cells.(158) Tissue damage that occurs from these vaso-occlusive events is a source of
morbidity in SCD and result in serious life-long complications like pain crises, acute
chest syndrome, renal dysfunction, and retinopathy.(159-162)
The most devastating complication of SCD is ischemic or hemorrhagic
stroke.(163) An ischemic stroke will occur in 37% of SCD patients by the age of 14 and
an overt stroke in 11% by the age of 20.(163) The high incidence of stroke in SCD
patients requires the establishment of new monitoring strategies that can accurately
identify SCD patients at risk of stroke. Functional hemodynamic measures by MRI could
aid in establishing defining biomarkers of stroke risk in SCD. In addition, these
measurements would improve our knowledge of how SCD disrupts normal cerebral
hemodynamics, which could contribute to our understanding of the observed decreased
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neurocognitive performance. Areas of attention, executive function, and intelligence are
especially pertinent in the SCD population.(164,165)
As described in Chapter 2.7, SWI is a 3D, high resolution, fully velocity
compensated, T2* weighted GRE technique that creates contrast in the image by
exploiting the difference in various tissues magnetic susceptibility.(75,76) The cerebral
venous system is visualized in SWI by exploiting the magnetic susceptibilities difference
between paramagnetic deoxyhemoglobin and the adjacent diamagnetic oxygenated
tissues. SWI is also sensitive to other substance like iron and calcium. As a result, SWI
is emerging as an important technique for imaging the cerebrovascular system and has
shown clinical utility in multiple areas including imaging stroke, multiple sclerosis, and
tumors.(166,167)
Unfortunately, there are still considerable gaps in our understanding of how
cerebral hemodynamics pathophysiology is altered in SCD. Research designed to
investigate alterations of cerebral hemodynamics versus SCD severity may improve
stroke risk stratification and help determine action mechanisms that contribute to chronic
SCD morbidities. Our current knowledge of SCD hemodynamics is that an abnormally
high transcranial Doppler ultrasonographic (TCD) blood velocity identifies SCD patients
at risk of stroke.(168) Significantly higher gray matter perfusion is also measured in
SCD patients compared to healthy controls.(169,170) Cerebral autoregulation of CBF
and arterial oxygen concentrations (CaO2) is well established.(171) CBF is elevated in
response to decreases in CaO2. The chronic hemolytic anemia, which decreases the
oxygen carrying capacity of arterial blood, could contribute to the decreased CaO2.
However, more studies are necessary to investigate the pathophysiological changes that
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result in altered CBF. These missing pieces of information are critical in determine
disease severity and evaluating therapeutic response. However, less is known about how
SCD pathophysiology alters other hemodynamic-based image contrast such as SWI.
The appearance of veins in SWI is the result of magnetic susceptibility effects
from the concentrated deoxyhemoglobin. Hence, physiological conditions that alter
deoxyhemoglobin concentration should vary the venous contrast. For example, the
hypoperfused tissue in an ischemic stroke increases the deoxyhemoglobin concentration
and thereby increases the venous conspicuity.(172) In contrast, hyperperfused tissue
decreases deoxyhemoglobin concentration and decreases venous conspicuity. This blood
oxygen level-dependent (BOLD) venous contrast in SWI has been demonstrated in a
series of experiments using caffeine and carbogen gas to alter the subject’s
CBF.(173,174) However, changes in SWI venous contrast has not been thoroughly
studied in SCD. Investigating how SWI venous contrast is modulated in relation to SCD
physiology could provide a new contrast mechanism for investigating stroke risk and
disease severity in this population. An important advantage in investigating SWI venous
contrast is the vast distribution of veins throughout the brain. Therefore, physiological
information is collected throughout the brain and any locally varying venous contrast will
represents territorial changes in physiology.
Chapters 6 and 7 present studies of SWI venous contrast in SCD patients.
Chapter 6 investigates SWI venous contrast in SCD patients and healthy controls and
examines if common hematologic variables correlate with venous contrast. Chapter 7 is a
continuation of the work presented in chapter 6. The work in chapter 7 presents a novel
post-processing framework to improve the accuracy of venous segmentation results
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presented in chapter 6. Chapter 8 presents a clinical study using MR to measure blood
velocities in major intracranial vessel of SCD patients. The MR blood velocities are
compared to the blood velocities measured by TCD ultrasound.
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MR IMAGING ASSESSMENT OF TUMOR PERFUSION AND 3D SEGMENTED
VOLUME AT BASELINE, DURING TREATMENT, AND AT TUMOR
PROGRESSION IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE
INTRINSIC PONTINE GLIOMA

4.1

Introduction
Children with DIPG continue to have a very poor prognosis, with a median

survival rate of less than 1 year.(99,175) Standard therapy consists of conventionally
fractionated RT, which only temporarily improves the patients’ clinical and neurologic
status. The use of chemotherapy has shown no benefit in children with DIPG. The
overall outcome of DIPG remains poor.(99) In a phase I clinical study (NCT00472017)
conducted at our institution, vandetanib (Caprelsa; AstraZeneca, Macclesfield, United
Kingdom), a vascular endothelial growth factor receptor 2 and an epidermal growth
factor receptor inhibitor, was given orally in conjunction with standard RT to children
with newly diagnosed DIPG.(176) To better understand the mechanisms of tumor
growth, such as vascular proliferation, and response to therapy, we used advanced
functional and anatomic MR imaging techniques to closely monitor tumor response and
progression during this study.
An earlier imaging study of children with DIPG found no prognostic significance
of conventional MR imaging assessment but suggested that quantitative parameters of
advanced MR imaging techniques may serve as surrogate markers for therapy response
and prognosis.(102) Therefore, the objective of our prospective imaging study was to
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evaluate tumor perfusion, tumor blood volume, and high-resolution 3D segmented tumor
volume as potential predictive markers for treatment response and tumor progression in
children with newly diagnosed DIPG.

4.2

Materials and Methods

4.2.1

Phase 1 Clinical Study
The imaging study was conducted between June 2007 and August 2010 at our

institution.(176) A total of 35 patients (15 boys, 20 girls; median age, 6 years; age range,
2–16 years) with newly diagnosed DIPG were enrolled. The maximal tolerated dose of
vandetanib was determined by escalating dosage levels of 50 (n=3), 65 (n=3), 85 (n = 3),
110 (n = 16), and 145 (n = 10) mg/m2 per day.Vandetanib was administered orally once
daily and was continued for up to 2 years. Conformal RT was given in 1.8-Gy fractions 5
days a week for 6 weeks, for a total dose of 54 Gy to the planned target volume.
Treatment with vandetanib and RT started on the same day. Corticosteroids were
administered as necessary on an individual basis to control symptoms related to edema
and mass effect, with the goal of discontinuing use when clinically applicable. The
outcome of patients enrolled in the phase I study remained poor, with a 1-year OS of
37.5% ± 10.5% and a 2-year OS of 21.4% ± 11%. Only 2 patients remain alive, with 1
patient free of progression 58 months after diagnosis.(176)
The institutional review board approved this protocol before initial patient
enrollment, and continuing approval was maintained throughout the study. Written
informed consent for participation was obtained from the parents or legal guardians of the
patients, and assents were obtained when appropriate.
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4.2.2

MR Imaging
MR imaging was scheduled at baseline (within 2 weeks before initiation of RT

and vandetanib), 7 ± 3 days after the start of RT, and at the middle (week 3) and end of
RT (week 6). Follow-up MR imaging examinations were assessed every other month
after RT until the patient was taken off the study. Most patients were sedated during MR
imaging. To account for the effect of sedation (177), diastolic blood pressure and etCO2
levels were recorded during MR imaging perfusion scans. MR examinations were
performed mostly on a 3T Trio MR imaging scanner (Siemens, Erlangen, Germany).
Because of relocation of the 3T MR imaging scanner during the study period, 3 patients
mainly underwent MR examinations on a 1.5T Avanto MR imaging scanner (Siemens)
because their baseline examination was performed at 1.5T. Eight patients received 1 or 2
midtime course examinations on the 1.5T scanner for the same reason. For longitudinal
data uniformity, the 1.5T examinations were later removed from the data analysis. At
each imaging time point, tumor perfusion was measured by use of both ASL and DSCPWI. Tumor blood volume was also assessed by DSC-PWI. Tumor volume was
evaluated on a T2-weighted high-resolution whole-brain 3D dataset acquired by a T2weighted 3D turbo spin-echo sequence with variable flip angles (178), with a TR of 3000
ms and a TE of 345 ms. Automatic segmentation (179) of gray matter and WM was
conducted on a T1-weighted high-resolution whole-brain 3D dataset acquired by
magnetization-prepared rapid acquisition of gradient echo (180), with a TE of 2.44 ms;
TI, 900 ms; and TR, 1920 ms.
First, perfusion imaging was performed by use of a pulsed ASL (71) sequence
with an EPI readout consisting of 11 ascending sections with the following parameters:
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TR, 2280 ms; TE, 23 ms; matrix, 64 Χ 64; field of view, 210 Χ 210 mm2; 5-mm section
thickness with 1-mm gap; and inversion times, 700 ms for TI1 and 1400 ms for TI2. A
total of 50 label-control pairs and a spin attenuation map were collected and corrected for
motion.(181) Second, perfusion imaging was performed by use of DSC-PWI. Dynamic
T2*-weighted images were acquired by EPI with 11 interleaved sections with the
following parameters: TR, 1800 ms; TE, 28 ms; acquisition matrix, 64 Χ 64, interpolated
by k-space zero-filling to 128 Χ 128; field of view, 210 Χ 210 mm2; and 5-mm section
thickness with a 1-mm gap. The EPI readout was repeated 90 times to image the first
pass of the contrast agent bolus. DSC-PWI sections were positioned to anatomically
coincide with ASL imaging sections. Baseline images were acquired for approximately
30 seconds, followed by a rapid intravenous bolus injection of 1-mL/kg gadopentetate
dimeglumine (Magnevist, Berlex; Bayer HealthCare Pharmaceuticals, Wayne, New
Jersey) with a power injector at a rate of 0.8-1.0 mL/s (depending on the peripheral
venous catheter size), followed immediately by a 20-mL saline flush at the same rate.
Approximately 5 minutes before the DSC-PWI measurement, the extravascular space of
the tumor was presaturated with the same 1-mL/kg gadopentetate dimeglumine dose to
minimize potential compromising effects of a rapidly extravasating contrast agent.(182)

4.2.3

Image Postprocessing
ASL images were bicubically interpolated to a matrix size of 128 Χ128 to match

the DSC-PWI images, and absolute ASL-CBF maps were calculated according to a
previously reported method and were adjusted for intersection acquisition delays.(183)
The first-pass DSC-PWI data were processed by use of the PWI Task Card for SyngoMR
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(Athinoula A. Martinos Center, Massachusetts General Hospital, Boston, Massachusetts)
by selection of a global arterial input from the middle cerebral arteries and calculation of
perfusion and blood volume maps.(184,185) Ratios of CBF and CBV were calculated
between the median values of the 3D segmented tumor region of interest and the normalappearing WM region of interest resulting from automated tissue segmentation. The
mean ASL and DSC-PWI images, T1WI and T2WI, were coregistered by use of FLIRT
(186) (FMRIB Software Library; www.fmrib.ox.ac.uk/fsl). The tumor, defined as T2
hyperintense, was then manually segmented from the 3D high-resolution T2-weighted
image. Applying the tumor region of interest as an exclusion mask, we automatically
segmented the T1-weighted images by using FAST (179) (FMRIB Software Library),
generating 3D regions of interest of gray matter, WM, and CSF. We then transformed
the tumor, gray matter, and WM regions of interest to the spatial resolution of DSC-PWI
and interpolated ASL data, thereby facilitating size-matched tumor and tissue region-ofinterest evaluation.

4.2.4

Statistical Analysis
The change in tumor perfusion and 3D volume from baseline to post-RT was

investigated with use of the Wilcoxon signed-rank test. The changes in tumor perfusion
and 3D volume were analyzed by 2 separate mixed-effects models: one from baseline to
the end of RT and another from the end of RT to the end of study. We investigated the
association between tumor volume and perfusion in a cross-sectional manner at each
scheduled MR time point by using Spearman rank correlation (baseline and weeks 1, 3, 6,
16, 24, and 26+ from the start of therapy).
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The association of tumor perfusion and volume with PFS and OS were
investigated by use of Cox proportional hazards models. PFS was defined as the time
from the start of therapy to the date of tumor progression or death, and OS was defined as
the time from the start of therapy to death. Patients who did not have an event for PFS or
OS were censored at their last follow-up dates. For a given variable of interest, the Cox
survival model included the baseline assessment and the change during RT as fixed
covariates, and the change following RT as a time-dependent covariate. To increase the
usefulness of the ASL method, which measured perfusion values close to its noise levels
in the image, we categorized tumor ASL-CBF values into 5 groups: group 1 (below
sensitivity: ASL-CBF <10 mL/min/100 g), group 2 (comparable with WM: ASL-CBF 10
to < 30 mL/min/100 g), group 3 (between gray matter and WM: ASL-CBF 30 to < 50
mL/min/100 g), group 4 (comparable with gray matter: ASL-CBF 50 to <70 mL/min/100
g), and group 5 (above gray matter: ASL-CBF >70 mL/min/100 g).
To account for the effect of sedation (177), we studied the associations of tumor
perfusion with physiologic measures of etCO2 and diastolic blood pressure in a crosssectional fashion by using Spearman rank correlation coefficients and in a longitudinal
fashion by using mixed-effects models.
Given the exploratory nature of these studies, the P values were not adjusted for
multiple testing, and the findings must be considered in a hypothesis-generating context.

4.3

Results
Of the 35 patients enrolled in the study, 2 patients had shunts, which caused

image artifacts and compromised quantitative MR imaging perfusion measurements.
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These patients were excluded from the analysis. Overall, 205 MR examinations from 33
patients were processed, of which 28 scans were acquired at 1.5T and were therefore
removed from the final analysis to maintain standardization of image data acquisition.
Three patients who had mainly 1.5T examinations were removed completely. Of the
remaining 30 patients, 175 3T MR examinations were analyzed. There were 3 patients
with 8 examinations each, 8 patients with 7 examinations, 10 patients with 6
examinations, 4 patients with 5 examinations, 2 patients with 4 examinations, 1 patient
with 3 examinations, and 2 patients with 2 examinations. Of the remaining 30 patients,
29 had a baseline scan and at least 1 on-treatment scan, and 22 patients had a baseline
scan and an immediate post-RT scan; thus, pre-RT vs post-RT comparisons were only
possible for this cohort of 22 patients.

4.3.1

MR Imaging
Qualitative image assessment showed a bright tumor signal in T2-weighted

images at baseline, which decreased during the end of RT, accompanied by a decrease in
3D tumor volume (Figure 4-1, row A). After RT, the T2-weighted signal of the tumor
became hyperintense again, and the tumor volume also increased. The analyzed tumor
region of interest outlined in red on the T2-weighted image was transformed to the
perfusion maps outlined in white (Figure 4-1, rows B-D).
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Figure 4-1
T2-weighted image with outlined tumor region of interest (row A) and
corresponding maps of CBF (row B), CBV (row C), and ASL-CBF (row D, color bar of
ASL-CBF is given in absolute units of milliliters per minute per 100-g tissue) of different
time points during therapy. The course of therapy and time points of the images are
depicted at the bottom. Changes of tumor tissue appearing in T2-weighted images and
changes in tumor perfusion can be seen.

Median changes in tumor CBF, CBV, and ASL-CBF plotted as time progressed
showed a distinct elevated tumor perfusion immediately after RT (Figure 4-2, box plots).
Wilcoxon signed-rank tests revealed that these increases in tumor ASL-CBF (P = .006),
CBF (P < .0001), and CBV (P < .0001) were statistically significant (TABLE 4-1). On
the contrary, there was a significant decrease (P < .0001) in 3D tumor volume between
baseline and the immediate post-RT scan (TABLE 4-1).
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Figure 4-2 Time course of ASL-CBF (A), CBF (B), CBV (C), and tumor volume (D)
during and after RT. Beginning and end of RT are marked by dotted straight gray lines at
time points 0 and 1.4 months. Red bold dashed curves indicate the time trend of the most
statistically significant linear or quadratic model. Solid lines denote individual time
course of each patient and patients who used steroids after RT are marked in blue. Box
plots were overlaid to highlight the distribution of values at each time point.
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TABLE 4-1 Baseline and immediate post-RT parameters compared by the Wilcoxon
signed-rank test
Baseline (n = 29)a

Post RT (n = 22)a

Difference (n = 22)a

P Value

ASL-CBF/mL/min/100-g
tissue

11.9/22.2/29.1

11.7/37.8/78.7

-45.6/ 32.7 /50.9

.006b

CBF

0.67/0.82/0.88

0.63/1.04/1.24

0.14/0.29/0.48

<.0001b

CBV

0.55/0.71/0.79

0.74/0.92/1.10

0.1/0.26/0.46

<.0001b

21.07/23.1/34.44

10.13/16.24/27.33

-15.4/ -10.13 /-6.02

<.0001b

Tumor volume/mL
a
b

Values represent the ﬁrst quartile, median (in bold), and third quartile, respectively.
Signiﬁcant at P = .05.

To evaluate the changes of tumor parameters with time during treatment and
follow-up, we constructed 2 separate mixed-effects models for all time points before the
end of RT (baseline and during RT) and after RT. The combined average fit of these 2
models is illustrated in Figure 4-2 by the dashed red lines. Details of the models are
presented in TABLE 4-2. Our model suggested a quadratic behavior (P < .0001) for
tumor ASL-CBF during RT: it first decreased and then increased during RT, followed by
a gradual linear decline after RT (P = .0002). Tumor volume, on the contrary, showed an
opposite trend: it had a nonlinear decline during RT (P = .0001) and then a gradual
nonlinear increase after RT (P = .0002). Both CBF and CBV linearly increased during
RT (P = .0003 and P = .0001, respectively), followed by a gradual linear decrease (P =
.0015 and P = .0035, respectively) after RT. A cross-sectional Spearman rank correlation
analysis between tumor perfusion and tumor volume showed no convincing overall
association of tumor perfusion with tumor volume, except for a suggestive positive
correlation between CBF and tumor volume at the end of RT (TABLE 4-3).
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TABLE 4-2 Results of linear and quadratic mixed-effects models of parameter
changes with time evaluated for time points during
During RT
Tumor Parameter

Model

Variable

Estimate

P Value

Estimate

P Value

ASL-CBF

Linear

Time

19.2

.0009a

-4.5

.0002a

Quadratic

Time

-24.5

.012

-4.6

0.16

Time2

39.1

<.0001b

-0.01

0.97

-0.033

.0015a

CBF

CBV

Tumor volume

a
b

After RT

Linear

Time

0.17

.0003a

Quadratic

Time

0.05

.49

-0.07

.0185

Time2

0.11

.036

0.004

.17

Linear

Time

0.169

.0001a

-0.028

.0035a

Quadratic

Time

0.146

.0326

-0.076

.06

Time2

0.019

.70

0.005

.23

1.40

.0011a

Linear

Time

-6.17

.0001a

Quadratic

Time

-1.09

.45

-1.98

.0037a

Time2

-4.44

.0001b

0.40

.0002b

Values represent significant linear estimates at P = .05.
Values represent significant quadratic estimates at P = .05.

TABLE 4-3 Spearman rank correlation coefficients (ρ) in a cross-sectional analysis
of association of tumor volume with tumor perfusion variables CBF and ASL-CBF
Tumor Volume
CBF
ASL-CBF
Time Point
ρ
P Value
ρ
P Value
-0.31
.11
-0.12
.57
Week 0 (RT starts)
-0.23
.25
-0.03
.87
Week 1
0.11
.57
0.07
.74
Week 3
a
a
0.52
.012
0.3
.18
Week 6 (RT ends)
0.22
.31
0.2
.38
Week 16
0.06
.80
0.02
.92
Week 24
-0.16
.47
-0.21
.32
Week 26+
a
Significant at P = .05.
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4.3.2

Survival Analysis
Survival analysis on the basis of Cox proportional hazards models showed no

significant association of vandetanib dose, age at diagnosis, or sex with PFS (P values =
.065, .10, and .075, respectively), or with OS (P values = .125, .18, and .11, respectively).
Cox model results for the association of categorized ASL-CBF, CBF, CBV, and tumor
volume with PFS and OS are presented in TABLE 4-4. These multivariable survival
models suggest that patients with higher CBF at baseline have longer PFS (P = .0061 and
P = .011 for categorized ASL-CBF and CBF, respectively), keeping the other covariates
in the model fixed. Also, patients with higher increase in CBF during RT had more
favorable PFS than those who had lower increase or decrease in CBF during RT (P =
.044 and P = .0057 for categorized ASL-CBF and CBF, respectively), keeping the other
covariates fixed. After RT, categorized ASL-CBF and CBF were both positively
associated with a more favorable PFS (P = .0034 and P = .001, respectively). Keeping
the other covariates fixed, patients with a steeper decline in tumor perfusion had shorter
PFS on average, whereas patients with slower decline or an incline in CBF had more
favorable PFS on average.
In addition, larger tumor volumes at baseline were associated with more favorable
PFS (P = .013) than smaller tumor volumes, likely because larger tumors at baseline
tended to have better RT response (Spearman rank correlation of 0.61 with P < .001,
comparing pre-RT and immediately post-RT tumor volume measurements). Patients
with smaller decline or increase in tumor volume during RT had less favorable PFS (P =
.019) than those with a greater decline in tumor volume. As expected, an increase in
tumor volume after RT led to earlier progression overall (P < .0001). The multivariable
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models did not indicate any statistical association of changes in the CBV of the tumor
with PFS or OS.
None of the tumor volume or CBF measurements at baseline, during RT, or postRT was significantly associated with OS. However, CBF indicated that patients with
higher tumor perfusion at baseline had slightly more favorable OS (P = .041) (TABLE
4-4) than patients with lower tumor perfusion at baseline.
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TABLE 4-4 Cox proportional hazard ratios and P values of PFS and OS associated
with tumor parameters at baseline and their change during RT as fixed covariates
and after RT as time dependent covariates relative to baseline
Tumor Parameter
PFS
OS
a
Categorized ASL-CBF
No. of events
22
21
b
Baseline (Pre-RT)
.38 (.0061)
.68 (.165)
.67 (.044)b

Change during RT (Post-RT–Pre-RT)

b

Change after RT (time-dependent)
CBF
No. of events
Baseline (Pre-RT)
Change during RT (Post-RT–Pre-RT)
Change after RT (time-dependent)
CBV
No. of events
Baseline (Pre-RT)
Change during RT (Post-RT–Pre-RT)
Change after RT (time-dependent)
Tumor volume
No. of events
Baseline (Pre-RT)
Change during RT (Post-RT–Pre-RT)

.76 (.14)

.46 (.0034)

.74 (.22)

22
.004 (.011)b

21
.46 (.041)b

.024 (.0057)b

.63 (.64)

b

.95 (.001)

.99 (.33)

22
.04 (.074)
.72 (.32)
.98 (.064)

21
.13 (.28)
.45 (.50)
.997 (.82)

28
.944 (.013)b

27
.986 (.45)

1.29 (.019)b

1.046 (.24)

Change after RT (time-dependent)
1.06 (< .0001)b
1.01 (.068)
Note:—For ASL-CBF, CBF, and CBV, and tumor volume readings, cell content is
hazard ratio (P value).
a
Because of their high variability, ASL-CBF values were categorized as described in the
Materials and Methods section.
b
Values represent a significant association of the tumor parameter with PFS or OS at
P = .05.

4.3.3

Sedation Effects
Cross-sectional analysis of the association between tumor perfusion and

physiologic measures evaluated to account for the effect of sedation (177) did not reveal
a significant correlation, except for etCO2 and ASL-CBF at week 3 (P = .017) (TABLE
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4-5). Longitudinal post-RT evaluations by the mixed-effects models showed some
evidence that etCO2 is associated with ASL-CBF (P = .03). ASL-CBF changes pre-RT to
post-RT were not associated with changes in etCO2 during RT (Spearman rank
correlation of 0.23 with P = .32).

TABLE 4-5 Spearman rank correlation coefficients (ρ) in a cross-sectional analysis
of association of diastolic blood pressure and etCO2 with tumor perfusion variables
Diastolic
BP
-.20 (.32)

CBV
Exhaled
CO2
.16 (.41)

Diastolic
BP
-.22 (.27)

CBF
Exhaled
CO2
.22 (.27)

1

.04 (.87)

-.10 (.66)

.15 (.52)

.11 (.63)

-.10 (.70)

.41 (.088)

3

.16 (.46)

-.02 (.94)

-.01 (.96)

.02 (.92)

- .39 (.09)

.52 (.017)a

6 (RT ends)

.23 (.30)

-.41 (.052)

.22 (.32)

-.30 (.16)

-.04 (.85)

.03 (.91)

16

-.09 (.70)

.23 (.32)

-.23 (.31)

.24 (.31)

-.10 (.68)

.13 (.60)

24

.16 (.51)

.25 (.29)

-.13 (.60)

.11 (.65)

-.32 (.23)

.29 (.28)

26+

.13 (.57)

-.17 (.47)

-.03 (.91)

.07 (.76)

.16 (.48)

.32 (.16)

No. of
Weeks
0 (RT starts)

a

ASL-CBF
Diastolic
Exhaled
BP
CO2
-.11 (.61)
.38 (.072)

Significant at P = .05.

4.4

Discussion
Because the overall outcome of DIPGs remains poor, the development of novel

treatment strategies and advanced imaging markers to adequately monitor clinical trials is
of high importance. To better understand the mechanisms of tumor growth, such as
vascular proliferation, and their response to therapy, we closely monitored tumor
perfusion and tumor volume of patients with newly diagnosed DIPGs treated with
combined conventionally fractionated conformal radiation and antiangiogenic therapy.
We found an increase in median tumor perfusion and blood volume and a
decrease in tumor volume at the end of RT. After RT, the elevated tumor perfusion and
blood volume steadily decreased with time, with tumor volume increasing concurrently.
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The observed quadratic time dependency of ASL-CBF during RT, as opposed to the
linear time dependency of DSC-CBF, may be caused by the different measures of
absolute quantitative tumor perfusion by ASL and the relative quantitative ratio between
tumor and WM perfusion by DSC. As expected, there was a significant association of
decreased tumor volume during RT and maintenance of low tumor volumes thereafter
with longer PFS, which demonstrates that tumor volume is still an important determinant
in the evaluation of treatment response. Also, in our study progression was based on
tumor size (187), which was assessed during the regular reading of conventional axial
and sagittal 2D MR imaging by pediatric neuroradiologists, if the product of the maximal
perpendicular diameters of the tumor increased by more than 25% compared with
baseline. The association of larger tumor volumes at baseline with longer PFS in our
study agrees with findings of the Pediatric Brain Tumor Consortium (188), which may be
because larger tumors at baseline showed a higher decrease in tumor volume at the end of
RT, indicating a better response to therapy. Poussaint et al (188) suggested that these
larger tumors at baseline may represent less aggressive neoplasm because they were
allowed to slowly grow to a larger size before clinical detection. The absence of
association between 3D tumor volume and OS is in agreement with previous studies on
DIPG.(102)
We found no direct association between tumor perfusion and 3D tumor volume;
therefore, the known interdependency among tumor size, tumor interstitial pressure, and
tumor perfusion may not explain our observations.(189,190) However, the confined
localization of the tumor may confound the correlation analysis between tumor volume
and perfusion. The qualitatively observed decrease in the T2-weighted tumor signal
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(Figure 4-1) may suggest that diffusion imaging would be useful in elucidating if changes
in tumor perfusion are secondary effects of changes of edema and, therefore, interstitial
pressure in the tumor.(7)
Patients who had higher tumor perfusion had longer PFS than those who had
lower tumor perfusion. This association was also found for OS and CBF at baseline.
These results suggest that tumor perfusion may be a useful prognostic factor for
progression and outcome in DIPG treated with RT and vandetanib. Our findings are
consistent with those of a recent study showing increased survival duration in patients
with glioblastoma who respond to antiangiogenic therapy with elevated blood
perfusion.(191) However, because we did not have a control group in our phase I study
and the natural perfusion history of this tumor is not known, we are not able to determine
whether this observation of increased perfusion with longer PFS and OS was a result of
the antiangiogenic therapy (7), RT alone, or the combination of these 2 treatments.
Furthermore, these results could also have been found to be very different for patients
receiving RT only or for untreated patient cohorts. Nevertheless, we are very confident
that our findings are a true effect of therapy because increased tumor perfusion coincides
with the onset of treatment and the decrease in tumor volume.
The median CBV ratio of the whole tumor region of interest was not significantly
associated with PFS or OS. The measured CBV ratio was less than or approximately 1,
in contrast to a CBV of more than 1.75 observed in high-grade gliomas, which was a
prognostic factor of poor outcome.(192) A recent study recommending the use of DSCPWI imaging in DIPG showed that increased blood volume at baseline or on follow-up
examinations was associated with reduced survival duration.(193) However, in our study
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blood volume was used as a continuous variable, but Hipp et al (193) evaluated blood
volume as a binary variable with increase or decrease in blood volume as the 2 values. In
another study, small distinct areas of focal anaplasia within DIPG were identified and
were characterized by a higher CBV than that of the rest of the tumor.(194) Therefore,
data evaluation in the future should investigate the heterogeneity (195) of CBV values
inside the whole tumor region of interest or in specific subregions of the tumor to test for
its potential prognostic value.
To account for the confounding effect of etCO2 on cerebral perfusion in sedated,
spontaneously breathing patients (177), etCO2 levels were recorded during perfusion
imaging. Cross-sectional analysis revealed a positive association of etCO2 and ASL-CBF
for the first 3 time points (baseline, week 1, and week 3), and a longitudinal analysis after
RT also found a significant association between etCO2 and ASL-CBF. However, this
association was not observed in relative CBF (DSC-PWI), which suggests that the
vasodilative effect of CO2 may have a similar effect on both DIPG and WM perfusion.
Thus, relative perfusion measures are not as sensitive with respect to the systemic effect
of CO2. Because of the similarities in the longitudinal trends of tumor perfusion
measured by both ASL and DSC-PWI, we believe that our findings for ASL-CBF with
PFS and OS are still meaningful and are not compromised by etCO2. Nevertheless,
future studies should try to maintain a fixed etCO2 level during perfusion measurement to
avoid this potentially confounding factor.
A potential limitation of our study was the use of steroids, which were given on
an individual basis and were not recorded in detail during the study. In retrospect, we
could only identify patients who used steroids at 1 point after RT; these patients are
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indicated with asterisks and blue lines in Figure 4-2. Therefore, use and dosage of
steroids as a possible confounding factor could not be assessed in our analysis. Future
studies should investigate the use of steroids in the evaluation of tumor characteristics.
Furthermore, our EPI-ASL technique had low signal-to-noise ratio and was prone to
artifacts from field inhomogeneities in the area of the brain stem. Therefore, the use of
more advanced and robust ASL techniques such as 3D-GRASE-ASL (196) with
background suppression or Q2WISE (197) is recommended in future studies. The DSCPWI calculation used a global arterial input that was selected from the MCA far away
from the location of the tumor. Newer techniques that use a local arterial input that
closely resembles a pontine arterial input function could improve the reliability of CBF
and CBV measurements.(198) To increase the prognostic usefulness of tumor perfusion,
both diffusion and perfusion measurement should be made in conjunction to differentiate
the possible effects of tumor edema. Furthermore, because of the long period in which
the study was performed (ie, relocation of MR scanners), data standardization and
consistency were of particular interest and may have been potential limitations of our
study.
Because of the relocation of the 3T scanner during our study period, some
examinations were performed at 1.5T and were removed from the statistical analysis to
eliminate any potential confounding factors arising from different field strength. This
exclusion criterion also removed 3 patients who had mainly 1.5T examinations. Eight
other patients had a mixture of 1.5T and 3T examinations. We chose to keep the 3T
examinations of those 8 patients in the statistical analysis because the examinations are
independent of each other, and all 8 patients had 3T examinations at baseline. The
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removal of these 8 patients would have led to an overall sample size that would have
been too limiting for our longitudinal and survival models.

4.5

Conclusions
Our results suggest that tumor perfusion may be a useful predictive marker for the

assessment of treatment response and tumor progression in children with DIPG treated
with RT and vandetanib. The assessment of tumor perfusion yielded valuable
information about the tumor’s microvascular status and its response to therapy, which
may help to better understand the biology of DIPGs and monitor novel treatment
strategies in the future.
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Chapter 5
GRAY MATTER PERFUSION AND ITS ASSOCIATION WITH
NEUROCOGNITIVE PERFORMANCE TO EVALUATE LATE EFFECTS OF
CANCER TREATMENT

5.1

Introduction
Advances in cancer treatment have greatly improved survival rates for patients

with acute lymphoblastic leukemia (ALL) from 5% to 10% in the early 1960s to more
than 93% today.(130) Central nervous system (CNS) prophylactic therapy has
contributed greatly to this improved survival. However, several late effects are
associated with CNS prophylactic cranial radiation or intrathecal or high-dose
intravenous antimetabolite chemotherapy. Compared with sibling controls, children
treated with cranial radiation therapy (CRT) for ALL are at increased risk of developing
CNS infarcts as they age, as are long-term survivors of Hodgkin lymphoma
(HL).(151,199) Also, adult survivors of ALL and HL are at risk for neurocognitive
impairment.(151) With the increasing number of survivors of childhood cancer reaching
adulthood, understanding CNS-related consequences of the original therapy is important
to improve the quality of life for these survivors.
Arterial spin labeling (ASL) is a noninvasive magnetic resonance imaging (MRI)
technique to measure cerebral blood flow (CBF). Quantitative perfusion results acquired
through ASL are similar to those by H215O positron emission tomography
(PET)(200,201) but without the need for radiation exposure. The coupling of perfusion
and metabolism (202,203) suggests that ASL can be used as a functional marker of
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cerebral health. For patients with Alzheimer disease, perfusion measurements from ASL
have correlated with those from PET (154,204) and revealed regional patterns of
hypoperfusion that are associated with mild cognitive impairment.(152,153,205-208)
These studies illustrate the potential of ASL to noninvasively identify perfusion deficits,
which could serve as a biomarker of disease.
The patterns of perfusion changes associated with neurocognitive performance
have not been investigated in cancer survivors who are at increased risk of
neurocognitive impairment.(151,209) Previous neuroimaging studies on neurocognitive
late effects primarily focused on changes in fractional anisotropy or tissue atrophy
(146,210) but did not analyze long-term perfusion insults from CRT and chemotherapy.
Herein, we performed imaging studies on long-term adult survivors of childhood ALL
and HL to determine the association between gray matter (GM) perfusion assessed by
ASL and functional performance measured through neurocognitive testing. Our aim was
to identify areas of association between neurocognitive performance and perfusion in
order to elucidate the underlying pathophysiology of neurocognitive late effects of cancer
treatment.

5.1
5.1.1

Patients and Methods
Patients
Participants included childhood survivors of ALL and HL who were enrolled in

the St. Jude Lifetime Cohort (SJLIFE) study.(211) Inclusion criteria for SJLIFE were
treatment at St. Jude Children’s Research Hospital for the childhood malignancy, age ≥18
years, and ≥10 years from date of diagnosis. Exclusion criteria included relapse or
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diagnosis of a second malignancy or presence of a neurologic event unrelated to the
malignancy. Participants underwent a complete neurocognitive evaluation with a
certified examiner and an MRI exam that included ASL. The study was approved by the
institutional review board, and all participants provided informed written consent.

5.1.1

Neurocognitive Testing
Neurocognitive testing methods and results of the SJLIFE study have been

published.(151,210) Briefly, cancer survivors completed standard neurocognitive
assessment of the following domains (and instruments): intelligence (Wechsler
Abbreviated Scale of Intelligence);(212) memory (California Verbal Learning TestII);(213) processing speed (Grooved Pegboard, Stroop Color Word Test, and CPTII);(214,215) executive function (Trail Making Test Part B, Controlled Oral Word Test,
and Digit Span Backward subtest of the WAIS-III);(214,216) and attention (Trail Making
Test Part A, Conners’ Continuous Performance Test-II [CPT-II], and Digit Span Forward
subtest of the Wechsler Adult Intelligence Scale-III [WAIS-III]).(214-216)
Neurocognitive testing was conducted during a single 2-h visit within 3 days of MRI.
Because fatigue is a frequent concern in HL survivors,(217) the order of testing and
survivors’ schedules were controlled to limit the effect of fatigue and extraneous factors
on neurocognitive testing.

5.1.2

Magnetic resonance imaging and analysis
High-resolution structural and ASL-perfusion MRI was performed using a 3T

Trio MRI scanner (Siemens Medical Solutions, Erlangen, Germany). Structural imaging
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consisted of a three-dimensional (3D) whole-brain T1-weighted MPRAGE with TE=2.44
ms, TR=1920 ms, matrix size=256×256, FOV=210 × 210 mm2. Pulsed ASL (PASL)
perfusion imaging was performed with a Q2TIPS (71) sequence, with echo planar
imaging readout consisting of 11 ascending slices repeated for 50 label/control pairs and
a spin density map with the following parameters: TR=2280 ms, TE=23 ms,
matrix=64×64, FOV 210×210 mm2, slice thickness=5 mm with 1-mm gap, and inversion
times TI1=700 ms and TI2=1400 ms. Whole-brain coverage was achieved by shifting the
FOV and acquiring a second ASL scan.
The motion-corrected (181) ASL images were resized using bicubic interpolation
to a matrix size of 128×128. Quantitative CBF maps were calculated according to a
previously reported single-compartment model (183) and adjusted for interslice
acquisition delay by using an in-house MATLAB (The MathWorks, Natick, MA)
program. The skull was removed from the ASL and T1 images by using BET (218)
(FMRIB’s Software Library; www.fmrib.ox.ac.uk/fsl). Time series mean ASL images
were used for realigning the CBF maps to the T1-weighted structural images by using
FLIRT (219).
The T1-weighted structural images were segmented by the unified segmentation
procedure (220) (SPM 8, http://www.fil.ion.ucl.ac.uk/spm) to create gray and white
matter images. A Diffeomorphic Anatomical Registration Through Exponentiated Lie
algebra (DARTEL) (221) algorithm was used to create a study-specific GM template.
CBF maps were normalized to the template by applying the transformation from the GM
structural image and modulated to adjust or preserve the CBF signal in expanded or
compressed areas.(205,222) Modulated CBF images were mapped into Montreal
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Neurological Institute (MNI) brain template, re-sliced to an isotropic voxel of 1.5mm,
and spatially smoothed with a 12mm full-width at half-maximum Gaussian kernel.

5.1.3

Statistical Analysis
Mean CBF was calculated across voxels in the GM for each survivor. Group

comparison consisted of testing for differences in GM CBF between ALL and HL
survivors and between male and female survivors. CBF differences between groups were
assessed by the Wilcoxon rank sum test and were significant at P<0.05. A group
comparison also tested for GM perfusion differences between a subcohort of ALL
survivors who had received 18 Gy or 24 Gy of CRT. A voxel-wise 2-sample t-test
(SPM8) was also performed to test for regional differences in CBF related to cranial
radiation dose in ALL survivors. Voxel-wise imaging results were considered significant
at a family wise error (FWE)–corrected P<0.05.
A standard mixed-effects general linear model (GLM, SPM8) analysis was used
on a voxel-by-voxel basis to test the relation between CBF measurements and
neurocognitive scores across all survivors. Neurocognitive scores were used as
covariates of interest, and age was included as a nuisance covariate. Analysis was
performed both for a combined survivor group and for separate ALL and HL survivor
groups. Voxel-wise imaging results were considered significant at P<0.05, FWE
corrected. Neurocognitive performance measures were transformed to age-adjusted
standard scores (population mean=100, standard deviation [SD]=15) by using national
normative data. A z-test was performed to identify neurocognitive performance measures
that differed from the population mean.
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5.2

Results
The mean (SD) CBF for ALL survivors (n=33) was 60.6  7.9 mL·min-1·100 g-1

at an average age of 26.2 (3.5) years. The mean (SD) CBF for HL survivors (n=35)
group was 57.6 (6.9) mL·min-1·100 g-1 at an average age of 41.6 (4.0) years. Although
HL survivors had a 5% lower mean CBF than ALL survivors, this difference was not
significant (P=0.14). Female survivors had higher mean (SD) CBF than male survivors
in both the ALL [females=61.5 (7.2), males=59.3 (8.9) mL·min-1·100 g-1] and HL
[females=57.8 (5.8), males =57.4 (8.1) mL·min-1 ·100 g-1] groups, but this difference
was not significant (ALL group P=0.30; HL group P=0.86). There was no significant
difference in mean CBF between ALL survivors treated with 18 Gy (n=16) or 24 Gy
(n=17) of cranial radiation (P=0.84). Also, voxel-wise analysis did not reveal any spatial
regions with significant perfusion differences related to CRT dose.
Neurocognitive assessments revealed multiple domains showing higher rates of
impairment than those seen in the age-adjusted normative population (TABLE 5-1).
ALL survivors showed lower performance in the areas of Full Scale Intelligence [full
scale intelligence quotient (FSIQ); P=0.005], cognitive flexibility (P<0.001), attention
span (P≤0.001), working memory (P=0.01), and total memory recall (P=0.04) than ageadjusted norms. HL survivors showed lower verbal fluency (P=0.04) and short-term
memory recall (P=0.02) than age-adjusted norms.
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TABLE 5-1 Areas showing impaired neurocognitive outcome in survivors of ALL
and HL

Functional
Outcome
Full Scale
Intelligence
Focused Attention
Attention Span
Sustained Attention
Variability of
Sustained Attention
Attention
Detectability
Cognitive
Flexibility
Cognitive Fluency
Working Memory
Memory –
Total Recall
Memory – Shortdelay Recall
Memory – Longdelay Recall

ALL
%
Mean ± SD
Impaired*

P+

HL
%
Mean ± SD
Impaired*

P+

92.6±13.9

24%

0.005

99.2±14.7

11%

0.75

95.0±19.8
89.6±14.2
98.3±21.1

24%
48%
9%

0.06
<0.001
0.52

106.3±13.9
98.2±13.9
103.4±11.5

9%
25%
9%

0.012
0.47
0.18

95.9±10.7

15%

0.12

97.2±16.3

20%

0.26

96.9±11.6

12%

0.23

101.4±15.7

17%

0.59

82.5±24.6

39%

<0.001

101.2±15.2

14%

0.64

95.0±13.7
93.4±10.6

24%
21%

0.06
0.01

94.7±15.0
95.5±12.1

17%
20%

0.04
0.08

94.6±17.2

24%

0.04

97.3±15.5

23%

0.29

97.9±18.3

15%

0.43

94.0±14.1

14%

0.02

96.4±18.3

15%

0.16

95.2±13.8

23%

0.06

* Impairment defined as scores 1 standard deviation (SD) below the expected mean of
100.
+
P values based on the 2-sided z test, with an expected mean of 100 and SD of 15. P
values ≤ 0.05 in bold represent significant impairment compared with age-adjusted
national norms.

Voxel-wise GLM analysis of CBF maps revealed associations between
neurocognitive performance and perfusion. CBF was positively correlated with FSIQ in
areas of the left superior temporal gyrus (peak-level P=0.001, FWE corrected; Figure
5-1). A large cluster in the left temporal lobe was also positively associated with FSIQ
(P<0.001, FWE corrected). Perfusion was positively correlated with variability in
sustained attention in a large cluster (P<0.001, FWE corrected) spanning from the right
precuneus (peak-level P=0.023, FWE corrected) to the right posterior cingulate (peak89

level P=0.053, FWE corrected). A cluster of association was also found in the right
superior temporal gyrus (P=0.013, FWE corrected; peak-level P=0.054, FWE corrected)
and in the inferior parietal lobule, which approached our criteria of statistical significance
(P=0.054, FWE corrected; peak-level P=0.053, FWE corrected; Figure 5-2).

Figure 5-1 A red cluster in the left temporal lobe (P<0.001, FWE corrected) indicated a
positive association between resting-state blood flow and FSIQ in a combined group of
ALL and HL survivors. The arrow indicates (peak-level P=0.001, FWE corrected) that
the highest positive correlation was in the left superior temporal gyrus. The significance
level used for thresholding the T statistic map was P<0.001 (t>3.3, uncorrected).
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Figure 5-2 Resting-state blood flow in a combined group of ALL and HL survivors was
positively correlated with variability in sustained attention in a cluster (P<0.001, FWE
corrected, red) spanning from the right precuneus (peak-level P=0.023, FWE corrected)
to the right posterior cingulate (peak-level P=0.053, FWE corrected, red). A cluster was
also observed in the right superior temporal gyrus (P=0.013, FWE corrected; peak-level
P=0.054, FWE corrected, green) and in the inferior parietal lobule but did not reach
statistical significance (P=0.054, FWE corrected; peak-level P=0.053, FWE corrected,
blue). The significance level used for thresholding the T statistic map was P<0.001 (t
>3.3, uncorrected).

In separate voxel-wise GLM analyses of ALL and HL survivors, FSIQ was
positively correlated with perfusion in a cluster in the left-middle and superior temporal
gyri of HL survivors (P=0.004, FWE corrected; peak-level P=0.055, FWE corrected;
Figure 5-3). Also, in HL survivors, variability in sustained attention showed a cluster
(P=0.001, FWE corrected) of positive association with perfusion from the right
precuneus (peak-level P=0.043, FWE corrected) to the right posterior cingulate (peaklevel P=0.066, FWE corrected; Figure 5-4). However, the areas of association between
cognitive performance and perfusion found in HL survivors were not observed in ALL
survivors. No additional areas of association of cognitive performance and perfusion
were found in ALL survivors.
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Figure 5-3 The red cluster in the left middle and superior temporal gyri showed a
positive correlation with FSIQ and perfusion in HL survivors, as indicated by the arrow
(P=0.004 FWE corrected, peak-level P=0.055). The significance level used for
thresholding the T statistic map was P<0.001 (t>3.5, uncorrected).

Figure 5-4 Perfusion shown as a red cluster spanning from the right precuneus (peaklevel P=0.043, FWE corrected) to the right posterior cingulate (peak-level P=0.066, FWE
corrected) was positivity associated with variability in sustained attention in HL
survivors. The significance level used for thresholding the T statistic map was P<0.001
(t>3.5, uncorrected).

5.3

Discussion
Our study identified areas of association between resting-state CBF and

neurocognitive performance in long-term survivors of cancer. Specifically, there were
differences in the association between perfusion and the domains of FSIQ and sustained
attention in long-term survivors of HL and ALL. These areas of improved
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neurocognitive performance with higher resting-state perfusion in HL survivors were not
observed in ALL survivors who received CRT. Our findings suggest the presence of
cardiovascular effects on neurocognitive function in survivors of HL treated with thoracic
radiation or the potential decoupling of blood flow and neurocognitive performance in
survivors of ALL receiving CRT. Our study represents the first step in identifying the
possible vasculature mechanism of decreased neurocognitive performance in long-term
cancer survivors. Identifying and understanding the differences in outcome in long-term
survivors of cancer can aid the development of future treatment protocols or therapeutic
interventions, with the ultimate goal of improving the quality of life for long-term
survivors of cancer.
In our cohort of survivors, resting-perfusion was associated with FSIQ in a large
region across the left temporal lobe. Positive associations were identified in the middle
and superior temporal gyri of HL survivors only. Associations between intelligence and
physiology in cortical regions in the prefrontal, parietal, and temporal lobe regions have
been reported in structural MR (223-225) and resting-state functional imaging (226,227)
studies. On the basis of a large meta-analysis of neuroimaging studies, Jung and Haier
proposed the Parieto-Frontal Integration Theory (P-FIT) of intelligence, which includes
temporal lobe regions.(228) A study by Kilroy et al.(229) in typically developing
children and adolescents reported associations of resting-state perfusion by ASL and IQ
consistent with the P-FIT neural network, which included bilateral positive associations
in the superior temporal regions. Our results from HL survivors have found an
association in the left temporal regions only and not in other nodes in the P-FIT network,
such as the prefrontal cortex or the bilateral association in the superior temporal regions.
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These results suggests a divergence from a cognitively normal-derived P-FIT model of
intelligence in the HL survivors in our study, who are known to be at increased risk of
neurocognitive impairments. HL survivors are also at increased risk for cardiovascular
pathology (151), which may also contribute to the departure from the P-FIT model of
intelligence. ALL survivors in our study did not have a significant association between
resting-state perfusion and FSIQ. ALL survivors received CRT at a young age and had a
higher degree of FSIQ impairment than HL survivors. CRT applied to the total brain can
affect the total brain function and might contribute to the variability in outcomes or alter
development trajectories, which may explain the pathophysiologic changes from the PFIT model.
Sustained attention or vigilance - the ability to direct and focus cognitive activities
for the duration of a task - is an important attribute in maintaining goal-oriented behavior.
A positive association was observed in sustained attention performance and resting-state
perfusion in the area spanning the right precuneus to the right posterior cingulate and in
the inferior parietal lobule. These areas of association are particularly interesting,
because they are also common to the default mode network (DMN). The posterior
cingulate cortex, precuneus, ventromedial prefrontal cortex, and bilateral parietal cortex
constitute the major nodes of the DMN and have high metabolic demands during rest
periods.(230)
Our results show that higher resting-state perfusion in the right precuneus and
right posterior cingulate of the DMN contribute to less variability in sustained attention
performance. In healthy individuals and patients with traumatic brain injury, less
deactivation of the precuneus and posterior cingulate of the DMN is attributed to
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attention lapses and impairment in sustained attention.(231,232) Increasing deactivation
of the DMN is positively associated with more cognitively demanding tasks.(233,234)
Our study suggests that higher resting-state perfusion could lead to better regulation of
DMN deactivation, which contributes to improved sustained attention performance.
Similar to our results with FSIQ, the separate group analyses found a positive
correlation of resting-state perfusion and sustained attention performance in a smaller
area spanning the right precuneus to the right posterior cingulate in HL survivors only.
Overall, performances of sustained attention between HL and ALL survivors were
comparable, although there were more neurocognitively impaired survivors in the HL
group. Because the long-term effects of HL and ALL therapy in regulating DMN activity
remain an open question, it is difficult to assess how therapy-induced changes in DMN
activity are associated with variations in resting-state perfusion. In breast cancer
survivors, abnormal DMN connectivity patterns can distinguish between chemotherapytreated and non-chemotherapy- treated patients and healthy controls.(235) Kelser
reviewed DMN connectivity as a biomarker of chemotherapy-related brain injury.(236)
Longitudinal studies are needed to investigate the association of cancer therapy–induced
changes in DMN activity and developing neurocognitive dysfunction. Such studies will
aid the development of new treatment strategies, which can improve the quality of life for
long-term cancer survivors.
Although neural correlation of neurocognitive intelligence and sustained attention
performance with resting-state perfusion were observed in long-term cancer survivors,
we did not detect associations with other neurocognitive measures such as working
memory, attention, or verbal fluency. ASL measures GM perfusion and does not provide
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information on white matter integrity or function, which previous studies have
investigated with neurocognitive performance.(151,210) Variations in performance or
impairments in neurocognitive measures such as verbal fluency could reflect more
pathophysiologic changes of the white matter, such as the presence of
leukoencephalopathy, than can cause fluctuations in resting-state GM perfusion.
Furthermore, task-based activation measures, which are commonly employed in
functional MRI (fMRI) exams, offer a hemodynamic mechanism for investigating
variations in neurocognitive performance that can be an alternative to the steady-state
resting perfusion employed in this study. Kim et al.(237) reported variations in perfusion
activation in a task-induced working memory and visual sustained-attention fMRI study
between healthy controls and patients with traumatic brain injury. Our results of the
relation between perfusion and neurocognitive performance suggest that perfusion should
be incorporated into a multicontrast study with diffusion and fMRI.
We cannot determine whether our findings are the result of group differences
between ALL and HL survivors or other treatment-related factors such as age at
treatment or follow up. The ALL survivors had CRT very early in life, when
neurocognitive impairment is likely to affect primary and secondary education.(209)
CRT can induce a wide spectrum of changes in the brain, including vasculopathy and
increased risk of stroke, particularly in pediatric brain tumor survivors.(145)
Vasculopathy from CRT could contribute to more individual variations in resting-state
perfusion, thus decoupling the relation between perfusion and neurocognitive
performance in our cohort of ALL survivors. In neurocognitive assessments, HL
survivors performed better than ALL survivors. HL survivors are at increased risk of
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cardiac complications after anthracycline chemotherapy or thoracic radiation
(134,151,238), which could disrupt the normal resting-state CBF. Generally, it remains
unknown how resting-state perfusion correlates with neurocognitive performance even in
normal healthy controls.
The mean CBF values did not indicate differences in global perfusion by CRT (18
or 24 Gy) in ALL survivors. Voxel-wise analysis did not reveal regional perfusion
changes related to CRT dose. Without age-matched healthy controls, it was difficult to
determine whether CRT at an early age results in late effects related to perfusion changes
or whether the effect of 18 Gy or 24 Gy was similar. The difference in mean CBF
between ALL and HL survivors is consistent with age-related perfusion changes reported
previously (72,239,240) and suggests that CRT does not cause late effects related to
changes in global GM perfusion.
Our study has some limitations. The absence of a healthy control group precluded
the verification of the association between neurocognitive performance and perfusion
observed in this cohort of HL and ALL survivors. Also, we could not determine the
duration of diminished neurocognitive performance effect on regional perfusion.
Although perfusion was adjusted for age as a nuisance covariate, having age and age at
treatment match groups would have provided a preferable comparable study population.
Another limitation was the PASL exam, which was repeated twice to achieve wholebrain coverage. Alternatively, pseudo-continuous ASL and 3D single-shot readouts can
be used to provide whole-brain coverage, and are reported to provide improved signal-tonoise(241) and sensitivity at the subject level in fMRI studies.(242)
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5.4

Conclusion
We identified differences in the association between perfusion and neurocognitive

performance between HL and ALL survivors. Understanding cerebral perfusion changes
and the differences in neurocognitive late effects by treatment strategy in cancer
survivors is important to elucidate the mechanisms of impairments, which can direct
future treatment protocols and interventions to improve the quality of life for cancer
survivors.
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Chapter 6
EVALUATION OF SWI IN CHILDREN WITH SICKLE CELL DISEASE

6.1

Introduction
Stroke is one of the most devastating complications in children with sickle cell

disease (SCD).(163) The cause of stroke in SCD has both occlusive and hemodynamic
contributions.(243,244) The pathophysiology of vaso-occlusion is related to the poor
deformability of sickled red blood cells and the increased endothelial interactions of
erythrocytes and inflammatory cells, which can induce vascular injury.(158)
Hemodynamic contributions arise from a hemolytic anemia, creating a hyperemic state to
satisfy cerebral oxygen demands.(243-245) Transcranial Doppler sonography is
routinely used to screen for the risk for stroke, as the increase in cerebral blood flow in
the hyperemic state is known to increase the risk for stroke.(244,246-249) MR imaging
and MRA are also routinely used to assess parenchymal injury and the vascular integrity
of the cerebrovascular system to assess the risk for stroke in patients with SCD.(250)
In addition to MRA, SWI has evolved into an important technique for imaging of
the cerebrovascular system.(76) SWI enhances the venous contrast in the brain by taking
advantage of the difference in magnetic susceptibility between deoxyhemoglobin and
oxyhemoglobin. Because SWI is a blood oxygen level– dependent (BOLD) sensitive
technique, the image can be affected by CBF changes, as reported in studies that have
used carbogen or caffeine challenges or anesthesia.(173,174,177) Hyperemia is a welldescribed condition in SCD.(245,248,251,252) SWI has not been systematically
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investigated in SCD and may be a useful tool to study venous flow in conditions in which
CBF is increased.
In this study, we quantitatively compared the venous contrast in patients with
SCD with that of age- and sex-matched healthy control participants. The visible venous
volume calculated in each SWI examination was correlated with hematologic variables to
determine whether this quantitative SWI measurement could be used as a biomarker of
disease severity.

6.2

Materials and Methods

6.2.1

Patient Demographics and MR Imaging
This retrospective study was approved by our hospital institutional review board.

We analyzed diagnostic SWI scans from patients with SCD treated at our institution
between March 2010 and December 2010. Patients who were sedated (177), received
supplemental oxygen for the MR examination, had a history of stroke, Moyamoya
vasculopathy, encephalomalacia, or who had severe stenosis (>75%) or occlusion of
major intracranial vessels of the circle of Willis by MRA were excluded from analysis.
Of the 29 eligible patients, 7 were excluded because of severe motion artifacts on SWI,
and 1 patient was excluded for the hemoglobin SC genotype, yielding a final cohort of 21
patients with genotype hemoglobin SS (12 female, mean age, 12.9 ± 3.7 years; 9 male,
mean age, 12.3 ± 3.9 years). Patients were also categorized by treatment: hydroxyurea,
long-term transfusion therapy, or no therapy. Hemoglobin, percent hemoglobin F,
percent hemoglobin S, absolute reticulocyte count, and white blood cell count (TABLE
6-1) obtained within 30 days of the MR examination were used as covariates for SWI
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analysis in the SCD group. SWI examinations were also analyzed from 21 sex- and agematched healthy control participants (12 females, mean age, 12.7 ± 4.1 years; 9 males,
mean age, 12.3 ± 3.5 years). The healthy control participants were enrolled from the
community in an institutional review board–approved clinical trial examining neural
substrates of reading (National Institutes of Health R01HD049888). Hematologic
parameters were not available for the control group.

TABLE 6-1 Correlation of NVVV with hematologic parameters

Parameter
Hemoglobin (g/dL)
Absolute reticulocyte count
( Χ106/L)
White blood cell count
(Χ106/L)
Hemoglobin F (%)
Hemoglobin S (%)

N

Interval between
SWI and
Laboratory
Measurements (d)

Value

R (P
Value)*

21

-0.05 ± 2.4

8.51 ± 1.10

0.25 (.28)

21

-0.05 ± 2.4

0.23 ± 0.10

0.10 (.66)

21
18
18

-0.05 ± 2.4
-3.22 ± 9.38
-3.22 ± 9.38

10.10 ± 4.50
12.84 ± 9.40
68.06 ± 18.22

0.19 (.40)
-0.09 (.71)
-0.25 (.31)

Note:—Results presented as mean _ standard deviation.
* R(P Value) value for the correlation of each hematologic parameter and NVVV.

In the SCD group, 12 examinations were performed at 1.5T (Avanto and
Symphony; Siemens, Erlangen, Germany) and 9 examinations at 3T (Trio; Siemens). All
control examinations were performed at 3T. The SWI acquisition involved a 3D T2*weighted gradient-echo sequence with the following parameters: TE, 25 ms; TR, 56 ms at
3T and TE, 40 ms; TR, 60 ms at 1.5T; flip angle, 20°; section thickness, 2 mm; matrix
size, 384 Χ 257 Χ 72; FOV, 210 Χ 210 mm2; and a parallel imaging acceleration factor
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of 2. Sliding minimum intensity projections (mIP, 16-mm thick) were used in the image
analysis.
Because SWI was performed at 1.5T and 3T in the SCD group, another set of
healthy adult volunteers underwent scanning at 1.5T and 3T by use of the respective SWI
parameters to evaluate any potential differences in the SWI signal as a function of field
strength. Twelve healthy volunteers (3 females, mean age, 53.0±5.2 years; 9 males, mean
age, 38.1Χ14.9 years) were recruited and underwent scanning consecutively at 1.5T and
3T after informed written consent was obtained.

6.2.2

Image Analysis
The apparent venous contrast was quantified by segmentation of the venous

structures by a Frangi vesselness filter (253) in Matlab (MathWorks, Natick,
Massachusetts). The mathematic basis of the Frangi vesselness filter pertaining to vessel
segmentation has been shown previously (253-255), including the evaluation of SWI
contrast in multiple sclerosis.(256) In general, the line intensity profile of the
hypointense vein seen in SWI can be described as a Gaussian function with a uniform
intensity along the vessel. The second partial derivative of the image provided by the
Hessian matrix describes the local curvature along the vessel and its cross-section. The
degree of curvature is described in the eigenvalues of the Hessian matrix. The Frangi
vesselness filter analyzes the relationship of the eigenvalues to remove “blob” or
circlelike features and determines the likelihood of tubelike structures.
Vein maps were created by first removing the skull from the mIP images with the
Brain Extraction Tool (FMRIB Software Library; www.fmrib.ox.ac.uk/fsl).(218) To
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provide a similar signal intensity range for all images, the mIP images were normalized
to 98% of the maximum signal intensity before applying the 2D Frangi vesselness filter.
The 2 filter parameters (β and c), used to suppress bloblike structures and background
noise, were set to β = 0.5 and c = 20, as suggested in previous studies.(253,257) The
spatial scale of the filter was equal to the in-plane spatial resolution of the mIP (0.55
mm). The filter result is a probability estimate of the venous vesselness. Vein maps were
created by accepting a probability estimate of > 60%. The volume identified as veins
above the level of the M1 segment of the MCA was divided by the total intracranial
volume above the M1 segment to create a quantitative normalized visible venous volume
(NVVV). NVVV is a dimensionless ratio. Only the sections above the M1 segment
were used to avoid possible misidentification of these structures as veins due to inflow
effects that are sometimes seen in gradient recalled-echo acquisitions. This also avoided
susceptibility artifacts at the level of the paranasal sinuses.
All SCD and healthy control examinations were qualitatively graded for
hypointense arterial contribution above the M1segments on the mIP. An examination
with no hypointense arterial vessels on the mIP SWI in the Sylvian fissure received a
grade of zero. Examinations with a few arterial vessels in the anterior Sylvian fissure
received a grade of I. If the arterial vessels extended through the Sylvian fissure to the
posterior temporal lobe, the examination received a grade of II. An examination received
a grade of III if multiple tertiary arterial branches were present in the Sylvian fissure.
Finally, to evaluate potential differences in the apparent venous contrast due to
field strength and respective SWI parameters, calculated NVVVs at 1.5T and 3T were
compared in the same volunteer. The NVVV was calculated following the same
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procedure as described above. However, to ensure similar section position above the M1
segment, the 1.5T mIP images were realigned to the 3T mIP images by use of FLIRT
(FMRIB Software Library) (219) before the NVVV calculation.

6.2.3

Statistical Analysis
Statistical analysis was performed by use of Matlab. Variables were expressed as

means ± standard deviations. Group differences were assessed by use of the Wilcoxon
rank sum test. Differences between 1.5T and 3T NVVV in the healthy volunteers were
assessed by the Wilcoxon signed rank test. Linear dependencies of other physiologic
markers with NVVV were tested by the Pearson correlation coefficient. Group
differences or linear relationships were considered significant if P < .05.

6.3

Results
Of the 21 patients with SCD, 15 were receiving hydroxyurea therapy (mean years

of therapy, 5.4 ± 1.8 years; 1.5T = 7; 3T = 8), 2 were receiving long-term transfusion
therapy (mean years of therapy, 3.85 ± 0.91 years; 1.5T = 2), and 4 were not receiving
therapy (1.5T = 3; 3T = 1).
The SCD group had a visually lower venous contrast and overall visible venous
vasculature than the control group (Figure 6-1). The loss of visible venous vasculature in
the SCD group appeared to be global, with loss of venous contrast in both the deep
medullary and regional cortical veins. By radiologic review, there were no focal regions
of decreased or increased venous contrast. However, the presence of arteries (grade I, II,
or III) in the mIP SWI was observed in 18 (grade I = 7; grade II = 9; grade III = 2) of the
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21 SCD examinations and in none of the 21 healthy control examinations. Larger arterial
contributions (grade II or III) were more prominent in the 1.5T cohort (all grades: grade 0
= 1; grade I = 1; grade II = 8; grade III = 2) than in the 3T cohort (all grades: grade 0 = 2;
grade I = 6; grade II = 1; grade III = 0).

Figure 6-1 SWI, mIP SWI, and segmented vein maps for a representative control (top
row, NVVV = 0.032) and patient with SCD (bottom row, NVVV = 0.013). In the mIP
SWI and segmented vein maps, there is visually less venous contrast in the examination
from the patient with SCD. The arrows point to loss of cortical venous conspicuity in the
frontal (A), temporal (B), occipital (C), and deep medullary (D) areas, indicating a global
decrease in signal.
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Arterial signal contributions in the mIP SWI originated from hypointense signal in the
SWI magnitude images and not from the phase mask multiplication. Figure 6-2
illustrates that many of the hypointense-appearing vessels on the mIP SWI corresponded
to a hyperintense arterial signal on the mIP MRA. Because the arterial contribution could
not be removed from the mIP SWI, NVVV is overestimated in the SCD groups because
of the inclusion of these hypointense arterial vessels.

Figure 6-2 An SCD mIP SWI (A) with several hypointense-appearing vessels that could
be interpreted as veins (black arrowheads). The corresponding MIP TOF (B) indicated
that many of the hypointense-appearing vessels on the mIP SWI correlate with a
hyperintense arterial signal from the TOF (white arrowheads). The arrows indicated
arterial contribution of more distal branches of the left and right (anterior to posterior)
bilateral anterior, middle, and posterior cerebral arteries. This example received a grade
of II because of a hypointense arterial signal on the mIP SWI in the anterior Sylvian
fissure through to the posterior temporal lobe.

Because the examinations in the SCD group were acquired at 2 magnetic field
strengths, the first test analyzed differences in the NVVV by using the segmented vein
mask of healthy volunteers who underwent scanning at 1.5T and 3T. There was a
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significant difference (P = .03) in the NVVV between the 1.5T (0.024 ± 0.006) and 3T
(0.028 ± 0.009) examinations. This finding indicates a bias toward higher NVVV at 3T.
Figure 6-3 depicts a representative mIP SWI from the same volunteer who underwent
scanning at 1.5T and 3T.

Figure 6-3 Representative mIP SWI from the same volunteer who underwent scanning at
1.5T (A) and 3T (B) depicts similar venous anatomy. The combination of higher SNR
and venous contrast at 3T results in an improved venous conspicuity and a higher venous
vessel likelihood from the Frangi filter. Several veins (eg, deep medullary veins) appear
larger at 3T. The combination of larger appearing veins and a higher vessel likelihood we
believe were attributed to the increased conspicuity of NVVV at 3T.

The measured NVVV in the SCD group was 0.013 ± 0.004 (n = 12) and 0.011 ±
0.006 (n = 9) at 1.5T and 3T, respectively. The measured NVVV in the healthy control
participants at 3T was 0.031 ± 0.009 (n = 21; Figure 6-4). There was no significant
difference in NVVV measured at 1.5T and 3T in the SCD group (P = .21). The field
strength bias detected in the volunteers was not observed in the SCD group. No sex
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differences (P = .65) or age-related changes (P =.38) in NVVV were observed in the
healthy control participants and volunteers at 3T.

Figure 6-4 Boxplot of the NVVV in the SCD group (1.5T = 0.013 ± 0.004; 3T = 0.011 ±
0.006), control group (3T = 0.031 ± 0.009), and volunteers (1.5T = 0.024 ± 0.006; 3T =
0.028 ± 0.009). The difference in NVVV between the 3T SCD and control groups was
significant (P < .001) when assessed by the Wilcoxon rank sum test. Volunteer
measurements at 1.5T and 3T indicate increased conspicuity of NVVV at 3T (P = .03)
when assessed by the Wilcoxon signed rank test.

Because of the field bias observed in the volunteer measurements, cohort
differences were only analyzed from the 9 patients with SCD at 3T and their
corresponding 9 sex- and age-matched healthy control participants. There was a
significantly lower NVVV in the 3T SCD group when compared with the healthy control
group (0.034 ± 0.011; n = 9; P < .001). So we would not further reduce our SCD sample
size, we correlated NVVV with hematologic variables from all SCD examinations. The
correlation of NVVV with hematologic variables was evaluated to determine parameters
that may influence venous contrast in the SCD group. There was no significant
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correlation of NVVV (TABLE 6-1) with hemoglobin concentration (R = 0.25; P = .28),
hemoglobin F (R = -0.09; P = .71), hemoglobin S (R = -0.25; P = .31), absolute
reticulocyte count (R = 0.10; P = .66), or white blood cell count (R = 0.19; P = .40).

6.4

Discussion
This study was undertaken to compare the BOLD-sensitive SWI venous contrast

between patients with SCD and an age- and sex-matched healthy population and correlate
these findings with hematologic variables in patients with SCD. We found that SCD
affects the venous conspicuity of SWI. The NVVV was significantly lower in patients
with SCD than in healthy control participants. From a qualitative perspective, SWI in
patients with SCD produced a global isointense signal, which was similar in appearance
to the diminished venous conspicuity reported in high-flow conditions found during
anesthesia (177) and carbogen challenges (173). To better understand the
pathophysiology of decreased venous conspicuity in SCD, we investigated the
relationship between SCD SWI venous contrast and hematologic variables. There were
no correlations between the hematologic variables and SCD NVVV, suggesting that other
or more complex mechanisms affect venous conspicuity.
The Frangi vesselness filter was used to quantify venous contrast.(253) The
automated vesselness filter method is superior to a qualitative categoric grading system of
weak or strong contrast because it provides a continuous variable with which physiologic
parameters can be correlated and is not subject to user-dependent segmentation methods.
The mIP images were used in the analysis because they had higher conspicuity of the
venous vasculature than SWI, allowing better sensitivity of venous segmentation. The
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use of mIP images with the same section thickness in both the SCD and control groups
allowed a direct comparison between the groups. However, the use of mIP images will
overestimate a true venous volume because the same venous vessels are replicated on
multiple sections.
In this study, there was a significant difference in NVVV between patients with
SCD and healthy control participants. This difference is unlikely the result of a
morphologic decrease in the venous vasculature in patients with SCD but, instead, may
be caused by decreased venous contrast. We excluded patients with a history of stroke,
Moyamoya, encephalomalacia, severe stenosis, or major vessel occlusion to eliminate
any confounding variance from known macrovasculature or microvasculature disease that
could influence NVVV. Failure of the linear flow compensation observed in 86% of the
SCD examinations resulted in the inclusion of an arterial vessel signal in the NVVV.
This results in an overestimation of the true apparent NVVV and indicates a larger
difference between patients with SCD and healthy control participants. A hypointense
signal from arteries in a fully flow-compensated SWI sequence could indicate nonlinear
flow or high flow acceleration. The tortuous arterial vessels reported in SCD (258,259)
could attribute to the difference in flow compensation performance between the patients
with SCD and healthy control participants.
Given that SCD can affect the concentration of paramagnetic deoxyhemoglobin
(260), the source of contrast in SWI, it was expected that hematologic variables such as
hemoglobin levels or absolute reticulocyte count might correlate with the amount of
venous contrast in SWI. However, we did not find any significant correlation between
the hematologic variables and NVVV, which may be due to the relatively small number
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of patients in our study and the included arterial signal contributions. However, changes
in hematologic variables such as hemoglobin concentration can affect other important
parameters such as CBF (252,261), which may play a more primary role in affecting
NVVV. In this retrospective study, blood flow or perfusion values were not available to
investigate this relationship. From a physiologic standpoint, because of the lower
oxygen-carrying capacity of hemoglobin S and the chronic anemic state in SCD, CBF
increases to maintain a constant oxygen extraction fraction.(169,243) SWI is sensitive to
CBF changes (173,174,177), and CBF could be a cause for altered SWI contrast in SCD.
The elevated CBF reported in SCD (169,251), combined with the decreased
concentration of deoxyhemoglobin (260), may represent a complex multifactorial
physiologic mechanism that results in diminished SWI contrast in SCD.
There were no significant sex differences or age-related changes in NVVV in
either the patients with SCD or healthy control participants and volunteers at 3T.
Volunteer measurements at 1.5T and 3T detected a bias of higher NVVV at 3T. One
possible mechanism for the difference is that the TEs were not scaled proportionally for
the change in magnetic field. To produce similar phase effects, the product of magnetic
field strengths and TE should be equal.(81) A TE of 40 ms at 1.5T only produces 80% of
the phase offset of a TE of 25 ms at 3T. SNR also increases with higher field. The
combination of higher SNR and larger-phase offset at 3T improved contrast to noise and
conspicuity of smaller venous vessels at 3T and, thus, a larger NVVV. However, NVVV
was higher at 1.5T than at 3T in the SCD cohort. The higher NVVV could be attributed
to a larger degree of arterial contribution (grade II or III) in the 1.5T SCD examinations
than in the 3T SCD examinations.
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A limitation of this retrospective study was the small number of patients with
SCD. Several factors could have impeded our ability to elucidate hematologic effects
with NVVV, which included a small sample size, data at 2 different fields, and arterial
contribution. Further SWI sequence design to include acceleration compensation or
postprocessing techniques would be necessary in future studies to eliminate an arterial
signal to provide a better estimate of NVVV. Another study limitation was the absence
of flow data to determine its relationship with NVVV. The small number of patients with
SCD who did not receive treatment or received transfusions did not allow an analysis of
treatment related NVVV effects. A longitudinal prospective study at a single field across
different SCD treatment groups is needed with quantitative measures of cerebral flow to
determine the relationship of NVVV in SCD, and to assess if quantitative SWI measures
could be used as surrogate markers of disease severity and treatment success.

6.5

Conclusions
Our study is the first to describe a spectrum of SWI changes in children with SCD

across multiple therapies. SWI venous conspicuity (NVVV) was significantly lower in
patients with SCD than in healthy age- and sex-matched control participants. Given that
SCD produces a complex physiologic response to maintain adequate cerebral
oxygenation, several factors, particularly cerebral blood flow and perfusion, may play a
role in this decreased contrast in SWI. Prospective studies that include concomitant
longitudinal hematologic and flow measurements are required to determine the
physiologic mechanisms of decreased venous conspicuity in SCD and their usefulness as
a possible biomarker of disease severity.
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Chapter 7
REMOVAL OF ARTERIAL VESSEL CONTRIBUTIONS FROM
SUSCEPTIBILITY-WEIGHTED IMAGES FOR IMPROVED
QUANTIFICATION OF NORMALIZED VISIBLE VENOUS VOLUME

7.1

Introduction
SWI is a three-dimensional, velocity-compensated, gradient echo (3D-GRE)

technique that is sensitive to paramagnetic substances such as deoxyhemoglobin, blood
products, and iron.(262) The conspicuity of venous vessels in SWI results from
enhancement of the magnetic susceptibility differences between deoxyhemoglobin in
venous vessels and the adjacent oxygenated tissue. In addition, SWI can detect
pathophysiologic changes associated with an occluding thrombus and hypoperfused
regions of the at-risk tissue, which can be clinically useful in the diagnosis and
management of stroke.(263-266) Therefore, accurate quantification of venous
conspicuity, which reflects the changing venous flow physiology, is essential to
establishing a reliable biomarker for the management of stroke or stroke risk. Stroke is a
dreaded complication in children with sickle cell disease (SCD), occurring in
approximately 5-10% of this population before the age of 20 years.(163,267) Patients
with SCD routinely undergo magnetic resonance angiography (MRA) for assessment of
the integrity of the arterial component of the cerebrovascular system.(243) An
intracranial arterial stenosis places patients with SCD at an elevated risk of developing a
silent cerebral infarct or an overt stroke.(268) Additionally, accurate quantification of
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venous conspicuity in SCD patients could provide a measure of disease severity or
therapeutic response.
In physiological conditions where non-constant flow exists, first order gradient
moment nulling used in SWI may be insufficient. Rapid path changes of the blood
through tortuous arterial vessels and elevated flow velocities may cause nonlinear flow
terms. Tortuous arterial vessels and hyperemia are a reported pathophysiology of
SCD.(245,269) Irregular or tortuous hypointense arteries were consequently observed in
SWI exams in sickle cell patients.(270) The hypointense arterial signal emerged from the
magnitude images, and most likely originates in incomplete linear flow compensation.
Therefore, in quantification of venous conspicuity, the mixture of hypointense arterial
and venous vasculature will result in the overestimation of true venous vessel volume if
hypointense arterial vessels are not properly accounted for.
In this study, we propose a post-processing framework to remove the
contamination of hypointense arterial vessels in SWI exams by utilizing MRA’s.
Removal of the arterial vessels should increase SWI accuracy and improve quantification
of venous conspicuity in patients with SCD and other conditions with high flow or
tortuous arteries. The accurate quantification of venous conspicuity is essential to
investigate the potential use of SWI as a biomarker of disease severity.

7.2

Material and Methods

7.2.1

Patients and Study Design
We conducted a retrospective review of diagnostic SWI scans from 21 patients

with SCD, all with hemoglobin SS (12 female, mean age 12.9 ± 3.7 years; 9 male, mean
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age 12.3 ± 3.9 years). The study was approved by our institutional review board (IRB).
Twelve exams were performed on 1.5T scanners (Siemens Avanto and Symphony) and 9
exams on a 3T scanner (Siemens Trio). The SWI acquisition was a 3D T2*-weighted
gradient-echo sequence with the following parameters (3T/1.5T): TE = 25/40 ms, TR =
56/60 ms, FA = 20°, slice thickness = 2 mm, matrix size = 384 × 257 × 72, FOV = 210 ×
210 × 144 mm3, and IPAT = 2. A sliding minimum intensity projection (mIP, 16 mm
thick) was calculated from the SWI. The exam also included a 3D time-of-flight (TOF)
MRA optimized for high flow with the following parameters: TE = 4.25 ms, TR = 40 ms,
FA = 25°, slice thickness = 0.8 mm, matrix size = 512 × 512 × 82, FOV = 210 × 210 ×
96mm3, and IPAT = 2.

7.2.2

Qualitative Analysis
A neuroradiologist with 16 years of experience qualitatively assessed the

frequency and degree of hypointense arterial contributions above the M1 segments of the
middle cerebral artery (MCA) on the mIP SWI. Examinations were assigned a
qualitative score from 0 to III to reflect the degree of arterial vessel contribution: (0), no
hypointense arterial vessel contribution within the Sylvian fissure; (I), few arterial vessels
in the anterior Sylvian fissure; (II), arterial vessels extending through to the posterior
temporal lobe; and (III), multiple tertiary arterial branches in the Sylvian fissure.

7.2.3

Quantitative Analysis
The first step in quantifying the apparent venous contrast in the mIP SWI was

brain extraction with the Brain Extraction Tool (www.fmrib.ox.ac.uk/fsl) (218). From
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the mIP SWI brains, hypointense tubular structures were segmented by using a 2D Frangi
vesselness filter (253) in MATLAB (MathWorks, Natick, MA) with filter parameters of β
= 0.5 and c = 20. This method of vessel segmentation has been previously reported (253256). The normalized visible venous volume (NVVV) was calculated by dividing the
volume of venous vessels with probability >60% above the M1 segment of the MCA by
the total intracranial volume above the M1 segment of the MCA. NVVV is a
dimensionless ratio and is hereafter referred to as uncorrected NVVV (uNVVV) because
of the inclusion of any hypointense venous or arterial vessels.
Figure 7-1 outlines the method of removing arterial vessel contributions from
SWI. A realigned MRA is required for identifying the spatial location of arterial vessels
in SWI images, which was done by using normalized mutual information with SPM8
(www.fil.ion.ucl.ac.uk/spm). The same 2D Frangi filter (β = 0.5 and c = 20) was then
used to segment the hyperintense arterial vessels from the realigned MRA. Note, the
Frangi vesselness filter can be used to segment hypointense or hyperintense tubular
structures according to the sign of the second eigenvalue (hypointense = positive;
hyperintense = negative). An arterial mask was created by selecting voxels with a
probability >75% and was dilated by 2 voxels in-plane. The mask dilatation was applied
to minimize any vessel misalignment between the MRA and SWI. A new corrected 16mm sliding mIP SWI was calculated by excluding any signal identified as an arterial
vessel from the arterial mask. If the projection volume contained the arterial mask only,
which is possible when an artery is oriented parallel to the projection volume, the result
was chosen to reflect hyperintense signal intensity. The method describing the
calculation of the uNVVV was applied to segment the remaining hypointense structures
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from the mIP SWI and calculate a corrected NVVV (cNVVV). Repeated-measures
ANOVA was applied to test for differences between uNVVV and cNVVV with P<0.05
considered significance.

Figure 7-1 Diagram of the post processing workflow to remove hypointense arterial
vessels from SWI images for improved quantification of venous conspicuity. SWI,
susceptibility-weighted imaging; mIP, minimum intensity projection; MRA, magnetic
resonance angiography.

7.3

Results
The qualitative review revealed hypointense arterial signals in the mIP SWI in 18

of 21 (86%) exams, which had scores of I (n=7), II (n = 9), III (n = 2). The radiological
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review further confirmed that hypointense signals in the mIP SWI suspected to be arteries
agreed well with hyperintense arterial signal from the realigned maximum intensity
projection (MIP) TOF images. However, not all arteries in the MIP-TOF appeared
hypointense on the mIP SWI. The most prominent pattern of arterial vessel
contamination was observed in the anterior Sylvian fissure extending through to the
posterior temporal lobe. The framework for removing hypointense arterial vessel
contamination in SWI requires accurate arterial vessel segmentation of the TOF-MRA.
Figure 7-2 depicts a representative example that shows all images acquired and
created to generate a corrected mIP SWI. A MIP of the corresponding artery mask
created by the 2D Frangi filter, which identifies and segments hyperintense vessels in the
TOF, is shown in Figure 7-2C. The artery mask included M2, M3, and M4 segments of
the MCA and the anterior cerebral arteries (ACAs), which indicates the performance of
the 2D Fangi filter to segment both in plane and orthogonally oriented vessels. A
comparison between the original mIP SWI (Figure 7-2A), MIP TOF-MRA (Figure 7-2B),
and corrected mIP SWI (Figure 7-2D) showed that the method was effective in removing
hypointense arterial vessel contamination in SWI. Qualitatively, the corrected mIP SWI
showed very little venous vessel conspicuity indicating that most of the initial
hypointense vessel-like structures originated from arteries in this patient with SCD.
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Figure 7-2 Representative mIP SWI (A) from a patient with SCD showing several
hypointense vessels that could be interpreted as veins (uNVVV = 0.014). The
corresponding MIP TOF (B) of the mIP indicates that many of the hypointense vessels on
the mIP SWI correlate with the hyperintense arterial signal from the TOF. A MIP of the
corresponding artery mask which was created by the 2D Frangi filter (C). The corrected
mIP SWI (D) shows the effectiveness of arterial signal removal (cNVVV = 0.007).

Figure 7-3 shows representative patient examples for each degree of arterial
vessel contamination from the qualitative review (score 0 –III). The removal of arterial
hypointensities from the original mIP SWI was accomplished for all degrees of
contamination, demonstrating an effective approach independent of score.
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Figure 7-3 Representative original mIP SWI (left column), MIP TOF (middle column),
and corrected mIP SWI (right column) images from the qualitative review showing the
degree of arterial vessel contamination. (A)–(D) represent scans from patients with SCD
with increasing qualitative scores (scores 0 to III, respectively) of hypointense arterial
vessel contamination found in the original mIP SWI. The image in (D) demonstrates that
the amount of arterial vessel contamination can be quite large. Note the change in the
number of hypointense vessels between the corrected and original mIP SWI.

The quantitative analysis of NVVV revealed that contributions of hypointense
arterial vessels in the original mIP SWI was significant in this cohort of patients with
SCD and accounted for approximately 33% of the NVVV [uNVVV = 0.012 ± 0.005,
versus cNVVV = 0.008 ± 0.003 (mean ± SD), P < 0.01] (Figure 4).
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Figure 7-4 Box plot of the NVVV in 21 patients with SCD before [uNVVV= 0.012 ±
0.005] and after arterial signal correction [cNVVV= 0.008 ± 0.003 (mean ± SD)].

The performance of the proposed framework for removing hypointense arterial
vessel contamination was qualitatively reviewed again by the same radiological reviewer
to confirmed suppression of hypointense arterial signals in the mIP SWI. Hypointense
arterial vessels were removed in 20 of 21 mIP SWI exams. Figure 7-5A-B illustrates the
one exam with incomplete removal of the M1 segment of the MCA. The realignment
performance of the MRA with the SWI was sufficient to remove hypointense arterial
vessels in more superior portions of the brain as found in the Sylvian fissure and the ACA
in the corrected mIP SWI (Figure 7-5 C-D).
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Figure 7-5 Comparison of the original mIP SWI (A) and the corrected mIP SWI (B)
illustrates incomplete removal of the hypointense M1 segment of the MCA as indicated
by the arrows.

7.4

Discussion
In this study, we propose a simple yet effective framework to remove hypointense

arterial vessels from SWI exams by using MRA images to quantify venous conspicuity
more accurately. Removal of hypointense arterial artifacts will also aid clinician in the
qualitative interpretation of SWI exams. Our method measured significant volume
contributions from hypointense arterial vessels in the NVVV. The simple interpretation
of any hypointense tubular structures as venous vessels in SWI exams of patients with
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high blood flow, as observed in SCD patients, could lead to misclassification of the
venous vasculature and an overestimation of the visible venous volume.
SCD is shown to affect SWI contrast by producing a globally diminished venous
conspicuity.(270) The isointense venous presentation resembles the contrast seen in
high-blood-flow conditions induced through carbogen challenges and sedation.(173,177)
The investigation of possible physiologic mechanisms underlying decreased venous
conspicuity in order to establish its association with the risk of stroke in patients with
SCD requires the accurate quantification of venous contrast. Our improved method to
quantify venous conspicuity will help understand the varying contrast in SWI between
patients with and without SCD in the context of the risk of stroke.
In our patient study, 86% of SWI exams contained a mixture of arterial and
venous vasculature. Hypointense arterial vessels were observed not only in brain regions
ranging from the anterior Sylvian fissure and extending to the posterior temporal lobe but
also portions of the anterior and posterior cerebral arteries. The arterial vessels appeared
tortuous, which is characteristic of cerebral arteries in patients with SCD.(259,269) The
changing flow dynamics of blood through the tortuous arteries could contribute to
nonlinear flow terms, which result in signal dephasing and a hypointense arterial signal.
We recommend that hypointense arterial vessels should be avoided during SWI
acquisition. Therefore, future studies need to focus on developing an advanced SWI
sequence that incorporates both constant and accelerated flow compensation to reduce
arterial vessel contamination.(84) The retrospective nature of our study did not allow
testing of a modified SWI sequence in patients with SCD. The SWI sequence used in
this study was a standard clinical sequence that includes only linear flow compensation.
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However, our method improves the accuracy of NVVV quantification with an imperfect
SWI acquisition. The quantification of venous contrast before and after arterial vessel
removal by our method demonstrated that approximately one third of the apparent venous
volume by SWI was arterial. This finding indicates that appropriate methods must be
implemented during image acquisition or post-processing to eliminate the contribution of
hypointense arterial vessels in order to calculate the NVVV accurately.
To separate hypointense venous and arterial vessels in the SWI, our method used
TOF MRA to identify the anatomic locations of arterial vessels. TOF MRA is a routine
and robust imaging method to study arterial vasculature. Because MRA is usually a part
of the routine clinical MR exam of patients with SCD to screen for stenosis and help
assess the risk of stroke, our method will not require any additional exam time in most
cases.
Our framework of removing hypointense arterial vessels used the same
segmentation method for both MRA and SWI. An important consideration in applying
the arterial mask is that it will not affect the visualization of venous vessels in the mIP
SWI, which would result in an underestimation of the visible venous volume. Arterial
vessel masking was performed in the original SWI imaging space before the mIP
calculation in order to avoid the masking of any venous vessels in the larger projection
volume (16 mm). Applying an arterial mask directly to the mIP SWI will lead to
underestimation of the NVVV, because it would not account for the venous vessels
masked by the arteries in the projection.
The qualitative review of hypointense arterial vessel removal from the corrected
mIP SWI identified one exam with incomplete removal of hypointense arterial vessels.
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Figure 7-5 illustrates the importance of the realignment of the MRA to identify spatially
arterial vessels in the SWI exam. The realignment in this particular exam was sufficient
to remove hypointense arterial vessels in more superior portions of the brain but did not
completely remove all portions of the M1 segment of the MCA. The incomplete removal
of the M1 segment of the MCA did not affect NVVV calculation because quantification
occurred in slices above the M1 segment.
Our proposed method of arterial vessel removal has some limitations. Arterial
vessel enhancement in MRA is important and is limited to flow-related enhancement.
The MRA needs be optimized for the patient population, like for high flow in SCD
patients. Because MRA coverage should include all the areas of NVVV quantification, it
may be necessary to increase the coverage or reposition the standard clinical MRA
acquisition to include more superior portions of the brain. Incomplete overlap of the
MRA with areas of NVVV quantification could result in arterial vessels not included in
the mask, which could lead to only partial correction of NVVV. Furthermore, motion
artifacts in the MRA and SWI will limit the effectiveness of the Frangi filter to segment
vessels by reducing the vessel probability below the cutoff threshold. For MRA, motion
will result in an incomplete arterial mask and overestimation of NVVV. For SWI,
incomplete vessel segmentation will result in an underestimation of NVVV. However in
any case the error is smaller than if no correction was applied at all. The retrospective
nature of our study limited testing of our method only to SCD patients. However, we do
not foresee any specific limitation preventing its application to any patient population that
includes a high quality MRA.
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7.5

Conclusion
We found that a large percentage of SCD SWI exams had hypointense arterial

vessel contamination. Our proposed post-processing method identified and removed
arterial vessel contamination in SWI exams, which created a more accurate quantification
of venous vessel conspicuity. Our improved method of quantifying venous conspicuity
can help gain further insight into cerebral hemodynamics in oxygenation and the use of
venous conspicuity as a potential biomarker of disease severity or the risk of stroke.
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Chapter 8
MR FLOW MEASUREMENTS IN SICKLE CELL DISEASE

8.1

Clinical Significance of Velocity Measures in Sickle Cell Disease
One clinical complication of SCD is vaso-occlusive events, which result in tissue

ischemia, acute and chronic pain, and possible tissue damage. The most devastating
vaso-occlusive event occurs in the brain and results in ischemic strokes. An ischemic
stroke will occur in 37% of SCD patients by the age 14 and an overt stroke in 11% by the
age of 20.(163) Although stroke can occur at any age, the highest incident of ischemic
stroke occurs in the first decade of life.(163) These vaso-occlusive events or stenoses are
shown to occur primarily in the distal intracranial internal carotid artery (ICA) and
proximal middle cerebral artery (MCA).(247) In a series of seminal studies, abnormal
intracranial velocities by TCD ultrasound identified SCD patients at the highest risk of
cerebral infarction.(271,272) SCD patients with a time-averaged mean of the maximum
velocity greater than 200 cm/s in either the distal ICA or proximal MCA were classified
as abnormal and had a stroke risk 10x higher than SCD patients with blood velocities
below 170 cm/s.(272) In the Stroke Prevention Trial in Sickle Cell Anemia (STOP), the
efficacy of blood transfusion therapy for SCD patients identified with abnormal blood
velocities by TCD ultrasound was associated with a 90% reduction in primary stroke
risk.(272) The evidence from these studies forms the basis of the current clinical primary
stroke prevention recommendation to screen pediatric SCD patients yearly with TCD
ultrasound.(273) Figure 8-1 depicts the different acoustic windows in the skull that are
used to measure intracranial vessels blood velocities.
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Figure 8-1 A schematic of the transtemporal Doppler ultrasound approach to measure
blood velocities in the distal internal carotid and the proximal middle cerebral artery.
The schematic also illustrates the transorbital approach. The figure schematic was
adapted from Kassab et al. 2007.(274)

However, inferring stroke risk in SCD patients is limited by the variability in
TCD velocity measurements. In a large study where two or more TCD ultrasounds were
performed less than 6 months apart, the intra-subject variability was 14.9 cm/s with only
0.9% of subjects having a variation greater than 70 cm/s.(275) Different TCD ultrasound
systems can also affect the measured velocities. TCD imaging (TCDI) systems generally
report 10% lower velocities than the non-imaging TCD systems used in the STOP
study.(276) In approximately 5% to 10% of the pediatric population, a thicker trancranial
bone window results in insufficient insonification of the intracranial vessels to measure
velocities.(274) This particular TCD ultrasound limitation results in a subsection of the
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SCD population where stroke risk cannot be estimated. For this population, 4D flow by
MRI could provide an alternative method to measure blood velocities for stroke risk
assessment. The 4D flow method will also provide a high-resolution angiogram in
addition to a velocity measurement. This is another particular advantage of the 4D flow
technique because it will allow simultaneous visible inspection of any vessel
vasculopathy as well as a velocity measurement. TCD ultrasound only reports the
presence of abnormal blood velocities. The degree of stenosis or vasculopathy
contributing to the abnormal blood velocities can only be determined by performing a
separate imaging study with MRI.

8.2

4D Flow Validation Study
Before 4D flow measurements derived by MRI can be used as an alternative

method to TCD to assess stroke risk in SCD patients, flow phantom studies should be
performed to validate the 4D flow method for velocity measurement accuracy. A flow
phantom validation study testing for precision and accuracy and variation between
clinical field strengths (1.5T vs. 3T) showed an approximate 0.6% deviation in accuracy
from the reference flow meter for both 1.5T and 3T systems.(277) With the
reproducibility of the flow measurements approximately 0.2%, the study authors
concluded a high degree of flow precision and accuracy could be achieved at both 1.5T
and 3T systems with no significant difference between systems.(277) The study also
reported higher SNR at 3T, which will allow improved spatial resolution to resolve
velocities in smaller vessels.(277)
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8.2.1

Experimental Setup
Before flow velocities in SCD patient are compared with TCD ultrasound

velocities, a flow phantom experiment was performed to validate the accuracy of flow
measurements. An in vitro flow model was constructed with an approximately 15 foot
¼” diameter polyethylene tube running through a plastic bottle. The plastic bottle was
filled with a 1% agarose gel encasing the plastic tube in the center of the bottle. The ends
of the tubing were joined with a ½” diameter polyethylene tube. The large tubing was
connected to a reservoir and a peristaltic programmable pump. The system was filled
with water. Because the programmable pump could not achieve flow rate of clinical
interest, the tubing diameter though the plastic was reduced from ½” to ¼” to increase the
mean velocity thought the phantom.

Figure 8-2 A schematic diagram of the experimental setup for the flow calibration study.
In order for the pump to achieve the required high velocities, a reduction in the tube
diameter occurred before flowing into the imaging phantom. Note, the tube reduction
occurred outside of the MRI magnet. This was done to prevent any equipment damage if
a leak would occur at the tube union. The small tube was one continuous piece.
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Flow rates for the in vitro flow phantom were measured manually at a set of seven
predetermined flow pump settings. A flow rate at a programmed flow setting was
determined by measuring the output flow in a 100ml graduated cylinder for 15 seconds.
This measurement was repeated 5 times with the highest and lowest recorded volumes
being excluded. This procedure was repeated for all seven programmed flow settings.
Average velocity is the flow rate divided by the tube cross-sectional area.
Flow velocities were measured at 3T (Skyra, Siemens, Erlangen, Germany) with a
3D phase contrast GRE sequence with a TR = 41.76ms, TEeff = 6.6ms, flip angle (FA) =
15 degrees. Further sequence parameters include matrix =192x192x16, FOV =
210x203x16 mm, IPat = 2, velocity encoding (VENC) = 100,150, 200,250 cm/s, and 2D
zero-padding interpolation. The 4D flow sequence parameter where chosen to coincide
with sequence parameters chosen in the SCD patient study with the following
modification. For the in vitro flow phantom experiment, flow velocity measurements
were made at four different VENC values to test for errors in velocity quantification
introduced by the VENC setting. Because the phantom only produces a steady laminar
flow, electrocardiogram (ECG) gating was removed.
The flow sequence reconstructed phase difference and magnitude weighted
images. ROIs were manually drawn on the magnitude weighed images in MATLAB
(The Mathworks, Natick, MA) defining areas of flow and static tissue. Background
phase errors were removed from the phase images by subtracting the results of a fitted 2D
plane through the static phase tissue ROI.(278) Any nonzero phase difference in static
tissue background is assumed due to eddy current and other system imperfections.
Velocity aliasing will occur at lower VENC values and is determined when phase shifts
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are negative. Any negative phase is unwrapped by adding 2𝜋. Velocity was calculated
by the following relationship where Δφ is the phase difference:
𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 = (

∆𝜑
) ∙ 𝑉𝐸𝑁𝐶
𝜋

Eq. 8.1

The average velocity measured in the flow phantom was compared to the average
calculated velocity. For each VENC setting, linear regression and Pearson correlations
were performed to test the association between measured average velocity by MRI and
calculated average velocity. Bland-Altman plots were used to investigate systematic
differences between average velocity by MRI and calculated average velocity.

8.2.2

Calibration of flow measurements
Representative through plane direction (Z) phase difference images for VENC

value of 100 cm/s at different pump flow settings are shown in Figure 8-3. An example
of phase wrapping is seen in Figure 8-3 (E-H), and occurs when the velocity in voxel
exceeds the VENC value (100 cm/s). The programmed flow setting on the peristaltic
pump was able to produce average flow velocities ranging from 85 cm/s to 240 cm/s.
Under these experimental conditions, the flow pump settings will allow testing of flow
velocities in the expected velocity range and exceeds the SCD abnormal cutoff 200
cm/s.(271)

132

Figure 8-3 A representative magnitude weighted image slice through the flow phantom
(A). Through plane (Z direction) phase difference image (B-H) for different pump flow
settings. As the flow values increase from B to H, phase wrapping occurred in phase
images (E-H) as indicated by the change in the phase sign. This occurs when the
velocities exceeds the velocity encoding value.

Figure 8-4 shows the results of average flow velocities measured by 4D flow at
four different VENC values over the range of programed average flow velocities.
Generally, lower VENC values measured a slightly higher velocity then higher VENC
values. However, velocity estimates encoded with higher VENC values were within 4%
of the measured velocity measured encoded with VENC of 100 cm/s. The standard
deviation in average flow velocity between slices was less than 1% of the average flow
velocity for all flow rates and VENC values. The gray line in Figure 8-4 depicts the
result of linear regression for VENC =200 cm/s. TABLE 8-1 lists the results of linear
regression analysis for each VENC value. All VENC values measured an average
velocity that correlated well with the calculated average velocity produced by the
programmable pump. Overall, 4D flow underestimated average velocity with all
regression slopes less than 1. The VENC of 150 cm/s had the best correlation with a
slope of 0.98 and intercept of 1.4.
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Figure 8-4 Scatter plot of average velocity in a flow phantom by 4D flow MRI against
the average velocity delivered at several programmable peristaltic pump settings.
Different color markers represent the four different VENC values in cm/s. The gray line
represents the fitted linear regression for VENC = 200 cm/s (y= 0.96x+3.3, R=0.99).

TABLE 8-1 Results of the linear regression analysis from the average flow velocity
by MRI against the average velocity delivered by a programmable peristaltic pump.
The results indicate a high degree of correlation independent of the velocity
encoding value between average flow velocities.
VENC (cm/s)
Slope
Intercept
R
0.98
4.4
0.99
100
0.98
1.4
0.99
150
0.96
3.3
0.99
200
0.95
4.8
0.99
250

Figure 8-5 is the result of the Bland-Altman analysis comparing average flow
velocities between 4D flow with a VENC value of 200 cm/s and the calculated pump
velocities. The mean difference in average flow velocities is 3.3 cm/s with a STD of 2.3
cm/s. The result indicates a bias in measured velocities between the two methods. As the
average velocity increases, the degree of velocity underestimation by 4D flow increases
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when compared to the average pump velocity. This bias may be due to the manual output
volume measurement made per fix increment of time (15 s). These manual
measurements were used to calculate the average flow velocity produced by the
programmable pump. The bias indicates that as the flow velocities increased the error in
manually measuring the true output volume per fix increment of time increased. This
error could be reduced if volume outputs were collected and measured for a longer time
increment.

Figure 8-5 Bland-Altman indicating a bias in measured average flow velocities between
4D flow with VENC value of 200 cm/s and the programmable pump velocities. As the
average velocity increases, 4D flow measures a smaller velocity compared calculated
pump velocities. Overall, the mean difference is 3.3 cm/s with a standard deviation of
2.3 cm/s.

In summary, an in vitro flow model was constructed to test 4D flow
measurements with average velocities in the range of SCD abnormal blood velocity of
200 cm/s. 4D flow slightly underestimated average flow velocities but was within 3% of

135

the calculated pump velocities. Only small variations in measured flow velocities were
measured with different VENC values. With the uncertainty associated with phase
unwrapping, the larger VENC values for SCD exams would reduce the complexity of
processing the phase data without measuring large variation in velocities if smaller
VENC values used.

8.3
8.3.1

SCD MR 4D Flow Patient Study
Study Population
A total of 39 4D flow exams in SCD patients were performed in conjunction with

a TCD ultrasound to evaluate the 4D flow MRI technique as a potential alternative
method for measuring blood velocity in a SCD population with closed cranial windows.
Four exams from two patients were removed due to closed cranial window resulting in an
incomplete TCD examination. An additional eight 4D flow exams were removed due to
excessive motion compromising blood velocity quantification. This result in 27 4D flow
exams from 21 SCD patients (age 12.9 ± 3.1y; 9 Male, 12 Female) with an additional six
patients undergoing a second examination 1 year later. TCD exams were performed an
average of 5.8±16 days before the 4D flow exam. The study was approved by our local
ethics committee and informed written consent was obtained from all study participants.

8.3.2

MR Imaging and TCD Ultrasound
MR imaging measurements were performed on a clinical 3T MRI system (Skyra;

Siemens, Erlangen, Germany) with a 20-channel head coil. A low-resolution 3D time-offlight (TOF) MRA (flip angle 18, TE = 4.18, TR=23, spatial resolution 0.5x0.5x1.2 mm3,
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IPat = 4) covering the Circle-of-Willis was used to determine the exact anatomical
location of the MCA and ICA bifurcation. The central portion of the 4D flow volume
was positioned at the level of the MCA and ICA bifurcation. Special care was taken to
angulate the 4D flow volume to maximize vessel coverage in the circle-of-Willis.
The 4D flow imaging consisted of a 3D radio-frequency-spoiled gradient-echo
sequence with interleaved velocity encoding in all three spatial directions.(279) Imaging
parameters were as follow: FA = 15, TE = 6.6 ms, TR = 10.44 ms, IPat = 2, 2D zero
padding resulting in a final spatial resolution = 0.5x0.5x1 mm3. Data acquisition was
prospectively gated to the cardiac cycle with a temporal resolution of approximately 42
ms. To account for the potentially high blood velocities in SCD population, a VENC
value of 200 cm/s was used, which corresponds to the abnormal cutoff velocity
established in the STOP study.(271)
TCD examinations were performed with a non-duplex Doppler ultrasound
machine with a 2-MHz transducer (Viasya Sonara/tek, Ontario, CA). TCD
measurements were made following the procedures outlined in the STOP study and were
performed by a certified TCD sonographer.(271) Patients examinations were in the
supine position with the transducer placed in the temporal region of the skull. The
probe’s position and angulation along with the ultrasound’s depth setting were
manipulated to sample a volume of blood velocities in the major arterial vessels in the
circle-of-Willis. Vessels were identified by vessel depth and direction of blood flow.
The ultrasound’s software algorithms traced the measured velocity spectrum and
calculated the time-average mean of the maximal flow velocity (TAMMV). Multiple
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measurements were taken at varying depth along the vessel. The highest recorded
velocity measured in the left and right MCA were reported.

8.3.3

Data Processing and Flow Quantification
The 4D flow sequence software reconstructed source phase difference images in

the three spatial dimensions that included correction for Maxwell terms.(280) Additional
data processing included correction of eddy currents and phase unwrapping. Eddy
current corrections were estimated by fitting a 2D plane through the background phase of
static tissue in each slice.(278) Phase difference images were manually inspected for
phase wrapping errors by identifying voxels with rapid changes in the phase sign over
time or voxels with a phase sign different from surrounding tissue. No phase wrapping
errors were identified in this cohort with VENC of 200 cm/s. Manual inspection also
identified exams where excessive motion could compromise velocity quantification.
For each 4D flow examination, an MR angiogram of the circle-of-Willis was
created by manual threshold segmentation of the time averaged 4D flow magnitude data
in Amira (FEI, Hillsboro, OR). Vessel specific ROIs were created by manual
segmentation in Amira to identify the arterial vessels comprising the circle-of-Willis
from the MR angiogram. Vessel ROIs were further classified according to their left and
right anatomical orientation, for example separation of left and right MCA. Because 4D
flow is a phase difference method, subtraction artifacts can arise around the vessel wall
due to motion and changes in partial volume. Special attention was applied to the vessel
segmentation to include only central portion of the vessel and to not include these
periphery vessel artifacts. After manual segmentation of the vessel, vessel ROIs
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underwent an additional 2D erosion of 1 voxel to reduce the volume of the ROI to again
avoid partial volume effects.
For blood flow velocity quantification, the velocity magnitude was calculated for
each time point within the cardiac cycle from the three spatial directions using MATLAB
(The Mathworks, Natick, MA). To increase the robustness of the reported velocity
values, the magnitude velocity images were convolved with a 2.25 mm2 spatial average
filter for all slices and time points. A temporal mean velocity was calculated using the
spatial average filtered velocity images. The TCD equivalent velocity was reported by
finding the maximum temporal mean velocity inside a vessel’s ROI. Because limited
data was collected in the Z dimension, phase wrapping from the image reconstruction
occurred in the Z direction. To avoid any compromised velocity values, no velocity
values were reported from the four bottom and top slices.

8.3.4

Statistical Analysis
Correlations between maximal mean velocity by MRI and TAMMV by TCD

were estimated with the Pearson correlation coefficient. A Bland-Altman plot was used
to compare the measured velocities between the two methods. A Wilcoxon signed rank
test was performed to test for differences between the two methods. P values less than
0.05 was considered significant. Data analysis and calculations were performed in
MATLAB.
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8.3.5

Results
4D flow total scan time ranged from 14 to 20 minutes depending on the heart rate

of the patient. Due to the long scan times, eight scans were removed due to excessive
motion. Segmentation and quantification of smaller arterial vessels like the anterior
cerebral arteries (ACA) was limited due to 4D flow’s spatial resolution. Elimination of
slices because of phase wrapping artifacts from image reconstruction limited ICA
coverage. With these limitations, our analysis focused on correlating velocities between
4D flow and TCD ultrasound in the larger MCA M1 segment.
All SCD patients had normal TCD velocities (<170 cm/s) in the MCAs as defined
by the STOP study. The average TAMMV in the MCA by TCD is 119.1±19.1 cm/s.
However, 4D flow measured a lower average maximum mean MCA velocity of
90.4±18.1 cm/s. Figure 8-6 is a scatter plot comparing the maximum mean flow
measured in the left and right MCA by 4D flow and TCD ultrasound. The results of the
linear regression as shown by the gray line in Figure 8-6 showed a good correlation
(r=0.82) between the two methods with 4D flow underestimating the maximum mean
flow compared to TCD ultrasound.
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Figure 8-6 A scatter plot of the left (black) and right (red) maximum mean velocities
measured in the MCA by 4D flow and TCD ultrasound. The gray line is the linear
regression (r=0.82) with a relationship of y = 1.15x + 14.8.

Figure 8-7 is the result of the Bland-Altman analysis comparing maximum mean
velocity between 4D flow and TCD ultrasound. The mean difference between the
methods is 28.7 cm/s with a STD of 15.0 cm/s. The result indicates a bias in measured
velocities between 4D flow and TCD ultrasound. As the maximum mean velocity
increases, the degree of velocity underestimation by 4D flow increases when compared to
the TCD ultrasound.
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Figure 8-7 The Bland-Altman indicates a bias in maximum mean flow velocities
between 4D flow and TCD ultrasound measured in the left and right MCA. As the
maximum mean velocity increases, 4D flow measures a lower maximum mean velocity
compared TCD ultrasound. The mean difference between methods is 28.7 cm/s with a
standard deviation of 15.0 cm/s.

The maximum mean flow of 4D flow was significantly different from the
velocities measured by TCD ultrasound (P < 0.001). This difference is the result from
4D flow consistently underestimating the flow velocities compared to TCD ultrasound.
Underestimation of velocities occurred in all but one vessel as indicated in the BlandAltman plot in Figure 8-7. The Bland-Altman plot in Figure 8-7 also indicated that 4D
flow velocity underestimation increases as flow velocities increase.

8.3.6

Discussion
In this study, we evaluated the feasibility of using 4D flow MRI to measure flow

velocities in the circle-of-Willis of SCD patients as an alternative to TCD ultrasound to
assess stroke risk. 4D flow MRI is an emerging method in the clinic that can provide 3D
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visualization of blood flow velocities throughout the cardiac cycle. A few studies have
directly compared 4D flow velocities with TCD ultrasound velocities (281-285),
however, this study investigates the specific maximum mean flow velocity measured by
TCD ultrasound used to determine stroke risk in SCD patients.
A good correlation was observed between flow velocities of 4D flow MRI and
TCD ultrasound in the MCA M1 segment. However, 4D flow consistently
underestimated the maximum flow velocities in comparison to TCD ultrasound. These
lower velocities could be due to the temporal differences of how the data is acquired
between the two methods. While 4D flow can provide a voxel by voxel velocity
waveform of the cardiac cycle, it is not equivalent to the real time velocity measurements
that are made in TCD ultrasound. 4D flow’s temporal resolution is approximately 42 ms,
and its characteristic velocity waveforms represent the beat-to-beat average velocity over
the entire scan time of 14 to 20 minutes. It has been reported that variations in flow
velocities can vary as much as 10-15% over minutes to hours from natural physiological
variations in cerebral blood flow.(247) The recorded velocity from the TCD examination
is the maximum of these beat-to-beat variations in flow velocities.
The Bland-Altman result indicates a bias in flow velocities between the two
methods. The degree of flow velocity underestimation by 4D flow increased as flow
velocities increased. In our data, we typically observe higher flow velocities in proximity
to the ICA/MCA bifurcation. This bias could be the result of spatial sampling variations
between the two methods. Sampling volume in 4D flow was predefined by the manually
drawing ROIs identifying specific vessels comprising the circle-of-Willis. Vessel
identification by TCD ultrasound is a little more challenging than by 4D flow and
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requires special training to master the technique. These factors include depth and angle
of isonication and directionality of flow. For example, the MCA vessel is traced by 2
mm increments of increasing depths until bidirectional flow is detected where a
bifurcation velocity is recorded. The manually delineated MCA ROIs might not have
extended up to the location of bidirectional flow detected by TCD ultrasound, thereby not
including the faster velocities that are typically observed in close proximity to the
MCA/ICA bifurcation. Other studies have not reported a bias in velocities between 4D
flow MRI and TCD ultrasound.(274,282) Determination of sampling location by TCD
ultrasound, which is a blind technique and relatively nonspecific, for comparison with 4D
flow MRI is a problem that needs to be addressed in future studies.
4D flow MRI has several distinct benefits over TCD ultrasound. The primary
benefit of 4D flow MRI is its ability to serve as an alternative method to measure flow
velocities and assess the risk of stroke in approximately 5 to 10% of the sickle cell
population where TCD ultrasound cannot be performed due to insufficient insonation of
the intracranial vessels attributed to thicker bone windows.(274) Abboud et al reports
abnormal flow velocities indicating an elevated risk of stroke was detected by TCD
ultrasound before vessel pathophysiology changes were evident by MR
angiography.(286) This result suggests that MR angiography alone is not sufficient to
assess stroke risk in SCD patients where TCD ultrasounds evaluations are incomplete.
Another benefit is the spatiotemporal dynamic velocity visualization of all intracranial
vessels within the 4D flow imaging volume compared to spectral velocity profile of TCD
ultrasound restricted insonation volume. 4D flow visualization include vector field plots
and time-resolved 3D particle traces or pathlines.(88) Additional hemodynamic
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parameters such as wall shear stress and turbulence can be derived from 4D flow MRI
data that could be modeled into assessing stroke risk in SCD patients.(287,288)
The 4D flow MRI method for measuring intracranial blood velocities is not
without its limitations. The main limitation is the spatial and temporal resolution tradeoff that can result in long imaging times. In our study, effects of accumulated motion
during the long scan time resulted in eight of the 39 scans with severe motion related
artifacts compromising velocity quantification. Unfortunately, in this study cohort,
intracranial vessels comprising the circle-of-Willis are small and required a high spatial
resolution. Reducing the spatial resolution would increase the number of voxels
suffering from partial volume effects, undermining velocity quantification. Without
sacrificing temporal resolution and maintaining the required high spatial resolution,
higher acceleration factors are necessary to achieve overall shorter scan times. In our
study, GRAPPA acceleration was applied in only one direction. Additional imaging
acceleration with either GRAPPA or SENSE can be applied in the second dimension.
Image acceleration can be further increased by including techniques like kt-BLAST and
kt-SENSE in the temporal dimension.(289,290) PC VIPR is another 4D flow accelerated
imaging technique that utilizes radial undersampling. Radial undersamping results in
streaking artifacts and has been shown to be well tolerated in phase contrast
imaging.(291,292)
The highly accelerated PC VIPR technique offers several distinct benefits in our
application of measuring intracranial blood velocities. The radial sampling technique is
robust to motion artifacts due to oversampling the center of k-space.(293) The method
also provides isotropic spatial resolution in a larger imaging volume. With the limited
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imaging volume in the z direction in this study, the larger imaging volume of the PC
VIPR technique is particularly advantageous especially if it includes ICA velocity
quantification in the ICA siphon, which includes the cavernous and supraclinoid
segments.(294,295)

8.3.7

Conclusion
Our study compared the MCA’s time average max mean velocity measured by 4D

flow MRI and TCD ultrasound in a cohort of SCD patients to assess stroke risk. A good
correlation of measured velocities was observed between 4D flow MRI and TCD
ultrasound, but was systematically underestimated by 4D flow MRI. Additional 4D flow
imaging acceleration techniques can be employed to further reduce overall scan thus
increasing clinical feasibility. This is an area of work for future prospective studies. 4D
flow MRI is a promising technique in measuring intracranial blood velocities in SCD
patients to assess stroke risk according to the STOP criteria especially in the subset of
SCD patients were the TCD ultrasound technique fails.
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Chapter 9
CONCLUSION AND OUTLOOK

The focus of this work was to demonstrate the importance of developing new
physiologically based functional biomarkers to quantitatively assess and characterize
distinct neurological diseases. Multiple different MRI techniques were used to
characterize the cerebral hemodynamics of specific neurological conditions. The ability
to characterize biological changes robustly in MR images and techniques represents an
important advancement in the evaluation of disease and the next step in diagnostic and
prognostic medicine. Observing biological changes before the development of structural
abnormalities will minimize delays in starting alternative therapy and may eliminate
unnecessary therapy.
The first study focused on the longitudinal hemodynamic changes of pediatric
DIPG tumors. Two different MRI techniques, DSC and ASL, evaluated tumor CBF and
CBV with PFS and OS. Higher tumor CBF and maintenance of higher CBF were
associated with a more favorable PFS. However, DIPG tumors were hypoperfused when
compared to gray matter. The hypoperfusion and location of the tumor, represented a
unique challenge for ASL and an area of future study. The community consensus
recommends the pseudo-continuous ASL method.(296) The pseudo continuous ASL
method has been shown to provide higher SNR then the PASL method used in this
study.(297,298) Additionally, the implementation of multiple inversion times would
introduce a new physiological variable to evaluate tumor variability and its association
with patient survival.(299) Developing a robust ASL method for the evaluation of
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longitudinal changes in DIPG tumor perfusion would offer an additional clinical metric
with which to characterize the efficacy of newly developed DIPG treatment protocols.
Since not all neurological diseases result in structural abnormalities, imaging
diagnoses can be particularly difficult. Imaging hemodynamic variability or biological
variability to characterize pathological processes could overcome this limitation and
introduce a powerful new diagnostic tool. In the exploratory study evaluating resting
state perfusion and neurocognitive impairment in long-term survivors of pediatric ALL
and HL, systematic differences in resting state perfusion were observed between the
cancer survivor groups. There is evidence that CRT in the ALL patients could have
introduced more perfusion variability than was observed in the HL group. However,
future longitudinal studies are needed to evaluate group differences. Elucidating the
physiological differences in late effects between survivor groups can provide key insight
into the particular long-term biological effects associated with primary therapy.
However, this study only detected a limited number of associations between resting state
perfusion and neurocognitive impairment. Unfortunately, perfusion does not provide a
complete physiological assessment with information limited only to gray matter tissue.
This study would be improved if it included other biology-based metrics in addition to
gray matter perfusion in which to analyze neurocognitive impairment. Other metrics
could include but are not limited to white matter diffusion tractography analysis
(300,301), cortical thickness (302), or task based neuronal activation commonly
measured in functional MRI studies (242). Longitudinal studies, which include the multiparametric MR bases biological measurements, will provide critical knowledge in
distinguishing between normal and pathological neural development trajectory. These
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critical pieces of information will direct future treatment and interventions to provide a
higher quality of care and quality of life for the cancer survivors.
In chapters 6-8, different MR techniques were employed to characterize the
hemodynamic properties associated with the autosomal recessive blood disorder SCD.
SWI was used to investigate the integrity of the cerebral venous vascular system in SCD
patients and healthy controls. It was shown that SCD affects SWI venous conspicuity
with SCD patients having a lower NVVV then healthy controls. However, the
mechanism of decreased NVVV remained elusive and did not correlate with common
hematologic variables. This interesting result will require refinement of the method. In
this study, the normal physiological variation of venous volume could have obscured the
NVVV relationship with hematological variables. Another approach could investigate
the phase difference from a small ROI in the vein and surrounding oxygenated tissue. As
already discussed in chapter 6, future studies should also include ASL perfusion
measurements. Future studies are necessary to elucidate the hematological mechanism(s)
of decreased venous conspicuity. This is necessary to determine if decreased venous
conspicuity in SCD’s SWI exams represents a biomarker of disease severity. The actual
mechanism of decreased venous conspicuity is probably multiparametric with several
hematological variables highly correlated, making the contributions of individual
components difficult to isolate.
Although, isolating the mechanism of decreased venous conspicuity will remain
challenging if venous volume calculations remain inaccurate due to arterial vessels
contributions. In reviewing the systematic differences between SWI exams of healthy
controls and SCD patients, a large percentage of SCD’s SWI exams had hypointense
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arterial contributions above the M1 segment of the MCA in the Sylvian fissure. A new
post-processing method was created to improve the accuracy of venous volume
calculation in the presence of hypointense arterial contamination. The proposed method
combined the spatial arterial vessel information from a MRA with the SWI for an
improved calculation of NVVV. The study revealed that hypointense arterial
contributions are quite large and must be accounted for when calculating the NVVV in
SCD’s SWI exams. Although, the true NVVV can still remain elusive if the data is
corrupted by patient head motion. SWI is a rather long exam and addressing this problem
represents an area of future work. Shorter scan times can aid in reducing motion
accumulated data and are achievable with higher image acceleration techniques like
compressed sensing.(303) Alternatively, image navigators could be incorporated to
actively correct for head motion.(304,305) Either method or the combination of both
could be incorporated into SWI sequence to create high-resolution SWI exams for NVVV
calculations.
In the final study, blood velocity measurements were made in the circle of Willis
to study flow-related physiology of SCD patients. Blood velocity measurement by TCD
ultrasound is the current recommendation to assess stroke risk in SCD patients. The 4D
flow method has the unique ability to measure blood velocity for stroke risk assessment
in the subset of SCD patients where TCD ultrasound measurements are inconclusive.
The 4D flow blood velocity correlated well with TCD ultrasound but was systematically
underestimated. The underestimated velocity could be due to the much lower temporal
resolution of the 4D flow method when compared to the real-time temporal resolution of
TCD ultrasound.
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However, the primary limitation of 4D flow techniques is the relatively long
acquisition time, which should be addressed in future studies. The long imaging time
limits the spatial resolution, coverage volume, or temporal resolution. By simply
maintaining a temporal resolution similar to the one in the study; imaging time is
dependent on patient’s heart rate. Therefore, the only approach to increase either the
spatial resolution or volume coverage, or decrease imaging time must be to reconstruct
images from increasing amounts of undersampled data. There are several 4D flow image
data undersampling methods. Spatial undersampling methods include compressed
sensing techniques (306,307) or a radial projection method (291,292). Undersampling
the temporal dimension with k-t BLAST can also provide a higher degree of image
acceleration.(289,308) The radial projection method known as PC VIPR is a particularly
promising technique for our application of measuring intracranial blood
velocities.(291,292) This technique provides similar spatial resolution but with a much
larger imaging volume. In addition, the oversampled center of k-space is robust to
motion artifacts, which is beneficial for less than cooperative pediatric patients. A robust
and time efficient 4D flow technique would be a powerful diagnostic tool for the
evaluation of stroke risk in SCD. SWI and 4D flow represent important diagnostic tools
that would complement a comprehensive SCD exam to assess the risk of stroke or disease
severity.
In conclusion, quantitatively assessing and characterizing pathophysiology will
expand our knowledge of different neurological disease processes that will ultimately
translate into better patient therapies and outcome. This collection of works
quantitatively investigated cerebral hemodynamics as a functional biomarker of different
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neurological conditions. Further work is needed to improve the technical development of
imaging biological signals with the addition to basic studies to investigate different
biological processes. However, MR characterizations of dynamic biological signals and
their pathophysiology is the next step in disease evaluation because it provides the
necessary information required for personalized healthcare and therapy.
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